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Factors such as mammographic breast density and angiogenesis may be related to breast cancer 
development, though numerous questions about the etiologic mechanisms remain.  Percent 
density is positively associated with breast cancer risk, yet is negatively associated with another 
breast cancer risk factor, body mass index (BMI).  Vascular endothelial growth factor (VEGF) is 
a primary regulator of angiogenesis, yet its relationship to breast cancer risk is unclear.  We 
evaluated the longitudinal association between BMI and breast density in the Study of Women’s 
Health Across the Nation (SWAN) Mammographic Density Substudy (N=834).  Using adjusted 
random intercept models, changes in BMI were not associated with changes in dense breast area 
(β=-0.0105, p=0.34), but were strongly negatively associated with changes in percent density 
(β=-1.18, p<0.001).  Thus, effects of changes in anthropometry on percent breast density may 
reflect effects on non-dense tissue, rather than on the dense tissue where cancers arise. Breast 
density was measured from routine screening mammograms which were not timed with SWAN 
visits.  We developed a method to align the off-schedule mammogram data to the study visit 
times using linear interpolation with multiple imputation.  Our method was shown to be valid, 
with an average bias for dense breast area of 0.11 cm2.  In the random intercept models, use of a 
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simple matching algorithm to estimate breast density produced different (β=-0.0155, p=0.04), 
and likely incorrect, results.  Our linear interpolation with multiple imputations method may be 
applicable to other longitudinal datasets with important data collected off-schedule.  In a separate 
case-control study, the Mammograms and Masses Study (MAMS), we evaluated the association 
between serum VEGF levels and breast cancer (N=407).  Geometric mean VEGF levels were 
higher among cases (331.4 pg/mL) than controls (291.4 pg/mL; p=0.21).  In a multivariable 
logistic regression model, VEGF ≥314.2 pg/mL was positively associated with breast cancer 
(odds ratio 1.37, 95% confidence interval 0.88 – 2.12), albeit non-significantly.  Higher levels of 
VEGF may increase breast cancer risk.  We have identified roles for anthropometry and 
angiogenesis in breast carcinogenesis.  Enhancing knowledge of breast cancer etiology is a 
significant contribution to public health and may lead to improved opportunities for prevention 
or early detection.   
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1.0  INTRODUCTION 
Breast cancer is a significant public health problem in the United States.  Despite decades of 
promising research advances, the incidence of breast cancer continues to rise in the U.S.  
Although much is understood about the etiology of breast cancer, opportunities for its prevention 
are limited, and most of the decrease in breast cancer mortality has resulted from earlier 
detection and improved treatment of the disease.  One reason for the lack of preventive options 
for breast cancer is that research aimed at testing the efficacy of preventive interventions requires 
substantial commitments of time, participants, and monetary resources.  As an alternative to 
following subjects for an outcome of incident cancer, many cancer epidemiology studies employ 
a surrogate endpoint instead, thus allowing for the study to be performed over a shorter period of 
time and with fewer participants.  Mammographic breast density is determined by the relative 
proportions of fat and structural tissues in the breast and has been proposed for use as a surrogate 
endpoint in breast cancer prevention trials.  Breast density is highly related to the amount of fat 
in a woman’s breast, and how changes in weight relate to changes in breast density has not been 
documented.  This issue must be understood prior to widespread use of breast density change as 
an endpoint in longitudinal studies.   
Numerous biological processes such as angiogenesis are believed to play a role in breast 
cancer etiology.  Angiogenesis is known to be necessary for the growth of tumors beyond a few 
millimeters in size, and vascular endothelial growth factor (VEGF) is believed to be one of the 
most important angiogenic factors.  While some studies have reported that serum and plasma 
VEGF levels are higher among breast cancer cases than among controls, these studies have had 
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significant limitations including small sample size and failure to control for menopausal status.  
Thus, the role of VEGF in breast cancer etiology remains unclear. 
For these reasons, the purpose of the present research is as follows: 1) to evaluate 
longitudinally how anthropometry is associated with breast density, 2) to describe an approach 
for estimating data collected off-schedule from planned study visits, and 3) to evaluate how a 
biomarker of angiogenesis is associated with breast cancer.  The following literature review 
presents an overview of breast cancer epidemiology and known risk factors for breast cancer.  A 
more detailed background on mammographic breast density and angiogenesis as they relate to 
breast cancer is also provided. 
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2.0  LITERATURE REVIEW 
2.1 BREAST CANCER EPIDEMIOLOGY 
It is predicted that 178,480 American women will have been diagnosed with invasive breast 
cancer in 2007 alone.1  Breast cancer is the most commonly diagnosed cancer among women in 
the United States and accounts for 31% of all female cancers (excluding non-melanoma skin 
cancers and in situ cancers).1  Though breast cancer may occur in men, this is a rare event; the 
American Cancer Society estimates 2,030 new cases of male breast cancer will have been 
diagnosed in 2007.1  Among U.S. females breast cancer ranks second to lung cancer in terms of 
cancer morality, with 40,460 female breast cancer deaths predicted for 2007.1  Breast cancer 
deaths account for 15% of the burden of cancer mortality among female Americans.2  Mortality 
from breast cancer has decreased in recent years due to early detection and improved treatment 
of the disease.  Data from the National Cancer Institute’s Surveillance Epidemiology and End 
Results (SEER) program show that the breast cancer mortality rate declined 2.3% each year 
between 1990 and 2003.3  The percentage of women surviving at least five years after diagnosis 
has risen to 88%, and 5-year survival is 98% for women diagnosed with localized disease.3
3 
   
 
Figure 2.1 Age-specific breast cancer incidence rates among U.S. women by race, 1999-2003. 
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat 
Database: Incidence-SEER 9 Regs Public-Use, Nov 2005 Sub (1973-2003), National Cancer Institute, 
DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the 
November 2005 submission. 
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2.1.1 Menopausal status and breast cancer 
Many oncologists and cancer epidemiologists consider pre- and postmenopausal breast cancer to 
represent two different etiologic forms of breast cancer.  The overall incidence rate of breast 
cancer is low at younger ages (e.g. 1.4 per 100,000 among women ages 20-24).4  As women 
begin to transition through menopause the rates of breast cancer increase substantially; data from 
SEER (Figure 2.1) show that between 1999 and 2003 the incidence rate of breast cancer was 
119.3 per 100,000 for women ages 40-44, 249.0 per 100,000 for women ages 50-54, and 388.3 
for women ages 60-64.  The highest rate of breast cancer was observed among women ages 75-
79, in whom 490.4 incident cases of breast cancer were diagnosed for every 100,000 women in 
this age group.4  Further, since 1987 the incidence rate of breast cancer has been unchanged 
among women under age 40 and has decreased slightly among women age 40-49.  The incidence 
of breast cancer among women over 50, however, has exhibited a slight increase during this time 
period.3  Disease occurring among younger, premenopausal women tends to be more aggressive, 
and survival is lower among younger breast cancer patients.  Often when menopausal status is 
unknown in research studies, the woman’s age is used as a proxy with age 50 as the cutpoint to 
define pre- versus postmenopausal women.  SEER statistics show that 5-year survival from 
breast cancer, among cases diagnosed between 1996 and 2002, was 86.7% in women under age 
50 compared to 90.0% among women age ≥50.5
Indeed, some risk factors for breast cancer, such as family history and obesity, differ in 
their effect on breast cancer risk depending on the woman’s age or menopausal status (see 
section 2.3.2).  Mammographic breast density is a significant risk factor for breast cancer in both 
pre- and postmenopausal women, although, as reviewed by Boyd et al., there is some evidence 
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that it may be a stronger risk factor among postmenopausal women.6  Due to the significant 
differences in breast cancer incidence, effects of risk factors, and endogenous hormonal 
environments between pre- and postmenopausal women, it is important that studies of breast 
cancer epidemiology consider that associations may vary by menopausal status. 
2.1.2 Race/ethnicity and breast cancer  
Breast cancer rates also differ by race and ethnicity.  Although African American women have a 
lower overall incidence of breast cancer compared to Caucasian women (rates of 118.9 per 
100,000 vs. 137.6 per 100,000, respectively for 1999-2003),4 African Americans have a higher 
incidence of breast cancer before age 35.3  Breast cancer mortality was substantially greater at all 
ages among African Americans (34.4 deaths per 100,000) than it was among Caucasians (25.4 
deaths per 100,000) for the period 1999-2003.7  
The reasons for these disparities are not well-understood, although a number of possible 
explanations have been suggested and investigated: 1) differential utilization of mammographic 
screening and stage at diagnosis, 2) differential effect and/or distribution of breast cancer risk 
factors, 3) differences in inherent genetic susceptibility, 4) differences in tumor characteristics, 
5) differential access to treatment, and 6) differences in prevalence of comorbidities among 
women diagnosed with breast cancer.  Each of the six hypothesized explanations for the racial 
disparities in breast cancer incidence and mortality has some merit.  Mammography use is 
generally similar between African Americans and Caucasians,3 and differences in stage at 
diagnosis can be at least partially explained by differences in obesity.8  Therefore, screening and 
differences in stage at diagnosis are likely not the most important factors.  Likewise, access to 
treatment is important, but disparities in mortality exist even in systems in which African 
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Americans and Caucasians have equal access.9-11  Genetic susceptibility may also be important, 
yet the impact of such factors is not well-understood.12-15  It appears that the differential 
distribution of risk factors, especially obesity,16-18 differences in tumor characteristics,19-27 and 
differences in comorbid conditions28, 29 between African American and Caucasian breast cancer 
patients are largely responsible for the racial disparity observed in breast cancer. 
Breast cancer incidence and mortality are higher among African Americans and 
Caucasians than among other races and ethnicities.  According to SEER data, breast cancer 
incidence among Asians and Pacific Islanders in 1999-2003 was 93.5 per 100,000.  Incidence 
among Hispanics for the same time period was 87.1 per 100,000, while incidence among Native 
Americans and Alaskan Natives was 74.4 for 1999-2002.4  Mortality rates (per 100,000) for 
these time periods were 12.6 for Asians and Pacific Islanders, 16.3 for Hispanics, and 13.8 for 
Native Americans and Alaskan Natives.7  A variety of genetic, environmental, and behavioral 
factors may explain these racial differences.  Migration studies have documented that breast 
cancer risk is higher among Asian-American women born in the West compared to those born in 
the East (RR 1.6, 95% CI 1.2-2.1).30  Breast cancer risk is further increased along with the 
number of the woman’s grandparents born in the West (RR 1.89, 95% CI 1.2-3.0 for woman and 
1-2 of her grandparents born in the West compared to woman and all grandparents born in the 
East), and risk is decreased among more recent immigrants (RR 0.32, 95% CI 0.18-0.57 for 2-4 
years lived in the West) compared to those who have lived in the West their entire lives.30  A 
recent study also reported that breast cancer rates among Asian Americans in Los Angeles 
County rose substantially between 1993-1997.31  Most notably, the breast cancer rate among 
Japanese American women in this county was rapidly approaching that of non-Hispanic white 
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women.31  Factors such as acculturation and adoption of a Western diet may at least partially 
explain these recent trends.31
2.2 BREAST CANCER RISK FACTORS  
Besides age and race, a number of risk factors for breast cancer have been identified.  Table 2.1 
summarizes many of the known risk and protective factors for breast cancer.  Women having a 
first-degree relative with a history of breast cancer are at increased risk of the disease 
themselves.32, 33  The risk conferred by family history is further increased if the affected family 
member was diagnosed with the disease at a younger age.  For example, a woman with a first-
degree relative diagnosed with breast cancer before age 40 has a 5.7 times increased risk (99% 
CI 2.7-11.8) of being diagnosed with breast cancer before she is 40 compared to a woman of the 
same age but without a family history of breast cancer.34  Two genes, BRCA1 and BRCA2, have 
been implicated in familial breast cancer, but account for less than 10% of all breast cancer 
cases.49  BRCA mutations are most strongly related to breast cancer occurring in younger, 
premenopausal women.  Among women diagnosed with breast cancer before age 40, 9% have a 
BRCA mutation, compared to only 2% of women of any age diagnosed with breast cancer.37  
Modifiable risk factors for breast cancer, such as physical activity and alcohol intake, also have 
been documented.  Increased amounts of physical activity have been reported to result in slight 
decreases in the risk of breast cancer.47, 50, 51  Alcohol is also a risk factor for breast cancer, with a 
21% increase in breast cancer risk for women who consume two alcoholic drinks each day.44  
Despite its strong causal relationship with many other cancers, smoking does not appear to 
increase the risk of breast cancer.  A meta-analysis of 53 studies with over 22,000 breast cancer 
   
Table 2.1 Summary of known risk and protective factors for breast cancer* 
Characteristic      Estimate of Effect Study Design Reference
Risk Factors    
Older age IRR 2.09 age 50-54 versus 40-44; IRR 4.11 age 75-79 versus 40-44 Surveillance Data Calculated from SEER 
incidence rates4
Caucasian race IRR 1.16 for Caucasian versus African American; IRR 1.42 for 
Caucasian versus Asian/Pacific Islanders; IRR 1.57 for Caucasian versus 
Hispanic 
Surveillance Data Calculated from SEER 
incidence rates4
First degree relative with breast 
cancer 
RR 2.1, 95% CI 1.6-2.8 for mother diagnosed before age 40 versus 
mother not diagnosed with breast cancer; RR 1.5, 95% CI 1.1-2.2 for 
mother diagnosed after age 70 versus mother not diagnosed with breast 
cancer; RR 2.3, 95% CI 1.6-3.4 for one sister with breast cancer versus 
no sisters with breast cancer 
Prospective 
Cohort 
Colditz (1993)35
Personal history of benign breast 
disease 
RR 1.6, 95% CI 1.0-2.5 for proliferative disease without atypia; RR 3.7, 
95% CI 2.1-6.8 for proliferative disease with atypical hyperplasia 
Prospective 
Cohort 
London (1992)36
Presence of BRCA1 or BRCA2 
mutation 
BRCA1: lifetime risk 50-73% by age 50; 65-87% by age 70 
BRCA2: lifetime risk 59% by age 50; 82% by age 70 
Review National Cancer Institute 
(2005)37  
Early age at menarche RR 1.30 for age 12 at menarche versus age ≥15 at menarche, p trend 
<0.01 
Case-control Brinton (1988)38
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Table 2.1 (continued)    
 Late age at menopause RR 1.22 for age ≥55 at menopause versus age <45 at menopause, p trend 
=0.04 in analyses adjusted for interval between menopause and breast 
cancer diagnosis 
Case-control Brinton (1988)38
Later age at first birth OR 1.65, 95% CI 1.40-1.93 for age ≥31 at first birth versus <18 at first 
birth; OR 1.20, 95% CI 1.16-1.24 per 5 year increase in age at first birth 
Nested case-
control 
Lambe (1996)39
Oral contraceptive use RR 1.24, 95% CI 1.15-1.33 for current users versus never users; RR 1.01, 
95% CI 0.96-1.05 for 10 years since last use versus never users 
Meta-analysis Collaborative Group on 
Hormonal Factors in 
Breast Cancer (1996)40
Postmenopausal hormone therapy 
use 
HR 1.24, 95% CI 1.01-1.54 for estrogen + progestin users versus 
placebo; HR 0.80, 95% CI 0.62-1.04 for unopposed estrogen users versus 
placebo 
Randomized 
controlled trials 
Chlebowski (2003);41 
Stefanick (2006)42
Postmenopausal obesity RR 1.07, 95% CI 1.02-1.11 per 4 kg/m2 increase in BMI Meta-analysis van den Brandt (2000)43
Alcohol use RR 1.06, 95% CI 1.00-1.11 for alcohol intake >12g/day versus never 
drinkers 
Meta-analysis Ellison (2001)44
Mammographically dense breasts RR 4.64, 95% CI 3.64-5.91 for ≥75% density versus <5% density Meta-analysis McCormack (2006)45
10 
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Table 2.1 (continued) 
Protective Factors 
Increased parity OR 0.91, 95% CI 0.85-0.97 for 2 live births versus nulliparous; OR 0.67, 
95% CI 0.57-0.80 for 4 live birth versus nulliparous; OR 0.90, 95% CI 
0.88-0.91 per each additional live birth among parous women 
Nested case-
control 
Lambe (1996)39
History of breastfeeding Premenopausal: RR 0.78, 95% CI 0.66-0.91 for ever breastfed versus 
parous but never breastfed 
Postmenopausal: RR 1.04, 95% CI 0.95-1.14 for ever breastfed versus 
parous but never breastfed  
Case-control Newcomb (1994)46
Current physical activity RR 0.78, 95% CI 0.62-1.00 for >40 MET-hours/week current physical 
activity versus none; p trend =0.03 for increasing MET-hours/week 
current physical activity 
Prospective 
Cohort 
McTiernan (2003)47
NSAID use OR 0.80, 95% CI 0.73-0.87 for women using any NSAID vs. non-users Meta-analysis Khuder and Mutgi 
(2001)48
 
 
*Abbreviations used are incidence rate ratio, IRR; confidence interval, CI; hazard ratio, HR; relative risk, RR; MET, metabolic equivalent; NSAID, non-steroidal 
anti-inflammatory drugs
   
 
cases reported that the risk of breast cancer was not increased among ever smokers as compared 
to never smokers (RR 1.03, standard error 0.02).52 
The current knowledge about risk factors for breast cancer has led to the development of 
models which are useful for predicting a woman’s risk of the disease.  The Gail Model is a 
statistical model that is used to predict a woman’s 5-year and lifetime risk of breast cancer.53-55 
The model was developed using case-control data from the Breast Cancer Detection 
Demonstration Project.  Breast cancer risk factors included in the model are: current age, age at 
menarche, age at first live birth, number of previous breast biopsies, previous pathological 
finding of atypical hyperplasia on biopsy, and number of first degree relatives with breast 
cancer.54  This model allows for the prediction of individual probabilities for being diagnosed 
with breast cancer.55  The Gail Model has been validated and shown to be useful among women 
receiving annual screening, although limitations of the model have been noted.54, 56
2.2.1 Endogenous and exogenous estrogen and breast cancer 
Exposure to estrogen is believed to be the underlying cause of breast cancer.  Estrogen is a 
female sex hormone which is required for a number of processes in the body, including normal 
breast development.  Markers of exposure to endogenous hormones such as early age at 
menarche and late age at menopause have been found to increase breast cancer risk, while 
breastfeeding and increased parity have been consistently shown to decrease risk.38, 39, 46, 49, 57   
Increased levels of endogenous hormones have been implicated in breast cancer.  Numerous 
studies have consistently demonstrated that increased levels of endogenous estrogen are related 
to increased risk of breast cancer in postmenopausal women.58-62  For example, a meta-analysis 
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of nine prospective studies examining hormone levels in relation to postmenopausal breast 
cancer reported a two-fold increase (RR 2.00, 95% CI 1.47-2.71, p trend<0.001) in risk of breast 
cancer for women in the highest quintile of estradiol (E2) compared to those in the lowest 
quintile.59  The association between E2 and premenopausal breast cancer, however, is far less 
clear.  Estradiol levels fluctuate throughout the menstrual cycle, with peaks occurring towards 
the ends of both the follicular and luteal phases.63  Some studies have reported similar positive 
associations between E2 and breast cancer among premenopausal women,62, 64-66 while others 
have reported no association.67-73  Studies of E2 and premenopausal breast cancer have been 
limited by a number of factors, however, including small numbers,62, 65, 67, 70, 71, 73 failure to 
control for phase of the menstrual cycle,65, 72 and inclusion of cases that were premenopausal at 
the time of the blood sample but not at the time of breast cancer diagnosis.65, 68  The largest and 
most recent study, a nested case-control study of 197 cases and 394 matched controls from the 
Nurses’ Health Study II, reported that free E2 (RR 2.4, 95% CI 1.3-4.5 for 4th vs 1st quartile) and 
total E2 (RR 2.1, 95% CI 1.1-4.1 for 4th vs 1st quartile) levels during the follicular phase were 
positively associated with breast cancer, while free and total E2 levels during the luteal phase 
were not.64  Though this study was prospective, carefully controlled for phase of the menstrual 
cycle, and employed large numbers, the menopausal status of the cases at the time of diagnosis 
was unclear.   
Exposure to exogenous estrogen has been related to breast cancer risk.  Use of oral 
contraceptives has been shown to slightly increase the risk of breast cancer, primarily among 
women who are current or recent users.40, 49  Use of postmenopausal hormone therapy (HT) has 
been shown to increase risk of breast cancer by 10-80% depending on the duration of use.41, 74, 75  
The results of the Women’s Health Initiative, however, showed that this increased risk may 
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occur only among users of combined estrogen and progestin regimens41, 75 and not among 
women using unopposed estrogen.42, 76  Women randomized to take a combined estrogen and 
progestin pill had a 24% increase in risk of invasive breast cancer compared to those randomized 
to placebo (HR 1.24, 95% CI 1.01-1.54),41 while, in a separate study, women randomized to an 
unopposed estrogen pill had a similar risk of invasive breast cancer as women randomized to 
placebo (HR 0.80, 95% CI 0.62-1.04).42
2.2.2  Obesity and breast cancer 
Obesity has emerged as a significant risk factor for postmenopausal breast cancer and is possibly 
a protective factor for premenopausal breast cancer.  Further, adjustment for measures of obesity 
attenuates, but does not eliminate, the racial difference in stage at breast cancer diagnosis.77, 78  
The most frequently used measure of obesity is the body mass index (BMI).  BMI is a measure 
of weight for height and is calculated as weight in kilograms divided by the square of height in 
meters.  The World Health Organization has developed the following BMI categories: 
underweight (<18.5kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), and 
obese (≥ 30.0kg/m2).79
2.2.2.1 Obesity and postmenopausal breast cancer 
A striking difference in the effect of obesity on breast cancer risk appears when analyses are 
conducted separately among pre- and postmenopausal women.  Among postmenopausal women, 
some studies report either no association or only a weak association between BMI and breast 
cancer risk,17, 80-85 while the vast majority report that increased BMI significantly raises the risk 
of breast cancer.43, 85-98  For example, a large case-control study reported a 4% (OR 1.04, 95% CI 
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1.03-1.04) increase in the odds of postmenopausal breast cancer for every 1 kg/m2 increase in 
current BMI.95  A meta-analysis of prospective cohort studies found that the risk of breast cancer 
increased 7% with each 4 kg/m2 increase in BMI among postmenopausal women (RR 1.07, 95% 
CI 1.02-1.11).43  Some studies have reported that the positive association between BMI and 
postmenopausal breast cancer risk occurs only or more strongly among women with certain other 
risk factors, such as a family history of breast cancer97 or older age.91, 99  A consistent finding is 
that elevated BMI increases the risk of postmenopausal breast cancer only among women who 
have never used HT.90, 92, 100-103  For example, a study of postmenopausal women enrolled in the 
Women’s Health Initiative Observational Study reported no association with BMI among HT 
users (ever or current), but that the risk of breast cancer was more than doubled among obese 
women who had never used HT (RR 2.52, 95% CI 1.62-3.93 for BMI ≥31.1 vs. ≤22.6 kg/m2).102
Studies have also considered other measures of anthropometry in relation to risk of 
postmenopausal breast cancer.  Increased weight was positively associated with postmenopausal 
breast cancer in some studies43, 92, 95, 96, 104, 105 but was not associated with breast cancer in 
others.81-85  This association between increased weight and postmenopausal breast cancer risk 
may only occur among women who have never used HT.102  Central adiposity, commonly 
measured by waist circumference or waist-to-hip ratio, has been positively associated with 
postmenopausal breast cancer,106, 107 and one study reported that this effect was stronger in 
women who never used HT.106  Finally, multiple studies have reported that weight gain during 
adulthood increases postmenopausal breast cancer risk84, 92, 94, 95, 97, 103, 108-110 while weight loss 
can reduce this risk.110, 111  Thus it is well-documented that obesity increases breast cancer risk 
among postmenopausal women. 
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2.2.2.2 Obesity and premenopausal breast cancer 
On the contrary, obesity appears to have the exact opposite effect on breast cancer risk among 
premenopausal women.  Few studies report either a positive association87 or no association83, 86, 
89, 96, 98, 112 between BMI and premenopausal breast cancer.  Many studies, however, have 
reported that BMI is inversely associated with premenopausal or early-age breast cancer risk.43, 
80, 84, 85, 93, 103, 113  For example, the same meta-analysis that reported a positive association 
between BMI and postmenopausal breast cancer risk reported a significant negative association 
between BMI and premenopausal breast cancer risk, with an 11% reduction in risk for every 4 
kg/m2 increase in BMI (RR 0.89, 95% CI 0.81-0.97).43  The effect of BMI on premenopausal 
breast cancer risk may vary by race, with one study reporting a negative association among 
Caucasian women but no association among African American women.17
Similar relationships between obesity and premenopausal breast cancer risk are observed 
when other anthropometric measures are considered.  Weight has been reported to either be 
negatively associated43, 84, 85, 112-114 or not associated83, 96, 104, 105 with premenopausal breast 
cancer.  One study reported a positive association between waist-to-hip ratio and risk of 
premenopausal breast cancer,107 while another reported no association.106  The effect of weight 
gain on premenopausal breast cancer may also vary by race, with studies of Caucasian women 
reporting either no103, 108 or a negative association,112 while a study of Hispanic women reported 
a non-significant positive association.108  Overall, the totality of the current evidence suggests 
that obesity reduces the risk of premenopausal breast cancer. 
2.2.2.3 Mechanisms relating obesity to breast cancer risk 
At first consideration, it appears counterintuitive that a single risk factor could impart such 
opposite effects on the risk of one disease depending on the menopausal status of the woman.  
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Consideration of the biological mechanisms which may explain the associations between obesity 
and pre- and postmenopausal breast cancer, however, clarifies why such a paradoxical effect of 
obesity exists.  Both effects appear to be related to changes in endogenous hormone exposure 
which occur among obese pre- and postmenopausal women.  As noted in a review by Key et 
al.,115 in premenopausal women, obesity increases the number of anovulatory menstrual cycles.  
While this may have only a slight effect on altering estrogen levels due to homeostatic control 
mechanisms, progesterone levels are substantially decreased in anovulatory cycles.115  
Progesterone has been implicated in cancer risk, and decreased progesterone may thus decrease 
the risk of breast cancer among premenopausal obese women.115  Further, in postmenopausal 
women the ovaries no longer produce estrogen or progesterone, and levels of these sex hormones 
are significantly reduced relative to levels observed in premenopausal women.115  The primary 
source of estrogen in postmenopausal women is through the conversion of androstenedione to 
estrone catalyzed by aromatase which occurs in the adipose tissue, including the adipose tissue 
of the breast.115, 116  Estrogen levels among postmenopausal women have a strong, positive 
relationship with obesity,116 and this increased estrogen may promote carcinogenesis among 
postmenopausal women.  
In both pre- and postmenopausal women, sex hormone binding globulin (SHBG) is 
inversely associated with BMI.117  SHBG can bind estrogen and thereby reduce the pool of 
bioavailable estrogen.  In premenopausal women the body manages to maintain homeostatic 
control of estrogen levels such that the impact of decreased SHBG is minimal, while in 
postmenopausal women these controls do not exist and decreased levels of SHBG result in 
substantially increased levels of bioavailable estrogen.115  Thus this increased endogenous 
estrogen exposure among obese postmenopausal women may confer an increased risk of breast 
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cancer.  Other possible mechanisms to explain associations between obesity and breast cancer 
risk include effects of hyperinsulinemia as well as mechanisms involving leptin and 
adiponectin.116  These mechanisms are currently less well-understood in relation to breast cancer 
etiology and do not appear to account for the divergent effects of obesity on the risk of pre- and 
postmenopausal breast cancer. 
2.3 MAMMOGRAPHIC BREAST DENSITY 
It is generally accepted that mammography represents the best opportunity for early detection of 
breast cancer.  Current American Cancer Society guidelines state that women over the age of 40 
should receive annual mammograms as a means of screening for breast cancer.2  Although 
mammography is most often used to look for signs of tumors or other breast abnormalities, it is 
believed that the composition of the breast may also yield information about a woman’s risk of 
breast cancer.  The breast is composed of different types of tissues, and the composition varies 
from woman to woman.  The primary functional units of the breast are the lobules, which are 
connected to the nipple through a series of ducts; these structural and functional units are 
composed of epithelial tissue.  The majority of the breast is composed of fat tissue, except during 
lactation when the breast consists primarily of glandular units.  After menopause the number of 
lobules substantially decreases and the amount of fat tissue in the breast increases.118  Fat appears 
dark on a mammogram because it is radiologically lucent, while epithelial and connective tissues 
appear bright because they are radiologically dense. 
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2.3.1 Methods of measuring mammographic breast density 
There are a variety of methods that have been developed to measure mammographic breast 
density.  These methods can be grouped according to whether they represent qualitative or 
quantitative measurements. 
2.3.1.1 Qualitative methods 
Wolfe first hypothesized that the distribution of different types of tissue in the breast may be 
related to risk of breast cancer.119, 120  He proposed a classification system of breast density in 
which the parenchymal pattern was categorized in order of risk of breast cancer as N1 (primarily 
fat tissue), P1 (mostly fat tissue but with some dense areas of less than 25% of the total breast), 
P2 (more than 25% of the breast composed of dense tissue along with a noticeable ductal 
pattern), and DY (primarily homogeneous dense tissue and no conspicuous ductal pattern).120, 121  
Although these “Wolfe patterns,” as they are now called, are a qualitative measure of breast 
density and are, therefore, somewhat subjective, the P2 and DY patterns have been repeatedly 
linked to an increased risk of breast cancer as compared to the N1 and P1 patterns.120-123  
Subsequent to the development of the Wolfe patterns, other qualitative methods have 
been proposed.  The Tabar classification describes five patterns of breast density “based on 
anatomic-mammographic correlation using three-dimensional, sub-gross (thick-slice) 
technique.”124  Pattern I is considered low risk and is characterized by scalloped contours and 
Cooper’s ligaments, terminal ductal lobular units that are evenly scattered, and oval-shaped areas 
where fatty replacement of tissue has occurred.  Pattern II demonstrates complete fatty 
replacement and Pattern III shows a prominent duct pattern in the retroareolar area; both Patterns 
II and III also are considered low risk patterns.  Patterns IV and V are considered to be high risk; 
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Pattern IV is characterized by nodular and linear densities throughout the breast, and Pattern V is 
described as having extensive fibrosis with an appearance similar to ground glass.124  The first 
paper reporting the Tabar classification showed that agreement between the Wolfe method and 
Tabar method in terms of classifying high-risk versus low-risk mammograms was poor.124  This 
appeared to be largely because a large proportion (45.6%) of the evaluated mammograms were 
classified as Wolfe DY (high risk) yet Tabar Pattern I (low risk).124  The creator of the Tabar 
method performed both the Wolfe and Tabar assessments in this study, however, and this may 
have led to bias in the measurements. 
A third commonly used qualitative method for assessing breast density is the Breast 
Imaging Reporting and Data System (BI-RADS).  This method is the most commonly used 
method of assessing density by radiologists.  BI-RADS recognizes four class of density: 1) breast 
is composed almost entirely of fat, 2) breast contains scattered fibroglandular densities, 3) breast 
is heterogeneously dense, and 4) breast is extremely dense.125  The BI-RADS score is typically 
reported by the radiologist when reviewing mammograms.45, 125
Although each method has been well-described, the Wolfe, Tabar, and BI-RADS systems 
are all qualitative methods and are therefore prone to a high-degree of subjectivity and 
potentially lower reproducibility.  In fact, studies evaluating the reproducibility of these three 
methods between raters have reported only moderate reproducibility.126-128  For example, one 
study of Tabar patterns reported an intra-rater reliability of κ=0.65.127  A study of the reliability 
of Wolfe pattern assessment reported an intra-observer intraclass correlation coeffiecient (ICC) 
of 0.68 and an inter-observer ICC of 0.65,126 indicating good reliability.  Finally, a study of inter-
observer agreement of BI-RADS density assessments reported an overall reliability of κ=0.43, 
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with poor agreement for the “extremely dense” category (κ=0.17) and highest agreement for the 
“fatty” category (κ=0.76).128  
2.3.1.2 Quantitative methods 
More recently, methods have been developed which allow for quantitative measurement of 
breast density.  These studies report percent density, which is calculated as the percentage of the 
breast comprised of dense areas.  One method of quantitative assessment is manual planimetry. 
This method is performed by using a wax pencil to trace the total area of the breast and all areas 
of density (excluding biopsy scars, Cooper’s ligaments, and breast masses) onto a clear acetate 
sheet placed over the mammogram.  A compensating polar planimeter is then used to measure 
the total area of the breast and the area of breast density.129-131  Computerized planimetry can 
also be used in a similar manner.  This method uses either digital mammograms or film 
mammograms that have been digitized. The total breast area and areas of density are outlined on 
the computer using a mouse or other tracing device, and then the respective areas are calculated 
by the computer.132, 133  Intra-reader reliability is reported to be high, with intra-class correlation 
coeffiecients of 0.93 for percent density, 0.82 for absolute dense area, and 0.97 for non-dense 
area.133
A third method of quantitative density assessment is that of computerized thresholding.  
This technique can be used with either digital mammograms or film mammograms that have 
been digitized.  The mammogram is viewed on the computer and the reader first selects a 
“threshold brightness” that distinguishes the breast tissue from the background of the 
mammogram.  Next the reader chooses another “threshold brightness” which differentiates 
between dense and non-dense tissue.  The computer uses these thresholds to identify both the 
total area of the breast and areas of density, and the number of pixels within these areas are 
21 
   
summed to give a measure of the total breast area and the dense area.134-138  The intra- and inter-
reader reliability of density measurements using the computerized thresholding technique have 
been shown to be very high, both having ICCs >0.9.138
2.3.2 Mammographic breast density and risk of breast cancer 
Numerous studies have investigated associations between breast density and breast cancer since 
Wolfe hypothesized such a relationship over thirty years ago.  Recently, McCormack and dos 
Santos Silva performed a meta-analysis of such studies.45  These authors conducted a systematic 
review with well-defined search criteria to identify all published studies examining associations 
between mammographic breast density and breast cancer risk, including various methods of 
density measurement.  Their search strategy and eligibility criteria resulted in the identification 
of 42 articles which were further grouped into incidence studies, prevalence studies, and studies 
in symptomatic populations and by the type of density measurement used.  Overall, the results of 
the meta-analysis showed a high degree of consistency among the identified studies.  The 
combined relative risk from incidence studies of the general population using Wolfe patterns was 
1.76 (95% CI 1.41-2.19) for P1 versus N1, 3.05 (95% CI 2.54-3.66) for P2 versus N1, and 3.98 
(95% CI 2.53-6.27) for DY versus N1.  These point estimates are slightly higher than those 
calculated using prevalence studies of the general population: 1.25 (95% CI 1.02-1.54) for P1 
versus N1, 1.97 (95% CI 1.29-3.00) for P2 versus N1, and 2.92 (95% CI 1.98-2.97) for DY 
versus N1.  Combined relative risk estimates of the two studies using the BIRADS classification 
with fatty breast as the referent group were 2.04 (95% CI 1.56-2.67) for scattered density, 2.81 
(95% CI 2.13-3.71) for heterogeneously dense, and 4.08 (95% CI 2.96-5.63) for extremely 
dense.  Only one study used the Tabar classification, thus a combined relative risk was not 
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provided;45 this study, however, reported that the odds of breast cancer were substantially 
increased among women with Tabar pattern IV versus Tabar pattern I (adjusted OR 2.42, 95% 
CI 0.98-5.97).139
Similar combined estimates of relative risks using quantitative percent density 
assessments were also reported.  Compared to having less than 5% breast density, incidence 
studies had combined relative risks of 1.79 (95% CI 1.48-2.16) for 5-24% density, 2.11 (95% CI 
1.70-2.63) for 25-49% density, 2.92 (95% CI 2.49-3.42) for 50-74% density, and 4.64 (95% CI 
3.64-5.91) for ≥75% density.  The combined relative risk estimates for prevalence studies were 
similar but slightly lower: 1.39 (95% CI 1.10-1.76) for 5-24% density, 2.22 (95% CI 1.75-2.81) 
for 25-49% density, 2.93 (95% CI 2.27-3.79) for 50-74% density, and 3.67 (95% CI 2.72-4.96) 
for ≥75% density versus <5% density.45
The results of this meta-analysis demonstrate a number of important findings regarding 
breast density.  First, there is clearly strong evidence of an association between breast density 
and risk of breast cancer.  This finding is consistent regardless of the methods employed to 
measure breast density and whether the studies are performed using incident or prevalent cases.  
Second, the results show that masking bias, in which cancers are “masked” by high breast 
density, is relevant to the study of breast density and breast cancer.  Presence of masking bias 
would result in underestimated relative risks reported by prevalence studies, in which cancers 
were detected at the time of screening, and overestimated relative risks reported by incidence 
studies; this is consistent with the results of the present meta-analysis.  Relative risk estimates 
were also lower after excluding cancers diagnosed in the year after the density measurement.  
Comparing women with ≥75% density to those with <5% density, the meta-analysis reported 
combined relative risks of 4.64 (95% CI 3.64-5.91) for all eligible studies, 4.52 (95% CI 3.54-
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5.78) among studies excluding cancers diagnosed in the first year, and 13.38 (95% CI 2.73-66.6) 
among studies including cancers diagnosed in the first year.45  Third, the review and meta-
analysis reported that breast density remains associated with breast cancer risk regardless of age, 
menopausal status, or race.45
This meta-analysis included studies indexed in the Medline, EMBASE, and Pubmed 
databases on November 18, 2005.  Therefore, the same search strategy employed in this meta-
analysis was used to identify additional relevant articles published after this date through January 
31, 2007.  The search strategy used is well-described by McCormack and dos Santos Silva.45  
Briefly, the Medline, EMBASE, and PubMed databases were searched using keywords related to 
cancer, mammography, and breast density and results were limited to English language journal 
articles.  To update the literature review, the search was further restricted to articles published in 
2005-2007.  This search resulted in the identification of one additional article evaluating breast 
density in relation to breast cancer risk.140  Mitchell et al. reported that higher percent breast 
density remains a strong risk factor for breast cancer among women with known 
BRCA1/BRCA2 mutations.  The odds of breast cancer among mutation carriers with density 
greater than or equal to 50% were twice that of mutation carriers with less than 50% density (OR 
2.29, 95% CI 1.23-4.26).140
As noted previously, mammographic breast density may be a stronger risk factor for 
postmenopausal breast cancer than for premenopausal breast cancer.6  For example, a nested 
case-control study of 1,717 pre- and 1,208 postmenopausal women reported that breast cancer 
risk increased with increasing percent breast density, but that the point estimates were higher 
among postmenopausal women.  Compared to a premenopausal woman with 0% breast density, 
a premenopausal woman with 1-24% breast density had an odds ratio of 1.47 (95% CI 0.95-2.3) 
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and one with ≥75% density had an odds ratio of 3.79 (95% CI 2.3-6.2), while a postmenopausal 
woman had odds ratios of 1.79 (95% CI 1.3-2.5) for 1-24% density and 5.82 (95% CI 3.0-11.3) 
for ≥75% density compared to a postmenopausal woman with 0% density.141
Changes in breast density have also been related to subsequent changes in risk of breast 
cancer.  One study reported that women who consistently had high-risk Wolfe patterns (P2 or 
DY) had over twice the risk of breast cancer (RR 2.2, 95% CI 1.2-3.9) as compared to women 
who consistently had low-risk Wolfe patterns (N1 or P1).  Those women whose patterns on the 
first mammogram were either P2 or DY but then had a low-risk pattern on a subsequent 
mammogram had similar risk to women with consistently low-risk Wolfe patterns (RR 1.2, 95% 
CI 0.5-2.8).142  It appears that breast density may be useful as a biomarker of breast cancer risk.  
In fact, breast density has been used as an intermediate or surrogate endpoint in at least two 
intervention trials investigating the effects of diet on breast cancer risk.136, 143  Though the ability 
of breast density to change in response to known risk factors for breast cancer, such as use of 
postmenopausal hormone therapy, has been established (see section 2.4.3.2), it is unclear what 
these changes in breast density mean in terms of altering breast cancer risk.144  To date few 
studies have reported on how changes in breast density relate to changes in breast cancer risk.  
One case-control study that examined this issue reported no statistically significant associations 
between change in percent breast density and breast cancer risk.145  Further studies are reported 
to be currently in progress.144
2.3.3 Mammographic breast density and breast cancer risk factors 
In general, risk factors for breast cancer also increase mammographic breast density.  For 
example nulliparity and later age at first birth have been associated with increased density.146  On 
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the other hand, breast density has been shown to decrease with increasing age,146-149 although 
increased age is a risk factor for breast cancer.  This apparent contradiction has been explained 
by noting that breast density may be related to the rate of change in breast cancer incidence 
rather than the incidence of breast cancer itself.6  The menopausal transition may more strongly 
influence changes in breast density than age, however.  A study of women who were 
premenopausal at a baseline mammogram and then postmenopausal at a subsequent 
mammogram and were matched on age to women who remained premenopausal at both 
mammograms showed that percent density decreased more among the women who transitioned 
through menopause than those who did not.150  Age may not be related to breast density among 
women over age 70, however.151  A study of 239 participants from the Study of Osteoporotic 
Fractures (SOF) reported that only BMI, parity, surgical menopause, and current smoking status 
were significantly associated with mammographic breast density in multivariable analyses.  The 
mean age of these women at the time of consent for obtaining the most recent mammogram was 
78.6 (SD 3.8), thus indicating that the factors associated with breast density among older women 
may differ from premenopausal and younger postmenopausal women.151
It appears that there is a genetic component to mammographic breast density.  Boyd et al. 
reported the results of two twin studies, showing correlation coefficients for percent breast 
density of 0.61 and 0.67 for monozygotic twins and correlation coefficients of 0.25 and 0.27 for 
dizygotic twins.152  In these studies genetic factors explained 60-75% of the variability in percent 
breast density.152  Specific genes responsible for differences in breast density have yet to be 
conclusively identified, however. 
Despite the relationships between breast cancer risk factors and breast density, presence 
of other breast cancer risk factors does not fully account for the association between increased 
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breast density and risk of breast cancer.6  Mammographic breast density is indeed an independent 
risk factor for breast cancer. 
2.3.3.1 Endogenous hormones and mammographic density 
In general, studies have not shown statistically significant associations between levels of 
endogenous hormones and mammographic breast density.  The previously described breast 
density study from SOF reported no associations between percent breast density and total 
estradiol, estrone, free testosterone, total testosterone, dehydroepiandrosterone (DHEA) sulfate, 
or SHBG.151  Another study of postmenopausal women reported no associations between percent 
breast density and estrone, estradiol, free estradiol, testosterone, free testosterone, 
androstenedione, DHEA sulfate, SHBG, or follicle stimulating hormone (FSH) in women who 
had never used HT.153  This study did, however, report moderate negative associations between 
estrone, estradiol, free estradiol, testosterone, free testosterone, androstenedione, DHEA, and 
FSH among women who were former users of HT and had used HT within the previous 5 
years.153  It is important to note that this study population consisted of overweight, nonsmoking, 
postmenopausal women who were currently non-HT users enrolled in a separate randomized 
controlled trial, and who had a mammogram within 12 months prior through 1 month after 
enrollment; thus, this highly selected population may not be generalizable to other populations of 
women.  Further, only 88 women comprised the study population.153  Boyd et al.154 reported 
slight, negative associations between free estradiol and both percent density and dense area in 
postmenopausal women after adjustment for age and waist circumference.  They also reported a 
very small positive association between SHBG and percent density and dense area among these 
women that remained after adjustment for age and waist circumference.  Total estradiol and 
progesterone were not significantly associated with either percent density or dense area after 
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adjustment.154  An important limitation of this study, however, is that the blood samples were not 
taken at the time of mammography, but were 32 weeks after the date of mammography on 
average.154
A similar lack of associations has been observed in premenopausal women as well.  In 
the above-referenced study, Boyd et al. also demonstrated that no association between free 
estradiol, SHBG, or progesterone and either percent density or dense area was apparent in 
premenopausal women after adjustment for age and waist circumference.154  Another study of 
premenopausal women reported that progesterone, SHBG, estrone, total estradiol, and free 
estradiol were not associated with either percent breast density or dense area after adjustment for 
age, body weight, height, ethnicity, age at menarche, parity, and age at first birth.155  The timing 
of the blood draw in relation to the mammogram was unclear in this study, although care was 
taken to standardize the blood collection by menstrual cycle phase.155
2.3.3.2 Exogenous hormones and mammographic density 
Studies have repeatedly shown that increased breast density is related to use of postmenopausal 
hormone therapy (HT).156-172  The percent of women whose density changes after initiating HT 
varies by type of HT used, however, with increased density occurring more often in estrogen 
plus progestin regimens than with estrogen alone regimens.156-158, 162, 163, 165, 166, 168-170  In a sub-
study of the WHI, investigators reported that 75% of women on active treatment experienced an 
increase in breast density after 1 year.  The mean change in percent density from baseline to year 
1 was 6.0% (95% CI 4.6 – 7.5) in the treatment group compared to -0.9% (95% CI -1.5 – -0.2) in 
the placebo group.172  Studies have also reported that short-term cessation of HT use prior to 
mammography results in a decrease in breast density173 or less frequent increase in density 
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compared to women who continue to take HT,165 although even after more than 2 months of 
cessation, there appear to be residual effects of HT on density.174 
Data on the effect of oral contraceptive use on breast density are limited, likely because 
the majority of women for whom screening mammography is recommended (age ≥40) are 
postmenopausal and would not be currently using oral contraceptives.  One study has reported, 
however, that use of oral contraceptives prior to the first birth was not related to breast density 
later in life.175
2.3.4 Anthropometry and mammographic density 
As previously noted, increased BMI results in an increased risk of breast cancer among 
postmenopausal women (see section 2.3.2.1).  Studies of mammographic breast density, 
however, consistently report that increased weight or BMI is associated with lower percent breast 
density.127, 133, 175-181  For example, a study of pre- and postmenopausal women reported that the 
difference in percent density between the 3rd and 1st quartiles of BMI was a 5.2 percentage-point 
decrease among premenopausal women and a 4.7 percentage-point decrease among 
postmenopausal women.178
While one study evaluating the possibility of interactions between weight or BMI and 
breast density on risk of breast cancer found these interactions to be non-significant,180 others 
have noted significant effect modification.  Ursin et al. reported a U-shaped relationship, with 
women having the lowest and the highest BMI demonstrating the strongest association between 
breast density and risk of breast cancer.182  Duffy et al. also reported that when evaluating the 
relationship between high-risk Tabar patterns and breast cancer risk, only those women who 
were both overweight and had dense breasts showed an increased risk of breast cancer (OR 2.30, 
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95% CI 0.98-5.40 for women with BMI >25 kg/m2 and dense breasts compared to those with 
BMI <25 kg/m2 and non-dense breasts).183  Most recently, Boyd et al. investigated associations 
between anthropometry, breast density and breast cancer risk in a case-control study of pre- and 
postmenopausal women.184  Their results showed that BMI was not significantly associated with 
breast cancer in either pre- or postmenopausal women prior to adjustment for breast density.  
Additional control for percent breast density resulted in increased and statistically significant 
associations with breast cancer overall and for postmenopausal women.184  Further, the 
association between BMI and breast cancer among premenopausal women was strengthened and 
made positive with adjustment for percent density, yet still remained non-significant.184  
Analyses relating percent breast density to breast cancer risk showed increased odds ratios for 
this relationship after additional adjustment for BMI.  These findings led the authors to conclude 
that anthropometry and breast density are confounders of one another in relation to breast cancer 
risk.  Further, the authors suggested that failure to adjust for breast density in previous studies 
may explain the negative associations between BMI and breast cancer that are commonly 
reported among premenopausal women.184
Observed differences in mammographic density by race/ethnicity may also be explained 
by racial and ethnic differences in body size.134  Indeed, body size does confound the relationship 
between breast density and breast cancer risk and therefore anthropometric measures must be 
taken into account in studies of breast density.176, 177, 180
The amount of fat present in the breast is strongly related to BMI.185  Recent studies have 
therefore evaluated the effects of anthropometric measures separately on the size of the dense 
and non-dense areas of the breast.133, 179, 186  These studies have all shown that weight and BMI 
are positively associated with the size of the non-dense area.133, 179, 186  Two studies report 
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negative correlations between weight or BMI and the size of the dense area,179, 186 while the third 
reports a positive, yet non-significant, association.133  Boyd et al. reported the correlation 
between BMI and the size of the dense area to be -0.191 (p=0.002).  These authors also noted 
that weight and height differences explained significant amounts of the variance in size of the 
non-dense area but not of the size of the dense area.179  After controlling for non-dense area, both 
BMI and weight had weakly positive associations with dense breast area (both p=0.01).179  Haars 
et al. reported that BMI alone explains 40% of the variance in size of non-dense tissue, yet only 
17% of the variance in size of dense tissue.133  Both groups of researchers support the use of 
absolute measures of density, rather than a relative measure such as percent density, when 
studying mammographic breast density as an indicator of breast cancer risk.133, 179  No 
prospective study, however, has been specifically designed to evaluate the effect of weight 
change on the size of the dense and non-dense tissues of the breast. 
The majority of studies that have investigated associations between anthropometry and 
mammographic breast density have employed a cross-sectional design.  Therefore causality 
could not be established.  A few studies have investigated how change in anthropometric 
measures affects breast density (Table 2.2).  One study reported that the size of the dense area 
decreased among women who lost weight, although the average weight loss was quite small (0.3 
kg).136  A separate study reported that women who had gained weight in recent years had an 
increased risk of having a high-risk Wolfe pattern compared to women with a consistently 
elevated BMI throughout their lifetime.181  Finally, a recent study found that percent density 
decreased more slowly among overweight and obese women compared to normal weight 
women, with overweight women having a 1.9 unit decrease and obese women having a 3.6 unit 
decrease in percent density per decade.187  All three of these studies have significant
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Table 2.2 Summary of studies investigating the impact of change in anthropometry on mammographic breast density 
 
Author Population Study Design Results Other Comments
Boyd (1997)136 N=817 
Mean age=46 
Mean BMI=23kg/m2
Randomized 
controlled trial of 
low fat, high 
carbohydrate diet 
vs. usual diet 
Dense area decreases among women 
who lost weight (weight change β=98.8, 
p=0.04) 
Change only over 2 years; very small 
change in weight (-0.3kg in intervention, 
+0.9kg in control) 
McCormack (2003)181 N=1,298 
Mean age=51 
Middle quintile of 
BMI 25.16-27.57kg/m2 
Retrospective cohort High-risk Wolfe patterns increased 
among women with larger increases in 
BMI between ages 43-53 (OR 1.46, 95% 
CI 1.27-1.68) 
Used Wolfe patterns rather than a 
quantitative measure, only assessed one 
mammogram and closest BMI measure 
was an average of 2 years after the 
mammogram 
Maskarinec (2006)187 N=1,274 
Mean age=58.7 
Mean BMI=24.9kg/m2
Nested case-control Overweight and obese women have 
more gradual decline in percent density 
per decade (-1.9% p=0.04, and -3.6% 
p=0.01, respectively) compared to 
normal weight women 
Self-reported height and weight 
   
methodological limitations, including limited weight change, self-reported anthropometric 
measurements, or use of a non-quantitative measure of breast density.  Clearly the impact of 
changes in anthropometry must be understood, as failure to properly account for their influence 
on breast density could lead to incorrect analyses and conclusions of studies employing 
mammographic breast density as a surrogate endpoint.  Prospective studies examining 
longitudinal associations between anthropometric measures and measures of mammographic 
breast density, however, have not been conducted. 
2.3.5 Mammographic density as a surrogate endpoint for breast cancer 
A surrogate endpoint is a factor which may be measured and used as a substitute for the 
occurrence of a true endpoint, such as disease incidence, in observational and experimental 
studies.188  Such surrogate endpoints have numerous advantages, including allowing for studies 
to be conducted with fewer subjects and at a lower cost and also aiding in the understanding of 
the mechanisms of cancer development.188  Prentice has defined a surrogate endpoint as a factor 
for which testing the null hypothesis that an exposure is not related to the factor is equivalent to 
testing the null hypothesis that the exposure is not related to disease.188  Schatzkin and Gail 
outlined the following criteria for evaluating the validity of a factor as a surrogate endpoint: 1) 
the surrogate measure must be associated with the true outcome, 2) the exposure of interest must 
also be associated with the surrogate measure, and 3) the entire effect of the exposure on the true 
outcome must be mediated by the surrogate measure.189  Some have stated that these criteria are 
too stringent and have suggested modifications.188  Most notably, it is rare that criterion #3 is 
perfectly met, as few surrogate endpoints are able to capture the entire effect of an exposure on a 
true outcome.188, 189  
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Mammographic breast density may be useful as a surrogate endpoint in studies of breast 
cancer.  Indeed, some clinical trials have utilized changes in breast density as a surrogate 
endpoint rather than waiting to observe the true outcome of breast cancer.136, 143  Breast density 
does in fact satisfy criterion #1, in that higher breast density has been consistently shown to be 
strongly associated with risk of breast cancer (see section 2.4.2).  Whether or not the final two 
criteria are met for breast density, however, depends on the exposure being studied.  It is possible 
that a surrogate endpoint may be valid for some exposures yet not for others, and therefore the 
endpoint must be validated separately for each exposure.188, 189  As an illustration of this point, 
Figure 2.2 provides examples of exposures for which percent breast density may or may not be 
valid surrogate markers for breast cancer.  Use of postmenopausal hormone therapy (Figure 
2.2.A) is known to result in both increased breast density (see section 2.4.3.2) and increased 
breast cancer risk (see section 2.3.1); thus it satisfies both criteria #1 and #2.  It is unlikely that 
breast density mediates the entire effect of hormone therapy on breast cancer (criterion #3), 
however, and other mechanisms are likely involved as well.  It is rare that a surrogate endpoint 
fully satisfies criterion #3, however.188, 189   
Boyd et al. recently evaluated whether breast density was a valid surrogate endpoint in 
studies of hormone therapy as a risk factor for breast cancer.190  Their results showed that the 
association between hormone therapy use and breast cancer was only slightly attenuated after 
adjustment for breast density, thus failing to meet criterion #3.  The authors concluded that breast 
density is not a valid surrogate endpoint in this case.190  It should be noted, however, that 
hormone therapy use was not associated with breast cancer risk prior to adjustment for breast 
density either, although this association has been well-established by numerous previous studies.   
34 
   
B. Example of an exposure for which breast density is not a valid surrogate end-point: 
Postmenopausal obesity
High Percent 
Breast Density Breast CancerHormone Therapy
Other Mechanisms
High Percent 
Breast Density Breast Cancer
Postmenopausal 
Obesity
↑ Non-dense 
Breast Area
X
↑ Estrogen 
Exposure to Breast 
Tissue
A. Example of an exposure for which breast density may be valid as a surrogate 
end-point: Hormone therapy
 
Figure 2.2 Illustration of the validity of mammographic breast density as a surrogate endpoint for 
breast cancer 
 
 
Breast Density Breast Cancer
Reproductive 
FactorsGenetic Factors Behavioral Factors
 
Figure 2.3 Proposed causal pathway for breast cancer 
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Further, information on the types of hormone therapy used was not available.  This could explain 
the lack of significant findings if the study population was composed of users of combined 
estrogen formulations as well as users of unopposed estrogen formulations.  As previously 
discussed, the Women’s Health Initiative has shown that combined estrogen formulations 
resulted in increased risk of breast cancer while unopposed formulations did not.41, 42, 75, 76  Thus, 
although this appears to be the first study to evaluate breast density according to the criteria for 
surrogate endpoints, the study did have some important limitations and cannot be considered 
conclusive without corroboration by future studies. 
On the other hand, postmenopausal obesity (Figure 2.2.B) is known to result in decreased 
percent breast density (see section 2.4.4); thus the direction of the association between this 
exposure and breast density does not satisfy criterion #1.  Therefore, breast density is unlikely to 
be valid as a surrogate endpoint for breast cancer in studies evaluating postmenopausal obesity 
(or other anthropometric measures).  This lack of validity for the exposure of postmenopausal 
obesity may be explained by the fact that obese women have substantially increased non-dense 
breast areas.  Percent breast density is thus decreased in obese women because the non-dense 
area of the breast is so large relative to the size of the dense area.  An obese woman might have a 
higher dense area (and thus more tissue at risk for developing breast cancer) than a non-obese 
woman, however this fact would be obscured by studying only percent density.  Therefore 
absolute measures of breast density, such as the dense breast area, are likely to be more 
informative and less confounded by anthropometry than are relative measures, such as percent 
density.  Further, it is possible that for the exposure of obesity, the non-dense area of the breast 
may be highly relevant to breast cancer development.  As shown in Figure 2.2.B, higher non-
dense breast area, which represents adipose tissue, may result in increased estrogen exposure to 
36 
   
the nearby dense breast tissue due to the conversion of androstenedione to estrogen that occurs in 
adipose tissue.133, 187  This increased estrogen exposure of the ducts and lobules where cancers 
arise may result in increased risk of breast cancer.  Thus it appears that mammographic breast 
density may be a valid surrogate endpoint for some, but not all, relevant exposures.   
2.3.6 Proposed causal model for breast cancer 
A causal pathway for breast cancer relating breast density, genetic factors, reproductive 
factors, and behavioral factors is proposed in Figure 2.3.  In this model, genetic factors (e.g. 
family history of breast cancer, BRCA1/2 mutations), reproductive factors (e.g. age at menarche, 
parity), and behavioral factors (e.g. hormone therapy use, anthropometry) exert some of their 
effects on breast cancer risk through a pathway involving breast density.  Indeed, it has been 
suggested that mammographic breast density represents the cumulative exposure to estrogen 
over the lifetime.191  Residual effects of these factors (represented by dashed arrows) still can 
impact breast cancer development, however, through pathways that do not include changes in 
breast density.  Further, breast density has its own effect on breast cancer that is not entirely 
explained by its associations with genetic, reproductive, and behavioral factors.  Thus, this model 
proposes that mammographic breast density is a step on a causal pathway to breast cancer, of 
which there are potentially many, yet is also an independent risk factor for breast cancer in its 
own right.  This complex relationship thereby necessitates careful control of genetic, 
reproductive, and behavioral factors in studies examining breast density and breast cancer. 
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2.4 ANGIOGENESIS AND BREAST CANCER 
Angiogenesis is the process by which the body forms new blood vessels, and in healthy adults 
occurs only in the female reproductive system.  Folkman’s work generated much of the initial 
interest in angiogenesis, demonstrating that the ability of tumors to grow is dependent on 
angiogenesis.192, 193  Without vascularization, tumors are unable to grow beyond 1-2mm3 in 
size.194
2.4.1 Roles of vascular endothelial growth factor (VEGF) 
While angiogenesis is a tightly controlled biological process involving multiple factors, vascular 
endothelial growth factor (VEGF) has been identified as a primary promoter of angiogenesis.195  
VEGF is a potent endothelial cell mitogen, and does not act on other types of cells.195  VEGF has 
a wide range of functions, including promoting endothelial cell mitogenesis and survival, 
increasing stromal degradation by promoting the expression of enzymes involved in these 
processes, and promoting vascular permeability.196  These functions are carried out through 
interactions with three types of receptors for VEGF present on endothelial cells.195  There are 
multiple types of VEGF proteins, including VEGF-A, VEGF-B, VEGF-C, and VEGF-D.196  
VEGF-A is the most common form of VEGF; for this reason, VEGF-A is commonly referred to 
simply as “VEGF,” and from this point forward use of the acronym “VEGF” will refer to VEGF-
A unless otherwise stated.  VEGF-C has been shown to be present in tumors which metastasize 
to the lymph nodes, and VEGF-D appears to be present only in cases of inflammatory breast 
cancer.195, 197
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VEGF-A occurs in six different isoforms due to alternative splicing of the VEGF gene.198, 
199  The isoforms contain 121, 145, 165, 183, 189, or 206 amino acids.  The 121 and 165 
isoforms are the most abundant and are secreted as a soluble protein, while the other isoforms 
remain in the extracellular matrix.198, 199  An investigation of twenty-six existing breast cancer 
cell lines reported that five of the six isoforms were present in all cell lines, while the 206 
isoform was not observed in any of the cell lines.199  Further, while the expression levels of many 
of the isoforms were correlated with one another, no correlations were observed between 
expression of the various isoforms and clinicopathological features of the cell lines, such as stage 
or grade.199  The distribution of the VEGF isoforms is preserved even when the cells are stressed 
by changes in oxygen concentration, pH, or glucose availability, suggesting that these isoforms 
possess distinct biological functions.200  At least one study has reported that the 121 isoform 
promotes tumorigenesis more strongly in a mouse model than the other VEGF isoforms.201  
Further research is necessary to elucidate the differing roles for each of the VEGF isoforms. 
2.4.2 Angiogenesis and cardiovascular disease 
Angiogenesis is also recognized as playing an important role in other diseases, including 
psoriasis, diabetic retinopathy, rheumatoid arthritis, and atherosclerotic plaque formation.202  
Whether VEGF levels are increased among diabetics is unclear, with at least one study reporting 
no difference between diabetics and non-diabetics203 and another reporting increased VEGF 
levels among diabetics with hypertension versus subjects with only hypertension.204  
Angiogenesis appears to be related to cardiovascular disease in general.  One study reported that 
plasma VEGF levels among hypertensive individuals were positively correlated with 10-year 
risk of cardiovascular disease and cerebrovascular accident, as determined by Framingham 
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cardiovascular risk scores.205  A separate study of men recruited from a urology clinic reported 
significant increases in risk of acute myocardial infarction (HR 3.36, 95% CI 1.35-8.41), stroke 
(HR 3.98, 95% CI 1.61-9.86), and death (HR 1.74, 95% CI 1.01-3.00) for men with serum 
VEGF levels greater than 500 pg/mL at enrollment versus those with VEGF levels below 300 
pg/mL.206  In one study, plasma VEGF levels were higher among subjects with a history of 
myocardial infarction compared to participants with a primary acute myocardial infarction and 
healthy controls.207   
Despite these strong relationships, whether increased angiogenesis is the cause, or rather 
the result, of cardiovascular disease is unclear.208  One animal study reported that VEGF mRNA 
expression was increased in rats genetically modified to become hypertensive versus wild-type 
rats, and these investigators suggested that VEGF expression was increased as a means of 
compensating for the hypertension.209  Several human studies report that hypertensives have 
increased levels of VEGF compared to normotensive controls.205, 210-213  Further, some 
investigators have reported that treatment to lower blood pressure also has the effect of 
decreasing VEGF levels.205, 213, 214  The effect of VEGF on blood pressure is far less clear, 
however, when one considers the literature from other fields.  For example, blood pressure has 
been demonstrated to increase among cancer patients treated with angiogenesis inhibiting 
drugs.214, 215  One randomized trial of the angiogenesis inhibitor sorafenib for treatment of 
metastatic renal cell carcinoma reported that 43% of participants experienced hypertension.216  
Similarly, investigators have noted that women with preeclampsia, a condition of pregnancy 
characterized by hypertension and proteinuria, have substantially lower levels of VEGF than do 
healthy women.215  The mechanisms by which VEGF may regulate blood pressure are clearly 
complex, and further research in this area is warranted. 
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2.4.3 In vitro and animal studies of VEGF and breast cancer 
There is a vast literature reporting studies of VEGF and angiogenesis using in vitro and animal 
models of carcinogenesis.  This literature review will primarily focus on those studies directly 
related to carcinogenesis of the breast.  Angiogenesis can be induced in mice upon 
transplantation of tissue from biopsy samples of women with confirmed breast cancer.217  
Xenografts of tissue taken from healthy women undergoing breast reduction did not induce 
angiogenesis, demonstrating that the vascularization was caused by the tumor cells.217  In vitro 
experiments have demonstrated that VEGF is necessary for the invasion of breast cancer cells, 
though not for their proliferation.218, 219  VEGF is expressed in a variety of cell lines, as 
previously noted, and two studies reported that VEGF expression was highest in MDA-MB-231 
cells compared to other cell lines.220, 221  VEGF is necessary for the initial growth of tumors.  
Studies in which either VEGF or its receptors VEGFR-1 and VEGFR-2 are blocked show 
decreased tumor growth, size, and metastases in animal models.222-224  In a mouse model using 
inoculation with T47-D breast cancer cells to induce carcinogenesis, Yoshiji et al. reported that 
VEGF was essential for initial growth but its expression was not important once the tumors were 
established and of large size.225  Other angiogenic factors, including basic fibroblast growth 
factor (bFGF) and transforming growth factor-α (TGF-α), appear to be important for the 
continued growth of tumors after the initial growth for which VEGF is needed.225   
Part of VEGF’s role in promoting tumor growth may also be carried out through 
preventing apoptosis.  Bachelder et al. reported that blocking expression of VEGF in MDA-MB-
231 and MDA-MB-435 breast cancer cells resulted in a three-fold increase in apoptosis.226  In 
fact, VEGF has been shown to promote expression of the anti-apoptotic protein Bcl-2.  Pidgeon 
et al. demonstrated that MDA-MB-231 cells induced to express VEGF or supplemented with 
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exogenous VEGF overexpressed Bcl-2.227  Further, treatment of the cells with antibody to VEGF 
decreased expression of Bcl-2 and resulted in increased apoptosis.227  It is also possible that Bcl-
2 may regulate VEGF expression.  Biroccio et al. reported that MCF-7 breast cancer cells 
manipulated to overexpress Bcl-2 showed significantly increased expression of VEGF protein 
under hypoxic conditions as compared to the xenografts using control MCF-7 cells without 
altered Bcl-2 expression.228  Additionally, these investigators reported that mouse xenografts 
using the Bcl-2 overexpressing MCF-7 cells were more vascularized and showed increased 
VEGF by immunohistochemistry than did the control MCF-7 cells.228  Thus there does appear to 
be a relationship between VEGF, Bcl-2, and apoptosis, though the direction of this relationship 
remains unclear. 
The role of VEGF has been studied in relation to numerous factors believed to be 
involved in breast carcinogenesis.  In vitro and animal studies have reported that VEGF 
expression is correlated with cyclin I229 and NF-κB221 and is upregulated by both TGF-β1220 and 
tumor necrosis factor-α (TNF-α).230  VEGF levels have been shown to be increased via multiple 
pathways, including those involving extracellular matrix metalloproteinase inducer 
(EMMPRIN),231 heparanase and Src,232 and mitogen-activated protein kinase (MAPK) and 
phospatidylinositol-3-kinase (PI3K).233  The chemokines CCL5 and CCL2 were reported to have 
no effect on VEGF expression,234 though VEGF has been reported to regulate expression of the 
chemokine receptor CXCR4.218  The protein ErbB2 (also known as HER-2/neu) is related to 
increased VEGF protein synthesis in vitro.  Klos et al. reported that MDA-MB-435 cells 
modified to constitutively express ErbB2 had higher levels of VEGF protein synthesis in vitro 
and generated tumors with increased microvascular density in mice as compared to wild type 
MDA-MB-435 cells.235  High VEGF levels were also observed in the SKBR-3 cell line which 
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has endogenous overexpression of ErbB2.236  Further, the addition of 4D5, a monoclonal 
antibody specific to ErbB2 which is now known as trastuzamab or Herceptin, decreased VEGF 
protein production in these cells.236  Indeed, the role of VEGF in angiogenesis and 
carcinogenesis appears to be complex and likely involves interaction with multiple pathways. 
One of the strongest inducers of VEGF expression is the hypoxic environment of tumors.  
Bachelder et al. demonstrated that hypoxia significantly increased the expression of VEGF by 
MDA-MB-231 and MDA-MB-435 breast cancer cells and that cell survival under hypoxic 
conditions was dependent upon the actions of VEGF.226  Scott et al. studied VEGF expression in 
seven different breast cancer cell lines (MDA-MB-231, MDA-MB-435, MDA-MB-453, SKBR-
3, BT20, MCF-7, and T47-D) in response to perturbations in the cellular environment, such as 
hypoxia, lowered pH, hypoglycemia, and hormonal concentration.200  All cell lines except for 
MDA-MB-435 were observed to significantly increase VEGF expression under hypoxic 
conditions, with inductions ranging from 1.7 times normoxic induction in MDA-MB-231 cells to 
a 6.9-fold induction in T47-D cells.  Differences in the VEGF expression under hypoxic 
conditions were unrelated to differences in p53, ER status, or normoxic VEGF production among 
the cell lines.200  Hypoxia is believed to increase VEGF expression through a signaling pathway 
involving HIF-1α.200, 237  The hypoxia-induced expression of VEGF is further increased when 
BRCA1 is present.237  The mechanism by which BRCA1 exerts this effect is believed to involve 
an interaction with HIF-1α, as BRCA1 had no effect on VEGF levels when the VEGF promoter 
contained a mutation blocking its interaction with HIF-1α.237  Further experimentation implied 
that under hypoxic conditions BRCA1 is able to induce VEGF by blocking the degradation of 
HIF-1α normally carried out by the proteasome.237  Additional work in understanding the 
mechanistic relationship between BRCA1 and VEGF is needed. 
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Hormonal regulation of VEGF may also be important to angiogenesis in breast cancer.  
Hyder et al. reported identifying two estrogen response elements (ERE) in the rat VEGF gene, 
with one ERE in each of the 5’ and 3’ untranslated regions.238  Mouse models have shown that 
VEGF increases estrogen dependent tumor growth239 and that estrogen increases both tumor and 
extracellular levels of VEGF.240  Most studies using the estrogen-sensitive (expressing both ER-α 
and ER-β) breast cancer cell line MCF-7 have reported that estrogen increases VEGF mRNA 
and/or protein expression by these cells,241-246 although one study found no effect247 and another 
reported decreased VEGF expression induced by estrogen.248   The increase in VEGF expression 
can be blocked by incubation of MCF-7 cells with the pure anti-estrogen ICI 182,780,245 though 
this is not a consistent result.246   Further, estrogen has been reported to decrease expression of 
soluble VEGFR-1 in MCF-7 cells.242, 249  Estrogen has been shown to have no effect on MDA-
MB-231 cells, which expresses only ER-β,241, 243-245 or in the estrogen-insensitive cell line T47-
D.200  Estrogen can also increase VEGF expression in estrogen-sensitive ZR-75 cells250 and in 
SKBR-3 cells, in which a variant of ER-α was identified.251
The effects of tamoxifen, a selective estrogen-receptor modulator, on VEGF are far more 
controversial than those of estrogen.  Some studies report that tamoxifen treatment increases 
VEGF expression in MCF-7 cells,245, 248 while others report that VEGF expression in MCF-7 
cells is decreased by tamoxifen.242, 243, 252  Takei et al. reported that while tamoxifen had no effect 
on VEGF protein expression at concentrations ≤1 µM, a concentration of 1 µM showed a slight 
increase in VEGF protein and a concentration of 10 µM showed a strong increase.246 Similar to 
the in vitro results, while one study reported that tamoxifen increased both vascular permeability 
and VEGF protein in a mouse breast cancer model,248 another reported that extracellular VEGF 
was lower in tumors of mice treated with estrogen and tamoxifen as compared to those in mice 
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treated with estrogen alone.252  Levels of soluble VEGFR-1 were reported to increase in MCF-7 
cells treated with tamoxifen, with an approximately nine-fold increase in the ratio of soluble 
VEGFR-1:VEGF after tamoxifen treatment.242  One study using the MDA-MB-231 cell line 
reported that tamoxifen had no effect on levels of VEGF expression.243  Tamoxifen had no effect 
on VEGF expression in GI-101A cells compared to untreated cells.253  The synthetic estrogen 
diethylstilbestrol (DES) was shown to increase VEGF expression in these cells, however, and the 
addition of tamoxifen was able to block this DES-induced VEGF expression.253
Most studies exploring the effects of progestins in the progestin-sensitive T47-D breast 
cancer cell line report that progestin exposure increases VEGF expression,247, 254, 255 though at 
least one study has found no effect.200  Both natural and synthetic progestins are able to increase 
VEGF expression in vitro, and the synthetic progestin medroxyprogesterone acetate (MPA) is 
reported to have the strongest effect on VEGF expression by T47-D cells.247, 254  MPA is a 
synthetic progestin commonly used in postmenopausal hormone therapy, and Hyder et al. 
suggest that perhaps the strong effect of MPA on VEGF expression at least partially explains the 
increased breast cancer risk observed in women using estrogen + progestin preparations versus 
those using estrogen alone.254  Though more evidence is needed for this hypothesis, it is 
interesting to note that MPA was the synthetic progestin used in the Women’s Health Initiative 
clinical trial of hormone therapy.75  Further evidence for an effect of progestins on VEGF 
expression comes from studies showing that the anti-progestin RU-486 blocks the progestin-
induced expression of VEGF254 and from studies reporting no effect of progestin on VEGF 
expression in breast cancer cell lines known to be progestin-insensitive.238  Interestingly, the 
breast cancer drug faslodex (also known as ICI 182,780), an anti-estrogen drug which is used in 
women resistant to tamoxifen, has been reported to block VEGF mRNA and protein expression 
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through anti-progestin actions.256  Although further research is needed to fully describe the 
hormonal regulation of VEGF expression, it is quite clear that both estrogens and progestins, as 
well as their antagonists, play a substantial role in regulating VEGF and, therefore, angiogenesis. 
2.4.4 Human studies of VEGF and breast cancer 
The following sections review studies of the role of VEGF in breast cancer that have been 
conducted using human subjects and/or stored tumor tissue samples from breast cancer patients. 
2.4.4.1 VEGF and breast cancer prognosis 
The association between VEGF and prognosis after breast cancer has been extensively studied.  
Gasparini reviewed such studies in 2000, and concluded that the vast majority of them (8 of the 9 
published at that time) supported the conclusion that increased VEGF expression conferred a 
poorer breast cancer prognosis.257  The studies included in this review utilized populations of 
both node-negative and node-positive breast cancer patients.257  The results of more recent 
studies, however, appear to be far less consistent.  Although some studies have reported 
decreased disease-free survival and overall survival with increased tumor258-261 or serum262 
VEGF levels, numerous studies have reported no association between tumor VEGF levels 
measured by immunohistochemistry or enzyme-linked immunosorbant assay (ELISA) and 
disease-free survival263-268 or overall survival.264, 265, 268, 269  Interestingly, Nishimura et al. 
reported no association with plasma VEGF levels and overall survival in their full study 
population, but a significant inverse association was observed when analyses were restricted to 
postmenopausal women.269  One study reported that VEGF levels measured by 
immunohistochemistry were negatively associated with overall survival in univariate analyses, 
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but this relationship was no longer significant in multivariate analyses.270    Meo et al. reported 
that VEGF was not independently associated with risk of recurrence, though in a bivariate model 
they did observe a significant interaction between VEGF and plasminogen activator inhibitor-1 
(PAI-1) such that risk of recurrence was increased when both VEGF and PAI-1 levels were 
increased.271  The null findings of at least one study may be due to the few outcome events 
occurring in the study population.265   
The inconsistency in the findings may be due to the inclusion of heterogeneous types of 
breast cancer patients.  In fact, one study reported varying effects of tumor VEGF on survival 
depending upon the type of treatment the patient had received.  Foekens et al272 studied a 
population of 845 women diagnosed with invasive breast cancer who had experienced a 
recurrence of their disease; 618 were treated for the recurrence with tamoxifen, while 227 were 
treated with chemotherapy.  VEGF levels in the primary tumor were measured by ELISA and 
classified as low (<0.22 ng/mg protein), intermediate (0.22 – <1.73 ng/mg protein), or high 
(≥1.73 ng/mg protein).  Among those treated with tamoxifen, median time to progression of 
disease was 12.2 months for the high VEGF group compared to 18.4 months for the low VEGF 
group (OR for response to treatment 0.45, 95% CI 0.26-0.78 for high vs. low VEGF).  Among 
those treated with chemotherapy, median time to progression of disease was 6.6 months for the 
high VEGF group compared to 7.6 months for the low VEGF group (OR for response to 
treatment 0.31, 95% CI 0.14-0.68 for high vs. low VEGF).272  These differences in survival may 
reflect differences in the underlying pathology of the disease which dictate treatment course 
rather than differences due to treatment, however.  In exploratory analyses VEGF appeared to 
only confer a poor prognosis among the estrogen receptor negative (ER−) women treated with 
chemotherapy and the estrogen receptor positive (ER+) women treated with tamoxifen.272
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Other studies have also reported different findings when stratifying by ER or nodal status.  
Linderholm et al.273 reported that while the overall associations with disease-free and overall 
survival were either null or of borderline significance, VEGF was significantly predictive of both 
disease-free and overall survival among women diagnosed with ER+ disease.  On the other hand, 
Coradini et al.274 reported that addition of tumor VEGF level provided further information on 
prognosis to the Nottingham Prognostic Index only among women with ER− disease.  Some 
studies have reported significant associations with both types of survival in populations of 
women with node-negative disease,275-277 while others have not.278  Studies in populations of 
women with node-positive disease generally report no association between VEGF and 
survival.268, 279-282  A study of node-positive and ER+ breast cancer patients did report an 
interaction with ER level and VEGF such that increasing ER levels lessened or eliminated the 
negative impact of increased VEGF levels on disease-free survival.283  Polymorphisms in the 
VEGF gene may also be related to breast cancer survival; a recent study reported that individuals 
with a GG genotype at the common polymorphic site +405G/C had lower survival after breast 
cancer compared to women with the CC genotype (HR 1.6, 95% CI 1.0-2.5).284  A separate study 
reported that the -7C/T polymorphism was associated with overall survival.285  Overall, it 
currently appears that the effect of VEGF on breast cancer prognosis is controversial and further, 
more methodologically rigorous, studies are needed. 
2.4.4.2 VEGF and breast cancer tumor characteristics 
VEGF expression has been reported to be increased in tumor tissue as compared to adjacent, 
non-cancerous breast tissue286, 287 or samples from healthy controls,288 and expression of VEGF 
in tumor tissue is correlated with angiogenesis.289  Interestingly, one study reported a significant 
difference between cancerous and non-neoplastic tissue in postmenopausal women only.290  
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VEGF is believed to be important early in the development of cancer.  Indeed, a study of cases of 
ductal carcinoma in situ reported that approximately 50% of cases had strong expression of 
VEGF mRNA.291  In addition to being expressed by the tumor cells themselves, there is evidence 
that tumor-associated macrophages also produce VEGF and contribute to angiogenesis.292   
Numerous studies have investigated the relationships between VEGF in breast tumors 
and clinicopathologic features of the disease, yet these studies provide conflicting results.  For 
example, many studies report no association between tumor VEGF and tumor size,259, 264-266, 272, 
278-280, 287, 292-302 yet others report that tumor VEGF is positively associated with tumor size.258, 268, 
270, 271, 276, 277, 281, 303-305  In a study of 257 tumor samples, Coradini et al. reported a correlation of 
0.28 (p≤0.01) between VEGF and tumor size.303  Likewise, Linderholm et al. reported VEGF 
levels greater than the population median (2.40 pg/µg DNA) in 58.2% of larger size tumors and 
in 45.9% of smaller size tumors (p=0.008).276  Of note is that while half of the studies reporting 
no association between VEGF and size used immunohistochemistry and a subjective 
classification for VEGF expression, all but two270, 281 of the studies reporting positive 
associations with size measured VEGF using ELISA on tumor cytosols.  There are substantial 
differences in the sensitivity and reliability of these two methods, which thus may explain some 
of the conflicting results that have been reported.  Further, the studies reporting a significant, 
positive association tended to have larger sample sizes than those reporting no association. 
Similarly, some studies report positive associations between VEGF and grade of 
disease,258, 268, 270, 276, 281, 301, 304, 305 while most report no association with grade.259, 264, 272, 277, 279, 
280, 292, 294-296, 299, 306, 307  Additionally, one study reported a negative association between VEGF 
mRNA expression and grade of disease.302  Similar to the case with tumor size,  the studies 
reporting positive associations tended to have larger sample sizes than those reporting no 
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associations.  Thus these differences in methodology may explain some of the inconsistency in 
the findings. 
The majority of studies comparing VEGF expression or levels by nodal positivity status 
have reported no association.197, 259, 264-266, 269, 272, 279, 280, 287, 292-300, 302, 304, 307  Coradini et al., 
however, reported a significant correlation between number of metastatic lymph nodes and 
VEGF measured by ELISA (r=0.21, p≤0.01),303 and Zaman et al. reported a trend toward 
increased plasma VEGF among women with node-positive disease.305  Mohammed et al. 
reported that tumors with positive lymph nodes were also more likely to show high levels of 
VEGF expression by immunohistochemistry (76% node-positive vs. 29% node-negative, 
p<0.001),270 and a study by Valkovic et al. reported similar findings.301  Konecny et al. observed 
a positive association between VEGF and presence of positive lymph nodes when using an assay 
that recognizes isoforms VEGF121-206 (p=0.015) but not when using an assay that recognized 
only isoforms VEGF165-206 (p=0.444).268  Few studies have tested for associations between stage 
of disease and VEGF, but those that have report no significant association.279, 281, 293, 308
Associations between hormonal receptor status and VEGF have been extensively studied.  
Many studies report an inverse association between VEGF and ER status, such that VEGF levels 
are higher among women with ER-negative disease or are negatively correlated with ER 
expression.259, 265, 268, 270, 272, 279, 294, 300, 304  For example, one of the larger studies (N=845) 
reported that median tumor VEGF levels were higher in ER-negative disease than in ER-positive 
disease (0.45 versus 0.18 ng/mg protein, p<0.0001).272  Conversely, one study reported increased 
VEGF expression in ER-positive disease264 and another reported a positive correlation between 
VEGF and ER levels.295  Further, multiple studies report no association between ER status and 
tumor VEGF266, 271, 277, 278, 280, 293, 296-298, 302, 306 or serum VEGF.220, 299  Those studies reviewed 
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here which reported no association generally employed a small number of participants (range 
N=25 – N=574, with 11 of 13 having less than 300) while studies reporting inverse associations 
tended to have larger sample sizes (range N=177 – N=887, with 5 of 9 having more than 300).  
Thus it is possible that the lack of significant associations between ER status and VEGF may 
have been due to lack of statistical power in some studies. 
Results are similarly mixed for testing associations between PR status and VEGF.  Many 
studies report no association with tumor264-266, 271, 278, 279, 293, 294, 297, 298, 302, 306 or serum VEGF,299 
while many others report that levels of VEGF are negatively correlated with PR levels and/or 
that tumor VEGF levels are higher among women with PR-negative disease.259, 268, 270, 272, 277, 304  
Similar to the case of ER status and VEGF, the studies reporting significant inverse associations 
between PR status and VEGF tended to have larger study populations than did those reporting no 
associations; thus lack of statistical power may explain some of the conflicting results relating 
VEGF to PR status as well. 
Fewer studies have examined whether VEGF is associated with HER-2/neu expression.  
While one study reported a positive association between VEGF and HER-2/neu expression,268 
most studies report no association.264, 279, 294, 306, 308  One study did report a positive association 
among postmenopausal women only, however.294  On the other hand, a separate study reported a 
negative correlation between tumor VEGF expression and HER-2/neu expression.309  It is 
therefore unclear if an association exists between VEGF and HER-2/neu at the present time. 
Common to most of the studies exploring relationships between VEGF and 
clincopathological features of breast cancer is the use of a small sample size, as has been 
previously mentioned.  Further, most studies fail to do an adequate job of providing inclusion 
and exclusion criteria for their studies or of describing the demographic characteristics of their 
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population.  Thus from an epidemiologic perspective more careful design and reporting of such 
studies is needed before one can make valid conclusions about VEGF and tumor characteristics. 
2.4.4.3 VEGF in breast cancer cases and healthy controls 
It is also believed that serum and plasma levels of VEGF are higher among breast cancer patients 
as compared to healthy controls (Table 2.3).220, 305, 310-321  For example, Heer et al. reported that 
in a sample of 196 incident breast cancer cases and 88 healthy controls, the median serum VEGF 
level was higher in cases (305.9 pg/mL; interquartile range 156.7-451.6 pg/mL) than in controls 
(167.5 pg/mL; interquartile range 101.5-245.3 pg/mL).317  These studies, however, are all limited 
by small sample sizes, incomplete description of the study populations, and/or failure to control 
for potential confounders in the analyses.  Thus, the true associations between VEGF levels and 
breast cancer remain unclear. 
At least four studies have investigated the relationship between polymorphisms in the 
VEGF gene and breast cancer risk.285, 322-324  Jin et al. studied seven common polymorphisms in 
the VEGF gene (-2578C/A, -2549del/ins, -2489C/T, -2447G/del, -1154G/A, -634G/C, and 
+936C/T) and found no association with any of the polymorphisms and breast cancer risk.324  
Likewise, Balasubramanian et al. found no association between the -460C/T, +405G/C, -7C/T, or 
+936C/T polymorphisms and breast cancer risk, though there was an indication that the -
460T/+405C/-7C/963C haplotype was associated with a decreased risk of breast cancer.285  In a 
nested case-control study Jacobs et al. reported that homozygous presence of the -2578C or -
1154G alleles, both of which are believed to result in increased VEGF expression, were related 
to increased odds of invasive breast cancer (OR 1.46, 95% CI 1.00-2.14 and OR 1.64, 95% CI 
1.02-2.64, respectively), while another allele believed to increase expression of VEGF, +936C, 
was not associated with invasive breast cancer but reduced the risk of in situ breast cancer 
   
Table 2.3 Summary of studies examining differences in serum or plasma VEGF levels between breast cancer cases and controls 
Author Study Design Study Population Results Comments 
Yamamoto320
(1996) 
Case-control N=184 healthy controls; 132 male, 52 
females); age 21-59 
N=286 cancer patients (N=175 breast; 
137 primary, 38 recurrent); age not 
stated 
Menopausal status not stated 
Mean serum VEGF in controls 
77.0pg/mL; 19.7% of breast cancer 
cases have serum VEGF level > 
180pg/mL (mean + 2SD of control 
population) 
Unclear if cases were incident or 
prevalent and if blood samples were 
taken prior to onset of treatment; no 
formal significance testing comparing 
VEGF levels in breast cancer cases 
and controls reported; analyses not 
adjusted for confounders 
Dirix313  
(1997) 
Prospective Cohort N=146 cancer patients (N=17 treated 
for metastatic breast cancer, N=22 
untreated non-metastatic breast 
cancer) 
Age and menopausal status 
distributions not stated 
Serum VEGF levels >95th percentile 
of controls (500pg/mL) in 38% of 
untreated non-metastatic breast cancer 
cases; no statistics provided for 
metastatic breast cancer cases 
Control values taken from those 
reported by manufacturer of assay kit; 
no formal significance testing 
comparing VEGF levels in breast 
cancer cases and controls reported; 
small number of breast cancer cases; 
analyses not adjusted for confounders; 
also followed for prognosis 
Donovan220  
(1997) 
Case-control N=15 healthy controls; age-matched 
to cases 
N=26 breast cancer patients; age not 
stated 
Mean serum VEGF higher among 
cases (407.67±272.07pg/mL) than 
among controls 
(230.0±127.18pg/mL), p=0.03 
Small sample sizes; no selection 
criteria provided for cases or controls; 
analyses not adjusted for confounders 
Salven318  
(1997) 
Case-control N=113 controls with diabetes (N=7), 
rheumatoid arthritis (N=5), or healthy 
(N=81); 19 male, 94 female; age 20-
82 
N=97 cancer patients (N=33 breast 
cancer) (N=45 male, N=58 female); 
age 23-85 
Menopausal status not stated 
Serum VEGF levels higher among 
cancer cases (median 197pg/mL, 
range 8-1711pg/mL) vs. controls 
(median 17pg/mL, range 1-177pg/mL) 
(p<0.0001); median serum VEGF 
level higher among disseminated 
breast cancer cases (median 205, 
range 21-1347pg/mL) versus 
locoregional breast cancer (median 
150pg/mL, range 132-244 pg/mL) (no 
significance testing performed) 
Small numbers of breast cancer cases; 
no specific testing of breast cancer 
cases versus controls; analyses not 
adjusted for confounders 
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Table 2.3 (continued)    
Salven314
 (1999) 
Case-control N=73 patients undergoing breast 
surgery; histology reveals 18 benign 
tumors, 7 in situ disease, and 48 
invasive cancers; median age 59, 
range 22-95 
N=32 patients with metastatic breast 
cancer; 27 undergoing active 
treatment at time of blood draw; age 
distribution not stated 
Menopausal status not stated 
Serum VEGF levels higher among 
invasive cancer cases (median 
104pg/mL, range 11-593pg/mL) and 
metastatic cases (median 186pg/mL, 
range 7-1347pg/mL) versus benign 
tumors (median 57pg/mL, range 18-
328pg/mL) (p=0.13 invasive, 
p=0.0018 metastatic) 
Analyses not adjusted for 
confounders; controls not “healthy” 
but actually have benign breast 
conditions 
Adams315  
(2000) 
Case-control  N=12 women with benign breast 
disease; median age 47, range 32-63; 
6 pre- and 6 postmenopausal 
N=62 women with localized breast 
cancer; median age 56, range 29-85; 4 
peri-, 14 pre- and 44 postmenopausal 
N=42 women in remission from breast 
cancer; median age 54, range 38-85; 3 
peri-, 7 pre- and 32 postmenopausal 
N=22 women with metastatic breast 
cancer; median age 52, range 32-82; 7 
pre- and 15 postmenopausal 
N=63 healthy women; median age 37, 
range 20-72; 49 pre- and 14 
postmenopausal 
Plasma and serum VEGF levels 
significantly different among groups 
(p<0.001 plasma, p=0.048 serum); 
median plasma levels: 40.9pg/mL 
metastatic, 44.5pg/mL remission, 
31.3pg/mL local disease, 28.3pg/mL 
benign disease, 27.3pg/mL controls; 
median serum levels: 252.9pg/mL 
metastatic, 293.7pg/mL remission, 
244.2pg/mL local disease, 
264.8pg/mL benign disease, 
186.0pg/mL controls 
Analyses not adjusted for potential 
confounders; also noted that 80% of 
tumors expressed VEGF 
Heer317  
(2001) 
Prospective Cohort N=200 breast cancer cases; age range 
not stated 
N=88 healthy controls; age range 22-
79 
Menopausal status not stated 
Median serum VEGF higher in cases 
(305.9pg/mL, interquartile range 
156.7-451.6pg/mL) compared to 
controls (167.5pg/mL, interquartile 
range 101.5-245.3pg/mL) (p<0.0005) 
Analyses not adjusted for potential 
confounders; also followed for 
prognosis 
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Table 2.3 (continued)    
Benoy310  
(2002) 
Case-control N=104 breast cancer cases 
N=26 healthy controls 
Age and menopausal status 
distributions not stated 
Mean serum (347±276pg/mL) and 
plasma (45±32pg/mL) VEGF higher 
in cases than in controls 
(105±74pg/mL and 14±9 pg/mL, 
respectively), both p<0.0001 
Analyses not adjusted for potential 
confounders 
Wu319  
(2002) 
Prospective Cohort N=125 African American (N=57) and 
Hispanic (N=68) breast cancer cases; 
mean age 50.7±1.3 African 
American, 46.6±1.5 Hispanic; 51% 
African American and 35% Hispanic 
postmenopausal 
N=20 African American and Hispanic 
healthy women; age and menopausal 
status distributions not stated 
Cases (median 39.3 pg/mL, range 
20.9-417.2pg/mL) have higher plasma 
VEGF than controls (median 24.4 
pg/mL, range 18.0-77.7pg/mL) 
(p<0.0002) 
 
Analyses not adjusted for potential 
confounders; menopausal status 
determined by < or ≥ age 50; also 
followed for prognosis 
Coskun311  
(2003) 
Case-control N=38 metastatic breast cancer 
patients; mean age 50.0±13 
N=23 breast cancer patients in 
remission; mean age 48.3±9.6 
N=16 healthy controls; mean age 
47.4±9.4 
Menopausal status unknown 
Serum VEGF higher in patients with 
metastatic disease 
(252.7±147.5pg/mL) compared to 
patients in remission 
(137.2±64.7pg/mL, p<0.001) and 
controls (107.3±50.0pg/mL, 
p<0.001); remission and control 
groups not statistically significantly 
different (p>0.05) 
Analyses not adjusted for potential 
confounders 
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Table 2.3 (continued)    
Nishimura269
(2003) 
Case-control N=15 patients with benign breast 
disease; mean age 46.5, range 32-79 
N=187 patients with primary breast 
cancer; mean age 54.3, range 29-95 
N=32 patients with non-recurrent 
breast cancer; mean age 54.0, range 
35-86 
N=56 patients with recurrent breast 
cancer; mean age 57.9, range 32-85 
Significant differences in mean 
plasma VEGF levels observed among 
all groups: benign breast disease 
16.0±2.1 pg/mL, primary breast 
cancer 25.7±26.6 pg/mL, non-
recurrent breast cancer 18.9±12.7 
pg/mL, recurrent breast cancer 
44.7±53.8 pg/mL 
Analyses not adjusted for potential 
confounders; no inclusion or 
exclusion criteria stated; mean plasma 
VEGF values stated in text do not 
match those listed in figure 
displaying these results 
Granato316  
(2004) 
Case-control N=69 breast cancer patients; median 
age 67, range 51-92; menopausal 
status not stated 
N=54 healthy controls; median age 
60, range 51-77; menopausal status 
not stated 
Serum VEGF higher among cases 
(median 192.7pg/mL, range 22.7-
953.5pg/mL) than controls (median 
145.7pg/mL, range 0.0-707.6pg/mL) 
(p=0.055) 
Analyses not adjusted for potential 
confounders; not clear if cases were 
incident or prevalent; unclear why 
some subjects not included in 
analyses 
Hoar312  
(2004) 
Case-control N=51 breast cancer patients; mean 
age 57.3±11.1 
N=51 age and sex matched healthy 
controls; mean age 54.0±5.4 
Menopausal status not stated 
Plasma VEGF higher among cases 
(median 120pg/mL, interquartile 
range 15-8,000pg/mL) than controls 
(median 34pg/mL, interquartile range 
18-90pg/mL), p=0.03 
Controls said to have been age 
matched to cases, but difference in 
age is borderline significant (p=0.06), 
analyses not adjusted for potential 
confounders 
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Table 2.3 (continued) 
Teh321  
(2004) 
Prospective Cohort N=17 breast cancer patients; mean age 
61, range 48-72 
N=7 patients with fibroadenomas; 
mean age 30.2, range 25-35 
N=7 healthy controls; mean age 55, 
range 45-72 
Menopausal status not stated 
No difference in plasma VEGF levels 
between cases (pre-surgery 
96.58±26.6pg/mL) and controls 
(88±12.3pg/mL) (p=0.07) 
Small numbers therefore likely 
underpowered; analyses not adjusted 
for potential confounders; controls 
age-matched to breast cancer cases 
but age distributions are not equal 
Zaman305  
(2006) 
Case-control Unknown number of healthy controls; 
age ≥18 
N=17 breast cancer patients; age ≥18 
Menopausal status not stated 
Plasma VEGF significantly higher in 
cases (52.9±29.9pg/mL) than controls 
(37.6±25.5pg/mL) (p=0.04) 
Small numbers of cases and unknown 
number of controls; analyses not 
adjusted for confounders; little 
information provided regarding 
subject recruitment 
   
(OR 0.49, 95% CI 0.37-0.93).322  Krippl et al. reported that individuals with a +936T allele 
which is believed to result in lower VEGF levels, either homo- or heterozygous, had a reduced 
risk of breast cancer (OR 0.51, 95% CI 0.38-0.70).323  Despite these findings and those showing 
the importance of VEGF to cancer growth and progression, only one study has been conducted to 
determine if biological levels of VEGF are related to risk of breast cancer.  This study reported 
no association between the -460C/T, +405G/C, -7C/T, or +936C/T polymorphisms and plasma, 
serum, or tumor VEGF levels.285  Future studies are needed to verify these results and to relate 
blood and tumor VEGF levels to other common polymorphisms in the VEGF gene. 
2.4.4.4 VEGF and personal characteristics 
The variation of VEGF by personal characteristics of breast cancer patients or healthy controls 
has not been extensively studied.  In fact, a review of the literature identified comparisons based 
only on age, menopausal status, or BRCA1 genotype.  Many studies have examined associations 
between VEGF and age, with most finding no association.264, 270, 272, 276, 279, 280, 292, 295-299, 304, 306, 
307, 325  Three studies have reported a positive association between age and tumor VEGF 
levels,269, 277, 293 while two other studies found inverse associations between age and tumor 
VEGF.278, 281  Greb et al. reported a negative correlation between VEGF mRNA expression and 
age in non-neoplastic breast tissue, yet no association with age in cancer tissue from the same 
women.290  Further, one study reported no association between serum VEGF and age among 
women treated with chemotherapy, yet a positive association among women treated with 
tamoxifen.300  The majority of studies report no association between VEGF and menopausal 
status.259, 264, 266, 272, 278-280, 302, 326  However, one reported that VEGF levels were increased among 
premenopausal women294 while others reported higher tumor or plasma VEGF levels in 
postmenopausal women.269, 306  Also, Greb et al. reported that VEGF mRNA expression was 
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higher in the non-neoplastic breast tissue of premenopausal women, though no difference by 
menopausal status was observed for cancerous tissue.290  One study reported that serum VEGF 
was lower in breast cancer patients with a BRCA1 mutation compared to those without such a 
mutation.326  Studies do not appear to have investigated whether VEGF levels vary by other 
relevant factors such as race/ethnicity, family history of breast cancer, or use of HT or oral 
contraceptives; thus future research of the variation of VEGF by personal characteristics is 
warranted. 
2.4.4.5 Hormonal regulation of VEGF 
In healthy adults angiogenesis normally does not occur except in the female reproductive system.  
Many in vitro studies have reported that estradiol (E2) also induces VEGF (see section 2.5.2).  
Further, Dabrosin reported high correlations between plasma E2 (r=0.814, p<0.0001) and breast 
tissue E2 (r=0.67, p=0.004) with VEGF in breast tissue of 16 pre- and postmenopausal healthy 
women.327  Though the evidence is still preliminary, a relationship between estrogen and VEGF 
could suggest another mechanism by which estrogen acts to promote carcinogenesis in breast 
tissue and also adds support to the hypothesis that increased levels of VEGF are positively 
associated with breast cancer risk.  Other evidence that sex hormones can regulate VEGF include 
the observation that administration of follicle stimulating hormone (FSH) increases follicular 
VEGF levels among women undergoing in vitro fertilization,328 as well as evidence that 
administration of testosterone induces VEGF mRNA expression in murine breast cancer cells.245  
Thus sex hormones may play a significant role in regulating angiogenesis. 
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2.4.4.6 VEGF and the menstrual cycle 
There is some controversy regarding whether levels of angiogenic factors are affected by the 
menstrual cycle.  Some studies have not observed a cyclic variation in VEGF during normal 
menstrual cycles.315, 329-332  One study has reported that neither serum nor plasma VEGF levels 
varied during the menstrual cycle in a cohort of 20 healthy premenopausal women.329  A 
limitation of this study was that most of the plasma measurements were below the lower limit of 
detection of the assay used, thus preventing variability in the plasma levels from truly being 
assessed.  Other studies have reported cyclic variation in VEGF levels during the menstrual 
cycle.  For example, two studies reported that serum VEGF levels were lower in the luteal phase 
as compared to the follicular phase.333, 334  Both of these studies, however, included a small 
number of participants (14 in Heer et al. and 6 in Kusumanto et al.) and also failed to properly 
analyze the results as repeated measures, instead analyzing the results as independent 
observations.  Thus the results of these studies must be viewed with caution.  Other investigators 
have reported that VEGF is higher in the luteal phase.335, 336  Dabrosin et al. reported that VEGF 
levels in the extra-cellular fluid of breast tissue was increased in the luteal phase but that plasma 
levels showed no variability with phase of the menstrual cycle.336, 337  Further research is needed 
to understand the effects of estrogen and the menstrual cycle on VEGF levels.   
2.5 SUMMARY 
As evidenced by the substantial morbidity and mortality it causes, breast cancer is truly a 
significant public health problem in the United States.  Though great strides have been made in 
improving methods of early detection and treatment, both of which have led to reduced breast 
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cancer mortality, effective prevention of breast cancer still remains an elusive goal.  Much is 
currently known about risk factors for breast cancer, including reproductive history, genetic 
mutations, and hormone use.  It is also recognized that overweight and obesity are related to risk 
of postmenopausal breast cancer.  Interestingly, body weight is inversely related to percent breast 
density, which is considered to be a potential surrogate endpoint for breast cancer.  Studies have 
not been designed to look at relationships between anthropometry and breast density 
longitudinally.  Such investigations may help to understand the reasons for this contradiction and 
how to appropriately control for it in studies utilizing breast density as a surrogate endpoint.  It is 
also increasingly apparent that angiogenesis, and specifically vascular endothelial growth factor, 
plays an important role in the etiology of breast cancer.  Though in vitro and animal studies 
relating VEGF to breast cancer have been extensive, the focus of such research in humans has 
been primarily on prognosis after breast cancer diagnosis.  Those studies that have addressed the 
role of VEGF in breast cancer etiology using human subjects have been severely limited by 
selection bias, confounding, and lack of statistical power.  Further, very little is known about the 
correlates of VEGF among healthy women and women with breast cancer.  Thus we do not 
know if factors such as age, menopausal status, and hormone use affect serum levels of VEGF. 
We present a longitudinal evaluation of anthropometric measures (BMI, weight) and 
breast density (percent and absolute), a method for estimating outcome data collected off-
schedule from planned study visits, and a case-control study evaluating differences in serum 
VEGF levels between women with and without breast cancer.  This research tests novel 
hypotheses intended to enhance existing knowledge of breast cancer etiology and thus contribute 
to public health. 
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3.1 ABSTRACT 
High percent mammographic breast density is strongly associated with an increased risk of 
breast cancer.  Though body mass index (BMI) is positively associated with risk of 
postmenopausal breast cancer, BMI is negatively associated with percent breast density in cross-
sectional studies.  Longitudinal studies evaluating associations between changes in BMI and 
weight and mammographic breast density have not been conducted.  We studied the longitudinal 
relationships between anthropometry and breast density in a prospective cohort of 834 pre- and 
perimenopausal women enrolled in an ancillary study to the Study of Women’s Health Across 
the Nation (SWAN).  Routine screening mammograms were collected and read for breast 
density.  Random intercept regression models were used to evaluate whether longitudinal 
changes in BMI and weight were associated with changes in dense breast area and percent 
density.  The study population was racially diverse (7.4% African American, 48.8% Caucasian, 
21.8% Chinese, and 21.9% Japanese).  Mean follow-up was 4.8 years, and mean annual weight 
change was +0.22 kg/year.  In fully adjusted models, changes in BMI and weight were not 
associated with changes in dense breast area (β=-0.0105, p=0.34 and β=-0.0055, p=0.20, 
respectively), but were strongly negatively associated with changes in percent density (β=-1.18, 
p<0.001 and β=-0.44, p<0.001, respectively).  This study provides evidence that longitudinal 
changes in BMI and weight are not associated with the dense area, yet are negatively associated 
with percent density.  Thus, effects of changes in anthropometry on percent breast density may 
reflect effects on non-dense tissue, rather than on the dense tissue where cancers arise. 
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3.2 INTRODUCTION 
In 2007 alone an estimated 178,480 U.S. women will be diagnosed with breast cancer.1  Though 
substantial efforts have been devoted to studying breast cancer etiology and prevention, the pace 
of this research is often slow due to the decades needed for breast cancer to develop.  Therefore, 
cancer epidemiology studies are incorporating surrogate endpoints, which allow for studies to be 
conducted with fewer subjects and over a shorter time period while aiding in the understanding 
of the mechanisms of cancer development.2   
The breast is composed of different types of tissues, and the composition varies from 
woman to woman; fat appears dark on a mammogram because it is radiologically lucent, while 
epithelial and connective tissues appear bright because they are radiologically dense.  The areas 
of density can be measured and summed to determine the dense breast area.  Mammographic 
breast density is typically expressed as a percentage (dense area/total breast area*100%).    High 
mammographic breast density increases the risk of breast cancer more than fourfold compared to 
women with low breast density.3   
Body mass index (BMI) bears an idiosyncratic relationship to breast density and breast 
cancer.  It is related to an increased risk of postmenopausal breast cancer and a decreased risk of 
or no association with premenopausal breast cancer.4  However, cross-sectional studies of 
mammographic breast density in both pre- and postmenopausal women consistently report that 
increased weight or BMI is associated with lower percent breast density.5-12  For example, one 
study reported percent density was 5.2% lower among premenopausal women and 4.7% lower 
among postmenopausal women in the 3rd quartile versus 1st quartile of BMI.7
The amount of fat present in the breast is strongly related to BMI.13  Recent studies have 
evaluated the association between anthropometric measures and the dense and non-dense areas 
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of the breast.8, 10, 14, 15  Several studies have shown that weight and BMI are positively associated 
with the size of the non-dense area;8, 10, 14, 15 yet for the dense breast area, two studies reported 
negative correlations,8, 14 one reported a non-significant association,10 and another reported that 
the direction of the association varied by race/ethnicity.15  Only a few studies have used 
longitudinal data to evaluate associations between anthropometric measures and breast density.12, 
16, 17  These longitudinal studies have been limited by small numbers, self-reported 
anthropometric measurements, or use of a non-quantitative measure of breast density.   
In the current analysis we performed a prospective cohort study of 834 women enrolled 
in an ancillary study to the Study of Women’s Health Across the Nation (SWAN).  Our primary 
hypothesis was that time-related changes in weight and BMI would be positively associated with 
time-related changes in dense area and negatively associated with percent density. 
3.3 METHODS 
3.3.1 Study population  
SWAN began in 1994 to study the health of women as they transition from premenopause to 
postmenopause.18  Briefly, women eligible for SWAN were age 42-52, had ≥1 menstrual period 
in the previous three months, had a uterus and ≥1 intact ovary, and were not currently taking 
hormone therapy (HT) or oral contraceptives (OCs).  The SWAN Mammographic Density 
Substudy is an ancillary study to SWAN with the goal of examining factors related to 
mammographic breast density and how mammographic breast density changes as women 
progress through the menopausal transition.  Separate written informed consent and institutional 
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review board approvals were obtained for this ancillary study.  Participants from three SWAN 
sites (Los Angeles, CA, Oakland, CA, and Pittsburgh, PA) representing four races/ethnicities 
(African American, Caucasian, Chinese, and Japanese) were enrolled at their 5th or 6th annual 
visit.  Caucasian participants were enrolled from all three sites, while all African Americans were 
from the Pittsburgh site, all Chinese from the Oakland site, and all Japanese from the Los 
Angeles site.  Eligible mammograms included routine screening mammograms that were taken 
two years prior to the baseline SWAN visit through two years after the 6th annual SWAN visit.  
Mammograms of breasts that had undergone a biopsy or more extensive surgery were ineligible 
for the SWAN Mammographic Density Study.  Of those eligible for the SWAN Mammographic 
Density Substudy, 86.1% (N=1,055) consented and at least one mammogram was obtained from 
95.3% of these women (N=1,007).   
Participants were excluded from this analysis if they reported a history of breast cancer at 
SWAN enrollment (N=6) or had only one available mammogram (N=139).  Women who were 
diagnosed with breast cancer during their SWAN follow-up (N=21) were censored at the visit 
they reported this diagnosis.  Ten of these women had no mammograms prior to their breast 
cancer diagnosis and were excluded from this analysis.  After these exclusions 852 participants 
and 3,784 mammograms remained in the analysis.  Three participants reported being either 
pregnant or breastfeeding at the time of a SWAN visit, and these specific visits were not 
included in the analysis. 
3.3.2 Mammographic density readings  
The mammographic density assessments were performed by a single reader using craniocaudal 
views of the right breast.  Films of the left breast were used if a participant had a previous 
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surgery to the right breast or if the right breast films were of poor quality.  Prior to performing 
the density assessment, the reader rated the quality of each film as excellent, fair, good, or poor. 
Quantitative measures of density were made by tracing the total area of the breast and 
outlining the areas of density (excluding biopsy scars, Cooper’s ligaments, and breast masses) 
onto clear acetate placed over the mammogram.  A compensating polar planimeter (LASICO, 
Los Angeles, CA) was used to measure the total breast area and the dense breast area in cm2.  A 
blinded random sample of films (N=449) was used to assess the reproducibility of the density 
assessments.  This re-review showed good association between the initial and repeat readings of 
percent density (within-person Spearman correlation coefficient=0.96). 
3.3.3 Anthropometric measures  
Height was measured without shoes using either a metric folding wooden ruler or measuring tape 
(home and some clinic visits), or a fixed stadiometer (clinic visits).  Weight was measured 
without shoes, and in light indoor clothing, using a portable digital scale (home and some clinic 
visits) or either a digital or balance beam scale in the clinic.  Portable scales were calibrated 
weekly, and stationary clinic devices were calibrated monthly.  BMI was calculated as the weight 
in kilograms divided by the square of the height in meters. 
3.3.4 Additional variables 
Additional data were collected at the clinic visits by either interviewer- or self-administered 
questionnaires.  These data included demographic information, and personal and family history 
of breast cancer.  Cancer history was updated at each SWAN visit.  Reproductive variables 
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ascertained at baseline included age at menarche, age at first birth, number of births, and history 
of breastfeeding.  Number of births and breastfeeding history were updated at each SWAN visit.  
History and number of previous breast biopsies were reported at the time of enrollment into the 
SWAN Mammographic Density Substudy.  These data were used to calculate the Gail score for 
each participant.19, 20  Gail scores of 1.66 or higher indicate a high 5-year risk of breast cancer.  
History of atypical hyperplasia was not collected in this study and was listed as “unknown” for 
each woman in the calculation of the Gail scores. 
At baseline women reported their history of HT and OC use, as current users were 
initially excluded; current HT and OC use was updated at each SWAN visit.  Menopausal status 
was ascertained using an interviewer-administered questionnaire at each visit.  Women were 
asked about the frequency and regularity of their menstrual bleeding.  Women reporting no 
decrease in their menstrual regularity over the past year were classified as premenopausal.  Early 
perimenopause was classified as decreased menstrual regularity within the previous three 
months, and late perimenopausal was defined as no menstrual bleeding in the 3-11 months prior 
to the interview.  Women reporting no menstrual bleeding for at least 12 months prior to the 
interview were classified as postmenopausal.  Women reporting a bilateral oophorectomy and/or 
hysterectomy were defined as having a surgical menopause.  Those women reporting use of HT 
with some bleeding within the past 12 months were classified as unknown menopausal status.  
Women classified as postmenopausal remained classified as such thereafter, regardless of their 
HT use. 
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3.3.5 Statistical analysis   
Mammogram data and SWAN visit data for each participant were ordered chronologically.  
Because these routine screening mammograms were not performed as part of the SWAN study, 
the mammogram dates did not match the dates of SWAN visits.  We developed an algorithm to 
match retrieved screening mammograms to the nearest SWAN study visit, regardless of whether 
the mammogram preceded or followed the study visit.  To reduce potential error associated with 
variable time between mammograms and visits, only mammograms taken within 90 days of a 
SWAN visit were used as matches.  Mammographic breast density variables (total breast area, 
dense breast area, and quality of film) at other study visits were estimated with linear 
interpolation using the “ipolate” command in Stata version 10.0 (Stata Corporation, College 
Station, TX).  Separately for each participant, the interpolated estimates were calculated by 
constructing straight line segments between measurements from consecutive mammograms.  The 
value for an unmatched SWAN visit was calculated from the equation of the line segment, 
assuming that the change in density variables was linear between the two measurement dates that 
defined the line segment.  We did not use extrapolation to estimate breast density; therefore, 
visits without a mammogram both before and after the visit time were not included in the 
analysis.   
We added a noise term to each interpolated value of total and dense breast area to account 
for the error introduced by estimating the breast density measurements.  These noise terms were 
randomly generated from a normal distribution with a mean of 0 and standard deviation (SD) 
corresponding to the person-specific SD of the observed measurements for each participant.  
Multiple imputation was used to create ten analytic datasets.  Percent breast density was 
calculated by dividing the final (i.e. observed data if mammogram within 90 days, interpolated 
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data otherwise) dense area measurement by the final total breast area and expressing this value as 
a percentage.  Due to the addition of the random noise terms, some interpolated values (<1%) 
were considered to be implausible (i.e. total area<0, dense area<0, or dense area>total area); such 
values were discarded and additional random noise terms generated until acceptable imputed 
values were obtained.  After implementation of the matching and interpolation algorithms, 18 
participants were left with less than two mammographic density measurements due to the timing 
of their mammograms.  These participants were excluded from further analyses; the remaining 
834 participants had 3,746 eligible mammograms.  Women enrolled in the SWAN 
Mammographic Density Substudy but excluded from this analysis were of similar age, 
educational level, and menopausal status as those included.  Participants included were of 
slightly lower BMI (25.4 versus 26.4 kg/m2, p=0.06), less likely to be African American (7.4% 
versus 16.8%, p<0.001), and less likely to be from the Pittsburgh clinical site (23.7% versus 
43.9%, p<0.001; data not shown). 
Summary statistics were calculated for demographic, anthropometric, reproductive 
history, and mammographic breast density variables.  The averages of the mammographic 
density variables across the ten multiply imputed datasets were calculated and used for the 
descriptive statistics.  The length of time between the participants’ study visits and their nearest 
mammograms was calculated.  A square root transformation was applied to dense breast area 
after imputation to improve normality.  Analysis of variance (ANOVA) and Kruskal-Wallis tests 
were used to test for baseline differences in normally and non-normally distributed continuous 
variables, respectively, and chi-square tests were used to test for differences in categorical 
variables.  Bivariate cross-sectional associations between the anthropometry and breast density 
variables were assessed using ANOVA. 
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Random intercept models were fit with the participants’ age in days as the time scale 
using the Stata “xtreg” command.  Separate regressions were performed for the two primary 
mammographic breast density outcomes (dense breast area and percent density) for each of the 
two primary independent variables of interest (BMI and weight).  A total of four regressions 
were performed.  Variables included as possible covariates were: age (continuous), combined 
race and site (Caucasian/Pittsburgh, African American/Pittsburgh, Caucasian/Oakland, 
Chinese/Oakland, Caucasian/Los Angeles, Japanese/Los Angeles), family income (<$35,000, 
$35,000-$49,999, $50,000-$74,999, $75,000-$99,999, ≥$100,000), education (≤high school, 
>high school, college, post-college), age at menarche (<12, 12, 13, ≥14), age at first birth (<20, 
20-24, 25-29, 30-34, ≥35), breastfeeding history (nulliparous, parous/never, 1-4 months, 5-11 
months, 12-22 months, ≥22 months), number of births (0, 1, 2, ≥3), menopausal status (pre-/early 
perimenopausal, late perimenopausal/postmenopausal/hysterectomy with bilateral 
oophorectomy, unknown due to HT use), ever use of OCs prior to baseline (no, yes), ever use of 
HT prior to baseline (no, yes), current HT/OC use (no, yes), ever HT/OC use at each visit (no, 
yes), number of 1st degree relatives with breast cancer (0, ≥1), number of 2nd degree relatives 
with breast cancer (0, 1, ≥2), history of breast biopsy (no, yes), number of breast biopsies (0, 1, 
≥2), and Gail score (continuous).  Continuous variables were centered on the population mean.  
Time-varying variables were included as appropriate (e.g. menopausal status, hormone use).   
Model building using the first imputed dataset followed a backward selection of 
covariates, retaining covariates that were significant at the 0.10 level in the final model.  The 
“mijoin” and “micombine” commands in Stata were used to estimate the regression models and 
calculate multiply imputed estimates of the regression coefficients and their variances following 
the method of Rubin.21, 22  We report the results of three different models: Model 1, BMI or 
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weight only; Model 2, BMI or weight and age; and Model 3, BMI or weight and additional 
covariates. 
Analyses were repeated separately by race/ethnicity, baseline BMI, and menopausal 
status. All tests performed were two-sided with a p≤0.05 considered statistically significant.  All 
analyses were conducted using Stata version 10.0. 
3.4 RESULTS 
3.4.1 Characteristics of study population 
The 834 participants comprising the study population are described in Table 3.1.  The average 
age of the participants at SWAN enrollment was 46.5 years (SD 2.7).  This population was 
racially diverse, with 62 (7.4%) African American, 407 (48.8%) Caucasian, 182 (21.8%) 
Chinese, and 183 (21.9%) Japanese participants.  The majority of participants (57.5%) were 
categorized as normal weight at SWAN enrollment.  On average, participants had a low risk of 
being diagnosed with breast cancer within the next 5 years, with a mean Gail score of 1.06 (SD 
0.5).  By design all women were either premenopausal (58.3%) or early perimenopausal (41.7%) 
at enrollment.  The vast majority reported a previous use of OCs (75.4%) but no previous use of 
other exogenous hormones (86.4%) at enrollment.  Use of OCs or HT since the previous visit 
increased during follow-up, reaching a maximum of 27.4% at visit 6.  At visit 7, 26.2% of 
participants were premenopausal/early perimenopausal, 68.0% were late 
perimenopausal/postmenopausal, and 5.9% were of unknown menopausal status due to use of 
hormone therapy (data not shown). 
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The average follow-up time between the first and last SWAN visits included in this 
analysis was 4.8 years (SD 1.8).  Overall, participants tended to gain weight over follow-up 
(Table 3.2), with a mean annual weight increase of 0.22 kg (SD 1.84) and a mean annual BMI 
increase of 0.09 kg/m2 (SD 0.70).     
3.4.2 Breast density characteristics and cross-sectional associations with anthropometry 
Approximately half of all mammograms matched to SWAN visits 1-6 were taken within 90 days 
of the visit.  Of mammograms matched to SWAN visits 0 and 7, 28.4% and 36.9% were taken 
within 90 days of the visit, respectively (data not shown).  The mean dense breast area from 
participants’ first available mammogram was 46.2 cm2 (SD 26.7), and the mean percent breast 
density was 42.3% (SD 19.6; Table 3.3).  Dense breast area and percent density were positively 
correlated (r = 0.48, p<0.001).  When participants were cross-classified by quartiles of dense 
breast area and percent density from their first mammogram, 39.8% were ranked in the same 
quartile of both dense breast area and percent density. 
In cross-sectional analyses of the participants’ first mammogram and their height and 
weight at that time, dense breast area was positively associated with BMI category (p=0.01) and 
weight quartile (p=0.002).  Percent density was inversely associated with both BMI category 
(p<0.001) and weight quartile (p<0.001). 
3.4.3 Longitudinal associations between anthropometry and breast density  
The average annual change over follow-up was -0.58 cm2 (SD 3.32) for dense area and -1.01% 
(SD 2.38) for percent density (Table 3.2).  No longitudinal associations between changes in BMI 
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or weight and changes in the dense breast area were apparent (Table 3.4).  Age-adjusted 
regressions (Model 2) resulted in small, non-significant associations between BMI (β=0.00003, 
p=0.99) or weight (β=-0.0004, p=0.91) and square-root transformed dense breast area.  In models 
adjusted for age, race/site, menopausal status, family history of breast cancer, number of 
previous breast biopsies, and hormone use since previous visit (Model 3), small, non-significant, 
negative associations were observed for BMI (β=-0.0015, p=0.34) and weight (β=-0.0035, 
p=0.20). 
In contrast, changes in BMI and weight were significantly negatively associated with 
percent breast density (Table 3.4).  Percent breast density decreased by 1.30% per 1 unit increase 
in BMI in age-adjusted analyses (p<0.001) (Model 2), and this association was only slightly 
attenuated with additional adjustment for age, race/site, education level, menopausal status, 
number of previous breast biopsies, age at menarche, age at first birth, number of births, history 
of OC use at baseline, and hormone use since previous visit (β=-1.18, p<0.001) (Model 3).  
Similar relationships were observed for weight, with a decrease of 0.44% in percent breast 
density per kilogram increase in weight in a fully adjusted model (p<0.001) (Model 3). 
3.4.4 Longitudinal associations across initial BMI categories 
To assess whether the longitudinal associations between BMI and weight and breast density 
variables varied by initial BMI, regression coefficients for Caucasian participants were compared 
across categories of BMI at SWAN enrollment.  The Caucasian subgroup was the only one that 
included enough participants in the normal, overweight, and obese categories to provide reliable 
estimates.  For dense breast area, the regression coefficients for BMI decreased to negative 
values as the baseline BMI category increased (normal β=0.023; overweight β=0.018; obese β=-
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0.006), although they remained small and non-significant.  For percent density the regression 
coefficients remained negative yet became smaller as baseline BMI category increased: normal 
β=-1.27; overweight β=-0.56; obese β=-0.29 (data not shown).  Similar relationships were 
observed for regressions with weight as the primary independent variable. 
3.4.5 Sensitivity analyses 
The stability and consistency of these relationships were investigated through a series of 
sensitivity analyses grouping on potentially confounding factors.  Similar associations, as judged 
by the magnitude and direction of regression coefficients, to those observed in the complete 
cohort were observed in analyses restricted to racial subgroups, to women who did not use any 
exogenous hormones throughout follow-up (N=441), to women who remained 
premenopausal/early perimenopausal throughout follow-up (N=183), to women with ≥80% of 
mammograms taken within 90 days of a SWAN visit (N=98), to women with no breast cancer 
diagnosis during follow-up (N=824), and to observations with mammograms of good or 
excellent quality (N=819; data not shown).   
Further, we tested for interactions between our anthropometry variables and menopausal 
status.  We observed no significant interaction between BMI (p=0.29) or weight (p=0.11) and 
menopausal status in regressions on dense breast area.  We observed borderline significant 
interactions between BMI (p=0.06) and weight (p=0.09) and menopausal status in regressions on 
percent density. 
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3.5 DISCUSSION 
This analysis of data from a prospective, multi-ethnic cohort of 834 women revealed no 
association between longitudinal changes in anthropometric measures and the dense breast area, 
yet significant negative associations between changes in anthropometry and percent breast 
density.  This study is among the first to prospectively evaluate the effects of anthropometry on 
both relative and absolute measures of breast density.  Over time, a one unit increase in BMI was 
associated with a decrease of 1.18% in percent breast density and a one kilogram increase in 
weight was associated with a decrease of 0.44% in percent breast density.  Figure 3.1 shows 
estimated breast density measurements as a function of BMI to illustrate the observed 
associations between change in BMI and change in breast density.  Though our observations 
regarding percent density were in agreement with our stated hypothesis, the lack of a relationship 
with dense breast area was counter to what we hypothesized.  We did observe highly significant 
positive cross-sectional associations between BMI and weight and the dense breast area, but 
these associations did not persist in longitudinal analyses.     
Our results are largely in agreement with the many previous cross-sectional studies 
reporting significant inverse relationships between BMI or weight and percent density.5-7, 9-11, 14, 
15, 23, 24  We did observe a significant positive cross-sectional relationship between BMI and 
weight and dense area, in agreement with some,10 but not all, previous studies.14, 24  In one study, 
however, the association was made positive after adjustment for the non-dense breast area.24     
Few studies have used longitudinal data to analyze associations between anthropometry 
and mammographic breast density.  McCormack et al. reported that women with larger increases 
in BMI between ages 43 and 53 had an increased risk of having high-risk Wolfe patterns.12  
Their study, however, is not directly comparable to ours due to their use of a qualitative breast 
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density measurement and their use of longitudinal change in BMI yet only a single 
mammographic density assessment.  Boyd et al.16 related weight change over two years to 
change in breast density measurements over the same time period.  As in our analysis, Boyd et 
al. reported a significant negative association between weight change and percent density, such 
that percent density was increased in those who lost weight; however, their study also reported a 
significant positive association between weight change and the size of the dense breast area, such 
that dense breast area was decreased in those who lost weight.16  It is unclear why our findings 
differed from these latter results.  The characteristics of the two populations differed markedly in 
their age, ethnicities, baseline breast cancer risk, and observed weight change.  These differences 
may explain at least some of the discordant results of these two studies.  Indeed, a nested case-
control study of Native Hawaiian, Japanese, and Caucasian women recruited from the general 
population reported results similar to those we observed.  Maskarinec et al.17 reported that 
overweight and obese women had a more gradual decline in percent density over time as 
compared to women of normal weight.  Likewise, we observed that the regression coefficients 
for both BMI and weight with the outcome of percent density were more strongly negative 
among women of normal weight at study enrollment than among those who were overweight or 
obese at that time.  The authors did not report on the outcome of dense breast area, however, 
precluding a direct comparison to our results. 
The observation that anthropometry is related to the dense breast area in cross-sectional 
studies but not in longitudinal studies appears to be paradoxical at first consideration.  
Overweight and obese women may have a larger dense breast area than underweight or normal 
weight women simply because the total breast size is generally larger in women of greater 
weight; this explains the highly significant cross-sectional associations.  Indeed, in a previous 
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cross-sectional analysis of mammographic data from SWAN, significant positive correlations 
between BMI and the total breast area and also between the total breast area and the dense breast 
area were observed.15  After these cross-sectional differences are accounted for, further increases 
in weight and BMI appear to result in the accumulation of fat in the breast rather than altering the 
dense breast tissue.  Thus the total breast area increases while the dense breast area remains 
relatively constant.  As total breast area is the denominator when calculating percent breast 
density, increased total breast area results in a decrease in percent density. 
Overall, our results provide evidence that the consistently demonstrated relationship 
between anthropometry and breast cancer risk may not proceed through a direct effect of 
anthropometry on the size of the dense breast area.  The significant inverse association between 
increases in BMI and weight and percent breast density most likely reflects the effect of 
anthropometry on the non-dense area.  Indeed, this effect on the non-dense area may explain the 
effect of anthropometry on breast cancer risk.  In adipose tissue, such as that comprising the non-
dense area of the breast, androstenedione is converted to estrogen.25, 26  Higher non-dense breast 
area may therefore result in increased estrogen exposure to the nearby dense breast tissue due to 
this peripheral production of estrogen.10, 17  This increased estrogen exposure of the ducts and 
lobules where cancers arise may result in increased risk of breast cancer.  Therefore, observing a 
longitudinal decrease in percent density may actually reflect an increase in breast cancer risk if 
the decreased percent density results from an increase in non-dense tissue rather than a decrease 
in the dense breast area. 
Haars et al.10 noted that percent breast density may not be valid for etiologic inference 
because this measure incorporates information about both the dense breast area, believed to 
represent cells at risk for developing cancer, and BMI, an independent risk factor for breast 
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cancer.  Further, Haars et al. reported that only 37% of their participants were ranked in the same 
quartile of both percent density and dense breast area; in other words, a group of women with 
equivalent percent density may actually have a wide range in the size of their dense breast 
areas.10  Likewise, 39.8% of our participants had concordant classifications for quartiles of dense 
breast area and percent density.  Thus when one studies percent breast density as an intermediate 
endpoint, the results are also reflective of associations with BMI and do not necessarily reflect 
unique effects of the exposure being evaluated on the dense breast area.10  Our results, which 
show no longitudinal relationship between anthropometry and the dense breast area, yet a strong 
negative longitudinal relationship between anthropometry and percent density, support the 
recommendation by Haars et al. that the dense breast area be used as the outcome in studies 
using mammographic breast density to make inference to breast cancer etiology.10  We add to 
their recommendation that the non-dense area should be considered etiologically relevant to 
breast cancer as well. 
Strengths of this study include its large sample size and multi-ethnic, population-based 
cohort.  Also, menopausal status and use of HT were carefully monitored in SWAN.  
Quantitative measurements of mammographic breast density were used, which are preferable to 
the qualitative and subjective measurements used in many previous studies.  The high reliability 
of the single reader of the mammograms is also a substantial strength.  Finally, we had the 
opportunity to demonstrate consistent findings when analyzing groups defined by race, 
exogenous hormone use, and menopausal status. 
Limitations to this study include potential residual confounding, despite careful 
adjustment for confounders.  Also, the participants in the SWAN Mammographic Density 
Substudy are not a representative sample of the areas from which they were recruited, and this 
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may limit the external validity of these results.  The most significant limitation is that the 
mammograms were not taken at the same time as the SWAN visits.  Therefore we used linear 
interpolation with multiple imputation of random noise terms to estimate the participant’s breast 
density at the time of her SWAN visit if the mammogram was not taken within 90 days of the 
nearest SWAN visit.  We have provided and in depth description and validation of our 
interpolation and imputation method in a separate manuscript (Reeves et al., in preparation)*.  
Further, we observed similar results to those observed in the entire cohort when we repeated 
analyses among women with the majority of their mammograms occurring within 90 days of a 
SWAN visit.  Future studies may benefit from incorporating mammograms into their study visits 
to avoid the estimation that was required in this study. 
This study provides evidence that changes in anthropometry are not longitudinally 
associated with changes in the dense breast area, yet are strongly associated with percent breast 
density, at least among women transitioning through menopause.  Our findings suggest that as a 
surrogate for breast cancer, the absolute dense breast area is likely to be the most relevant 
outcome, though the non-dense area may be important to disease etiology as well. 
                                                 
* Reeves KW, Stone RA, Modugno F, Ness RB, Vogel VG, Weissfeld JL, Habel L, Vuga M, Cauley JA. 
Linear Interpolation with Multiple Imputation to Account for Off-schedule Observations in a Longitudinal Study.  In 
preparation. 
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Table 3.1 Characteristics of the study population at SWAN enrollment, N=834
Baseline characteristic 
Total 
N=834 
Pittsburgh 
N=198 
Los Angeles 
N=321 
Oakland 
N=315 
P value*
General characteristics      
Age, years; mean (SD) 46.5 (2.7) 46.1 (2.5) 46.7 (2.7) 46.5 (2.7) 0.09 
Race/ethnicity; N (%)     <0.001 
African American 62 (7.4) 62 (31.3) 0 (0.0) 0 (0.0)  
Caucasian 407 (48.8) 136 (68.7) 138 (43.0) 133 (42.2)  
Chinese 182 (21.8) 0 (0.0) 0 (0.0) 182 (57.8)  
Japanese 183 (21.9) 0 (0.0) 183 (57.0) 0 (0.0)  
Family income; N (%)     <0.001 
<$35,000 126 (15.4) 50 (25.5) 25 (8.0) 51 (16.4)  
$35,000-$49,999 140 (17.1) 39 (19.9) 38 (12.2) 63 (20.2)  
$50,000-$74,999 212 (25.9) 53 (27.0) 74 (23.8) 85 (27.2)  
$75,000-$99,999 141 (17.2) 32 (16.3) 62 (19.9) 47 (15.1)  
≥ $100,000 200 (24.4) 22 (11.2) 112 (36.0) 66 (21.2)  
Education; N (%)     0.001 
≤ High school 136 (16.3) 38 (19.2) 38 (11.8) 60 (19.1)  
>High school 250 (30.0) 65 (32.8) 112 (34.9) 73 (23.2)  
College 223 (26.7) 38 (19.2) 95 (29.6) 90 (28.6)  
Post-college 225 (27.0) 57 (28.8) 76 (23.7) 92 (29.2)  
History of any cancer; N (%) 5 (0.6) 0 (0.0) 1 (0.3) 4 (1.3) 0.26†
Anthropometric characteristics      
Body mass index, kg/m2; mean (SD) 25.4 (5.9) 28.4 (6.0) 23.9 (4.7) 25.2 (6.2) <0.001 
Underweight: <18.5 kg/m2; N (%) 16 (1.9) 0 (0.0) 9 (2.9) 7 (2.2) <0.001 
Normal: 18.5 - <25.0 kg/m2; N (%) 474 (57.5) 63 (32.1) 216 (68.4) 195 (62.5)  
Overweight: 25.0 - <30.0 kg/m2; N (%) 202 (24.5) 71 (36.2) 64 (20.3) 67 (21.5)  
Obese: ≥30.0 kg/m2; N (%) 132 (16.0) 62 (31.6) 27 (8.5) 43 (13.8)  
Weight, kg; mean (SD) 66.3 (17.1) 75.6 (17.1) 61.5 (14.0) 65.4 (17.9) <0.001 
Reproductive history      
Age at menarche, years; N (%)     0.004 
<12 171 (20.6) 53 (26.9) 74 (23.2) 44 (14.0)  
12 234 (28.2) 55 (27.9) 91 (28.5) 88 (28.0)  
13 251 (30.2) 59 (30.0) 92 (28.8) 100 (31.9)  
≥14 174 (21.0) 30 (15.2) 62 (19.4) 82 (26.1)  
Age at first birth, years; N (%)     <0.001 
Not applicable 148 (17.8) 28 (14.1) 58 (18.1) 62 (19.8)  
<20 55 (6.6) 29 (14.7) 13 (4.1) 13 (4.1)  
20-24 160 (19.2) 52 (26.3) 55 (17.2) 53 (16.9)  
25-29 235 (28.3) 46 (23.2) 95 (29.7) 94 (29.9)  
30-34 145 (17.4) 28 (14.1) 61 (19.1) 56 (17.8)  
≥ 35 89 (10.7) 15 (7.6) 38 (11.9) 36 (11.5)  
  84
   
 
Table 3.1 (continued)      
Cumulative breastfeeding, months; N (%)     <0.001 
Nulliparous, never 148 (17.8) 28 (14.1) 58 (18.1) 62 (19.8)  
Parous, never 138 (16.6) 53 (26.8) 30 (9.4) 55 (17.5)  
1-4 months 145 (17.4) 32 (16.2) 59 (18.4) 54 (17.2)  
5-11 months 135 (16.2) 37 (18.7) 57 (17.8) 41 (13.1)  
12-22 months 141 (17.0) 24 (12.1) 63 (19.7) 54 (17.2)  
≥ 23 months  125 (15.0) 24 (12.1) 53 (16.6) 48 (15.3)  
Number of births; N (%)     0.22 
0 148 (17.8) 28 (14.1) 58 (18.1) 62 (19.7)  
1 138 (16.6) 32 (16.2) 57 (17.8) 49 (15.6)  
2 351 (42.1) 78 (39.4) 138 (43.1) 135 (42.9)  
≥ 3 196 (23.5) 60 (30.3) 67 (20.9) 69 (21.9)  
Menopausal status; N (%)     0.91 
Premenopausal 483 (58.3) 112 (57.1) 189 (59.1) 182 (58.2)  
Early Perimenopausal 346 (41.7) 84 (42.9) 131 (40.9) 131 (41.9)  
Ever used birth control pills; N (%) 627 (75.4) 152 (77.2) 85 (26.5) 239 (76.1) 0.60 
Ever used hormones other than birth 
control pills; N (%) 110 (13.2) 23 (13.3) 42 (13.2) 42 (14.4) 0.99 
Other characteristics      
Number of 1st degree relatives with breast 
cancer; N (%)     0.99 
0 755 (91.2) 180 (90.9) 291 (91.2) 284 (91.3)  
≥ 1 73 (8.8) 18 (9.1) 28 (8.8) 27 (8.7)  
Number of 2nd degree relatives with breast 
cancer; N (%)     0.12 
0 657 (79.4) 145 (73.2) 255 (79.9) 257 (82.6)  
1 132 (15.9) 39 (19.7) 50 (15.7) 43 (13.8)  
≥ 2 39 (4.7) 14 (7.1) 14 (4.4) 11 (3.5)  
Number of breast biopsies; N (%)     0.02 
0 730 (87.5) 171 (86.4) 279 (86.9) 280 (88.9)  
1 76 (9.1) 20 (10.1) 24 (7.5) 32 (10.2)  
≥ 2 28 (3.4) 7 (3.5) 18 (5.6) 3 (1.0)  
Gail score; mean (SD) 1.06 (0.45) 0.95 (0.5) 1.13 (0.5) 1.05 (0.4) <0.001 
<1.66; N (%) 756 (91.8) 182 (92.9) 284 (89.6) 290 (93.3) 0.20 
≥1.66; N (%) 68 (8.3) 14 (7.1) 33 (10.4) 21 (6.8)  
 
 
*P values from two-sample t tests or Kruskal-Wallis tests for continuous variables and chi-square tests for 
categorical variables 
†P value from Fisher’s Exact Test 
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Table 3.2 Summary statistics for annual change in anthropometric and breast density 
measures from participants’ first to last observations with mammogram data 
 N Mean (SD) 25th – 75th  
Percentile 
P Value*
Annual change in BMI (kg/m2)†     
Total population 802 0.09 (0.70) -0.10 – 0.33  
Race/ethnicity    0.05 
African American 59 0.05 (1.26) -0.29 – 0.53  
Caucasian 389 0.10 (0.79) -0.10 – 0.39 0.18 
Pittsburgh 132 0.11 (0.73) -0.15 – 0.45  
Oakland 133 0.08 (0.72) -0.13 – 0.33  
Los Angeles 124 0.12 (0.90) -0.05 – 0.45  
Chinese 176 0.06 (0.37) -0.10 – 0.22  
Japanese 178 0.12 (0.44) -0.07 – 0.31  
BMI category at SWAN enrollment    0.51 
Underweight: <18.5 kg/m2 15 0.16 (0.22) 0.04 – 0.28  
Normal: 18.5 - <25.0 kg/m2 460 0.14 (0.45) -0.04 – 0.32  
Overweight: 25.0 - <30.0 kg/m2 196 0.11 (0.51) -0.16 – 0.38  
Obese: ≥30.0 kg/m2 126 -0.03 (1.32) -0.42 – 0.42  
Annual change in weight (kg) †     
Total population 807 0.22 (1.84) -0.25 – 0.89  
Race/ethnicity    0.03 
African American 60 0.12 (3.13) -0.50 – 1.47  
Caucasian 390 0.23 (2.16) -0.33 – 1.06 0.16 
Pittsburgh 133 0.22 (1.88) -0.33 – 1.19  
Oakland 133 0.21 (1.83) -0.38 – 0.91  
Los Angeles 124 0.26 (2.66) -0.10 – 1.18  
Chinese 178 0.16 (0.86) -0.24 – 0.52  
Japanese 179 0.29 (1.10) -0.16 – 0.80  
BMI category at SWAN enrollment    0.32 
Underweight: <18.5 kg/m2 15 0.44 (0.67) 0.12 – 0.81  
Normal: 18.5 - <25.0 kg/m2 462 0.35 (1.12) -0.08 – 0.83  
Overweight: 25.0 - <30.0 kg/m2 196 0.24 (1.38) -0.46 – 0.97  
Obese: ≥30.0 kg/m2 126 -0.14 (3.51) -0.97 – 1.13  
Annual change in dense area (cm2)     
Total population 834 -0.58 (3.32) -1.70 – 0.59  
Race/ethnicity    0.03 
African American 62 -0.46 (7.22) -3.21 – 3.27  
Caucasian 407 -0.84 (3.36) -2.18 – 0.45 0.54 
Pittsburgh 133 -1.06 (4.18) -2.30 – 0.35  
Oakland 138 -0.76 (3.04) -2.05 – 0.54  
Los Angeles 136 -0.69 (2.71) -2.01 – 0.45  
Chinese 182 -0.39 (1.51) -1.46 – 0.35  
Japanese 183 -0.22 (2.27) -1.23 – 0.69  
BMI category at SWAN enrollment    0.28 
Underweight: <18.5 kg/m2 16 -0.0003 (1.25) -0.78 – 1.01  
Normal: 18.5 - <25.0 kg/m2 474 -0.61 (2.53) -1.66 – 0.36  
Overweight: 25.0 - <30.0 kg/m2 202 -0.61 (3.59) -1.80 – 0.91  
Obese: ≥30.0 kg/m2 132 -0.50 (5.16) -2.17 – 1.28  
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Table 3.2 (continued)     
Annual change in percent density (%)     
Total population 834 -1.01 (2.38) -2.16 – 0.13  
Race/ethnicity    0.07 
African American 62 -0.52 (3.75) -2.07 – 1.00  
Caucasian 407 -1.22 (2.17) -2.43 – -0.04 0.99 
Pittsburgh 133 -1.30 (2.79) -2.39 – 0.08  
Oakland 138 -1.20 (1.86) -2.06 – -0.08  
Los Angeles 136 -1.16 (1.70) -2.45 – -0.09  
Chinese 182 -0.91 (1.96) -2.07 – 0.08  
Japanese 183 -0.81 (2.60) -2.06 – 0.27  
BMI category at SWAN enrollment    <0.001 
Underweight: <18.5 kg/m2 16 -1.14 (2.42) -2.86 – 0.38  
Normal: 18.5 - <25.0 kg/m2 474 -1.16 (2.35) -2.56 – -0.11  
Overweight: 25.0 - <30.0 kg/m2 202 -1.03 (2.10) -1.87 – 0.10  
Obese: ≥30.0 kg/m2 132 -0.50 (2.78) -1.08 – 0.43  
 
 
* P values from Kruskal-Wallis test due to non-normality and heteroskedasticity 
†Number of observations for annual change in BMI and weight are <834 because some participants were missing 
height and/or weight data at their first or last study visits with mammogram data
   
  88
    
Table 3.3 Summary statistics of participants’ initial mammographic breast density measurements, N=834*
Dense Breast Area
(cm2) 
Percent Density 
(%) 
 N Mean (SD)  25th – 75th 
Percentile 
P value Mean (SD) 25th – 75th 
 Percentile 
P value 
Total population 834 46.2 (26.7) 28.9 – 59.2  42.3 (19.6) 29.3 – 57.4  
Body mass index category    0.01   <0.001 
Underweight: <18.5 kg/m2 15 32.5 (12.9) 21.3 – 42.2  61.9 (19.0) 45.4 – 77.6  
Normal: 18.5 –  <25.0 kg/m2 453 43.8 (23.4) 28.8 – 54.2  50.7 (16.8) 39.1 – 63.3  
Overweight: 25.0 – <30.0 kg/m2 206 50.0 (25.3) 32.9 – 62.9  39.1 (16.1) 27.8 – 50.1  
Obese : ≥30.0 kg/m2 142 49.8 (36.7) 22.7 – 73.1  23.7 (16.5) 10.2 – 35.0  
Weight, kg    0.002   <0.001 
1st Quartile: 39 – <55.0 207 39.0 (19.9) 25.4 – 48.7  54.6 (16.5) 42.8 – 68.0  
2nd Quartile: 55.0 – <63.2 208 47.5 (24.6) 32.8 – 58.9  49.0 (16.3) 38.3 – 61.3  
3rd Quartile: 63.2 – <73.8 201 48.3 (24.4) 31.2 – 60.9  41.9 (17.1) 28.8 – 53.9  
4th Quartile: 73.8 – 153.9 205 50.1 (34.4) 25.1 – 67.4  27.5 (17.4) 12.8 – 41.2  
 
 
*Mammographic and personal characteristics are from the first timepoint at which the participant has mammographic density values, averaged across all 
imputations; in some cases the first timepoint did not correspond to the enrollment visit, thus the distributions of BMI and weight presented here differ from 
those in Table 3.1 
†P values from ANOVA across groups using the following transformations: square root (dense breast area), untransformed (percent density); means, SD, and 
range are all reported in the natural scale 
 
 
   
Table 3.4 Random effects regression estimates for the outcomes of dense area and percent density using 
multiple imputation*
 N β†  Standard Error 95% CI P Value 
Dense breast area      
Body mass index, kg/m2      
Model 1: BMI  830 -0.0152 0.0097 -0.0348 – 0.0043 0.12 
Model 2: BMI + age 830 0.00003 0.0101 -0.0205 – 0.0205 0.99 
Model 3: Fully adjusted** 824 -0.0105 0.0108 -0.0327 – 0.0117 0.34 
      
Weight, kg      
Model 1: Weight  830 -0.0055 0.0036 -0.0129 – 0.0019 0.14 
Model 2: Weight + age 830 -0.0004 0.0038 -0.0082 – 0.0073 0.91 
Model 3: Fully adjusted** 824 -0.0055 0.0042 -0.0142 – 0.0031 0.20 
      
Percent breast density      
Body mass index, kg/m2      
Model 1: BMI  830 -1.4601 0.0811 -1.6206 – -1.2996 <0.001 
Model 2: BMI + age 830 -1.2999 0.0858 -1.4710 – -1.1289 <0.001 
Model 3: Fully adjusted‡ 823 -1.1845 0.0934 -1.3714 – -0.9976 <0.001 
      
Weight, kg      
Model 1: Weight  830 -0.5170 0.0288 -0.5740 – -0.4600 <0.001 
Model 2: Weight + age 830 -0.4675 0.0301 -0.5273 – -0.4076 <0.001 
Model 3: Fully adjusted‡ 823 -0.4374 0.0341 -0.5056 – -0.3692 <0.001 
 
 
*Dense area was square root transformed due to non-normality; percent density was modeled in the natural scale 
†Regression coefficients have the following units: √cm2/(kg/m2) for regression of body mass index on dense breast 
area; √cm2/kg for regression of weight on dense breast area; %/(kg/m2) for regression of body mass index on percent 
density; %/kg for regression of weight on percent density 
**Model 3 for dense breast area is adjusted for age, race/site, menopausal status, 1st degree relative with history of 
breast cancer, number of previous breast biopsies, hormone use since previous visit 
‡Model 3 for percent density is adjusted for age, race/site, education, menopausal status, number of previous breast 
biopsies, age at menarche, age at first birth, number of births, history of oral contraceptive use at baseline, hormone 
use since previous visit 
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Figure 3.1 Dense breast area and percent density as a function of body mass index estimated from 
multivariable random intercept regression models* 
*Values were estimated by varying the values of body mass index while keeping all other variables in the model 
fixed at their mean or referent values.  For dense breast area, the values are for premenopausal, Caucasian women 
from the Pittsburgh site age 46.5 years with no 1st degree family history of breast cancer, no hormone use since 
previous visit, and no previous breast biopsies.  For percent density, the values are for premenopausal, Caucasian 
women from the Pittsburgh site age 46.5 years with no previous use of oral contraceptives at enrollment, a high 
school or lower education, no hormone use since previous visit, no previous breast biopsies, and who were 
nulliparous and age <12 at menarche. 
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4.1 ABSTRACT 
Data in epidemiological studies are sometimes collected off-schedule from planned study visits.  
In an ancillary study, longitudinal outcome data were collected retrospectively from 
mammograms that were not acquired at the study visits.  This created a missing data problem 
because the outcome of interest, breast density, was unknown at the time of the study visits when 
covariate data were collected.  We developed a method to estimate the off-schedule 
mammographic breast density measurements at study visits using a novel approach of linear 
interpolation combined with multiple imputation.  We evaluated the validity of this approach by 
using it to estimate known values of breast density and comparing the estimated values to the 
observed values.  We compared results of random intercept models assessing the association 
between body mass index (BMI) and dense breast area when breast density was estimated with 
our approach to results obtained by simply matching each mammogram to the nearest study visit.  
Our method had a small bias on average (0.11 cm2).  The association between BMI and dense 
breast area was statistically significant when estimation was based on simple matching (β=-
0.0155 p=0.04), yet was non-significant when based on interpolation and multiple imputation 
(β=-0.0098, p=0.38).  Simple matching may produce inaccurate estimates because it does not 
incorporate the time difference and change in breast density over time.  Our method of linear 
interpolation with multiple imputation may be applicable to other longitudinal datasets where 
important data were collected outside the scheduled study visits and the variable of interest 
changes linearly over time.  
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4.2 INTRODUCTION 
There are many situations in epidemiologic research where data are collected at times other than 
those planned in the initial study design.  Some studies may plan regular visits to collect data, yet 
additional data are collected at other times and may be considered off-schedule.  This can occur 
when longitudinal studies use retrospectively collected data, which are unlikely to exactly match 
the timing of the study visits, in addition to data from the regularly scheduled visits.  For 
example, medical records or other routinely collected medical data could be used in ancillary 
studies conceived after data collection for the main study has begun.   To address this issue in 
our own work, we propose a novel method for estimating the value of off-schedule 
measurements at the time of the study visits. 
We encountered the need to estimate breast density in the context of an ancillary study to 
the Study of Women’s Health Across the Nation (SWAN), the SWAN Mammographic Density 
Substudy.  In this ancillary study, routine screening mammograms from a subset of SWAN 
participants were collected retrospectively for measures of breast density.  Though these 
mammograms were taken during the period of time in which women were actively participating 
in SWAN, the timing of the mammograms rarely coincided with the timing of the SWAN visits, 
when other data of interest were collected.  This created a missing data problem, because the 
values of the breast density measurements at the time of the SWAN visits were mostly 
unobserved.  Thus, a method of estimating the mammogram data at the SWAN visits was 
necessary.  Simply matching each mammogram to the nearest SWAN visit was problematic, due 
to the high degree of both between- and within-subject variability in the timing of the 
mammograms and study visits.  A simple matching algorithm would not account for either the 
time between study visits and mammograms or changes in breast density occurring over those 
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periods.  Addressing this problem was crucial to our planned analysis using the longitudinal 
mammographic density data as the outcome in a study where the primary independent variable 
was body mass index (BMI).  Height and weight were measured at the annual SWAN visits and 
were used to calculate BMI as the weight in kilograms divided by the squared height in meters. 
To our knowledge, methods for estimating retrospectively collected, supplementary data 
at study visits have not been reported.  In this paper we describe a method to estimate off-
schedule outcome data at the time of the study visits using techniques commonly employed for 
handling missing data.  We used linear interpolation with multiple imputation to estimate breast 
density measurements at the time of SWAN visits based on the observed mammogram data. 
4.3 METHODS 
4.3.1 Study population 
SWAN is a prospective cohort study focused on the health of women as they transition from 
premenopause to postmenopause.1  Eligibility criteria for SWAN were age 42-52, ≥1 menstrual 
period in the previous three months, intact uterus and ≥1 intact ovary, and not currently on 
hormone therapy (HT) or taking oral contraceptives (OCs).  The SWAN Mammographic Density 
Substudy is an ancillary study to SWAN with the goal of examining how mammographic breast 
density changes as women transition through menopause.2, 3  Participants from three SWAN sites 
(Los Angeles, CA, Oakland, CA, and Pittsburgh, PA) were enrolled at their 5th or 6th annual visit.  
At the time of this analysis, data were available from the baseline visit and up to seven follow-up 
visits for each participant.  Of those eligible for the SWAN Mammographic Density Substudy, 
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86.1% (N=1,055) consented and at least one mammogram was retrieved for 95.3% of these 
women (N=1,007 participants, with 3,980 mammograms).  Women who enrolled in the SWAN 
Mammographic Density Substudy were of similar age, leaner, and less likely to be African 
American or Caucasian than women who were eligible but chose not to participate.  Participants 
provided written informed consent, and institutional review board approvals were obtained for 
both SWAN and the SWAN Mammographic Density Substudy. 
Participants were excluded from this analysis if they reported a history of breast cancer at 
SWAN enrollment (N=6) or had <2 available mammograms (N=157).  Women diagnosed with 
breast cancer during their SWAN follow-up (N=21) were censored at the time of diagnosis; ten 
of these women had no mammograms prior to their breast cancer diagnosis and were excluded.  
Mammograms of breasts that had undergone a biopsy or more extensive surgery were not read 
for density in SWAN.  After these exclusions, 834 participants and 3,746 mammograms 
remained in the analysis.  Women enrolled in the SWAN Mammographic Density Substudy but 
excluded from this analysis were of similar age, educational level, and menopausal status as 
those included. 
4.3.2 Description of data 
The collection of mammograms in the SWAN Mammographic Density Substudy has been 
described previously.2, 3  Briefly, starting after the time of the 6th annual SWAN visit, 
investigators obtained routine screening mammograms taken two years prior to the baseline 
SWAN visit through two years after the 6th annual SWAN visit.  Because these mammograms 
were not taken as part of the SWAN study, but rather depended upon each woman’s compliance 
with current breast cancer screening guidelines, the number of and interval between 
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mammograms obtained on each participant was highly variable.  The number of mammograms 
collected on the 834 participants in the present analysis ranged from 2 to 10 with a median of 4.   
Breast density measurements were performed by a single reader using manual 
planimetry.2, 3  The reader provided measurements of the total breast area and the dense breast 
area, as well as a rating of the quality of the mammogram film.  A blinded 10% random sample 
of films showed good association between the initial and repeat readings of dense area (within-
person Spearman correlation coefficient=0.96).  For the purpose of illustrating the statistical 
methods to estimate the mammogram measures at the time of SWAN visits, we focused on the 
dense breast area. 
The timing of each participant’s mammograms rarely coincided with the timing of her 
SWAN visits; mammograms and visits occurred on the same day for only 10 of 3,746 
mammograms (0.27%).  To illustrate the method, these coincident mammograms were estimated 
as well.  The length of time between each SWAN visit and the closest mammogram was quite 
variable, both between and within participants.  To illustrate the complexity of the available data 
for this analysis, Figure 4.1 shows a timeline of the SWAN visit and mammogram data on a 
representative participant.  This participant, referred to as Participant X, is used throughout this 
paper to illustrate the implementation of estimation algorithms.  Noteworthy features of this 
participant’s data include the lack of mammograms near the time of some SWAN visits 
(Baseline through Visit 2) and the variable timing of the mammograms in relation to the nearest 
SWAN visit (Mammogram 1, 37 days before Visit 3; Mammogram 2, 92 days after Visit 4; 
Mammogram 3, 135 days after Visit 5; Mammogram 4, 134 days after Visit 6).   
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4.3.3 Approaches for estimating dense breast area 
We considered five approaches for estimating breast density at the visit times: 1) a simple 
matching algorithm to match each mammogram to its nearest visit, 2) linear interpolation, 3) 
linear interpolation with addition of a singly imputed noise term, 4) linear interpolation with 
multiply imputed noise terms, and 5) linear interpolation with multiply imputed noise terms for 
visits >90 days from nearest mammogram and matching otherwise.   
For Approach 1, the matching occurred regardless of whether the mammogram preceded 
or followed the study visit and regardless of the time between the two events.  Because we 
believe breast density was unlikely to undergo substantial changes within a few months time, 
matches were maintained for mammograms taken within 90 days of a SWAN visit for Approach 
5. 
To implement the linear interpolation, mammograms and SWAN visits were ordered 
chronologically.  Data from the mammograms before and after a target SWAN visit were used to 
estimate breast density at that SWAN visit according to the following equation: 
Di,tj= Di,t- + s(Di,t+ – Di,t-)
 
with 
s = 
Ai,tj – Ai,t-
Ai,t+– Ai,t-  
where D is the dense breast area, i is a unique indicator for each participant, t denotes time with tj 
representing the time of the missing data (i.e., time of target SWAN visit) and t- and t+ 
representing the times of the mammograms before and after tj, respectively.  A scaling factor (s) 
for the time between the visit and the nearest mammograms was computed using age (A) at the 
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time of these events, measured in years to the first decimal place (using a similar notation as for 
D).  This method was based on the assumption that the change in breast density was linear 
between the two mammograms.  We did not use extrapolation to estimate breast density; 
therefore, visits without a mammogram both before and after the target SWAN visit time were 
not included in the analysis.  The linear interpolation was implemented using the “ipolate” 
command in Stata version 10.0 (Stata Corporation, College Station, TX). 
 To illustrate the use of the above equations, we calculated the dense breast area at Visit 4 
for Participant X.  Her age at Visit 4 was 46.2 (Ai,tj=46.2), at Mammogram 1 she was age 45.1 
(Ai,t-=45.1), and at Mammogram 2 she was age 46.4 (Ai,t+=46.4).  Her measured dense breast 
area was 93.6 cm2 at Mammogram 1 (Di,t-=93.6) and 90.2 cm2 at Mammogram 2 (Di,t+=90.2).   
Substituting these values into the above equations, we find: 
s = = 0.85 
46.2 – 45.1 
46.4 – 45.1  
and 
= 93.6 + (0.8462) (90.2 – 93.6) = 90.7
Therefo
Di,tj *
 
re the interpolated dense breast area at Visit 4 for Participant X was 90.72 cm2. 
Additionally, for Approaches 3-5 we added a noise term to each interpolated value to 
account for the error introduced by estimating breast density rather than measuring it at the time 
point corresponding to the SWAN visit.  For each participant we calculated the standard 
deviation (SD) of all observed dense breast area measurements (i.e. the SD of the observed 
mammogram data).  Person-specific normal distributions of noise terms were generated, which 
had a mean of 0 and SD equal to the participant’s calculated SD of dense breast areas.  Noise 
terms were randomly selected from this distribution and added to each interpolated value.  For 
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Approaches 4 and 5, multiple imputation was used to create ten analytic datasets, each with 
different random noise terms added to the same linearly interpolated value of dense breast area.  
The literature on multiple imputation recommends 3-5 imputations for most situations but notes 
that up to 10 may be needed in situations with a higher level of missing data.4, 5  Because we 
have used a novel application of multiple imputation, we explored the effect of the choice of 
number of imputations on the estimated variance of the regression coefficients calculated using 
up to 15 imputations.  We chose to use ten imputations because in our data the variances changed 
little beyond 10 imputations (data not shown).  Due to the addition of the random noise terms, 
some negative values for dense breast area were obtained (<1%) and were considered to be 
implausible.  These implausible values were discarded and additional random noise terms were 
generated and added to the interpolated values until acceptable imputed values were obtained.  
Figure 4.2 displays the observed and estimated mammogram data, using Approach 5, for 
Participant X. 
4.3.4 Design of validation study 
Using the observed mammographic density data among participants with at least three 
mammograms, data for one mammogram between the first and last mammogram was randomly 
set to missing.  Approaches 1-4 were each used to estimate the density measurements for the 
“missing” mammogram data.  For descriptive purposes, in Approach 4 the estimated value was 
calculated as the average of the ten imputed values.  Approach 5 was not considered because 
none of the participants had mammograms separated by less than 90 days.  Bias was calculated 
by subtracting the observed value from the estimated value for each approach.  We calculated 
summary statistics for bias for each approach.  Large values of bias were used as indicators that 
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the approach provided poor estimates for a participant.  We also used analysis of variance 
(ANOVA) to compare the magnitudes of the bias by the reported quality of the mammograms 
(poor, fair, good, or excellent).  We assessed the correlation between estimates from each 
approach with the observed data and with estimates from the other approaches using Pearson’s 
correlation coefficients. 
4.3.5 Illustration of effects of choice of estimation approach 
tion estimate 
of β, β*, is calculated as the arithmetic mean of the β from the set of m imputations: 
 
The variance of β*, T, is calculated as a function of the within-imputation variance, W, and the 
between-imputation variance, B, as follows: 
j=1 jjj=1
T=W + (1 + 1/m)B; where:
 
Confidence intervals and p values can then be d ined using a t distribution with degrees of 
freedom, ν, calculated as: 
To demonstrate the impact of the choice of estimation approach on regression results, we 
developed an example exploring the longitudinal relationships between BMI and the dense breast 
area.  A parsimonious random intercept regression model was built using the first analytic 
dataset.  The regression was repeated using breast density estimated under each of the five 
approaches.  For Approaches 4 and 5, this resulted in a set of ten regression coefficients and their 
variances.  These estimates were combined into an overall multiple imputation estimate of the 
regression coefficient and its variance using Rubin’s rules.4, 6  The multiple imputa
j=1
β*= (1/m)Σ βj
m
B=1/(m – 1) Σ(β *)2
m
– βW=(1/m) Σ W
m
eterm
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v=(m – 1) 1+ W(1+1/m)B
2
 
 
The participant’s age in days was used as the time scale in the regressions.  Random 
intercept models were fit using the “xtreg” command in Stata version 10.0.  Multiple imputation 
estimates of the regression coefficients and their variances were calculated using the “mijoin” 
and “micombine” commands in Stata.  The dependent variable, estimated dense breast area, was 
square-root transformed to improve normality.  Because race was confounded with site, we 
created a combined race/site variable with the following categories for inclusion in the model: 
Caucasian/Pittsburgh, African American/Pittsburgh, Caucasian/Oakland, Chinese/Oakland, 
Caucasian/Los Angeles, Japanese/Los Angeles.  Each model was adjusted for age, race/site, 
menopausal status, first degree relative with history of breast cancer, number of previous breast 
biopsies, and hormone use since previous visit (Reeves et al., in preparation).*  We compared the 
magnitudes of the regression coefficients and their variances across the five approaches 
considered.  All statistical tests performed were two-sided with a p≤0.05 considered statistically 
significant.   
                                                 
* Reeves KW, Stone RA, Modugno F, Ness RB, Vogel VG, Weissfeld JL, Habel L, Sternfeld B, Cauley JA. 
Longitudinal influence of anthropometry on mammographic breast density: the Study of Women’s Health Across 
the Nation (SWAN). In preparation. 
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4.4 RESULTS 
4.4.1 Validation study 
Table 4.1 describes the study population.  At baseline participants were on average 46.5 years 
old, 58.3% were premenopausal, 57.5% had a BMI in the normal range (18.5 – <25 kg/m2), and 
48.8% were Caucasian.     
The validation study included 710 participants with ≥3 mammograms.  The bias for 
estimating dense breast area using Approaches 1–4 compared to the observed values is 
summarized in Figure 4.3.  Mean bias was similar across approaches, yet the greatest variability 
in bias was observed with Approaches 1 and 3.  For Approach 4, mean bias was 0.11 cm2 and 
approximately 50% of the estimates were within 4 cm2 of the observed measurement.   
Figure 4.4 shows plots of the observed dense breast area versus the values estimated by 
each approach.  Approaches 2 (r=0.96) and 4 (r=0.96) produced the estimates most highly 
correlated with the observed values, though correlations with the observed values were also high 
for Approaches 1 (r=0.94) and 3 (r=0.93).  The estimates produced by the four approaches were 
highly correlated with one another (all r≥0.95), though some outliers were noted. 
Figure 4.5 shows examples where Approach 4 did (Participant Y) and did not (Participant 
Z) work well.  For Participant Y, the change in density across mammograms 4, 5, and 6 was 
approximately linear, and the multiple imputation estimate of dense breast area (32.2 cm2) was 
very close to the observed value (32.8 cm2).  Our method worked poorly when density 
underwent a non-linear change across the estimation interval.  We defined the method to work 
poorly when the bias was greater than 10 cm2 and the estimated value differed from the observed 
by more than 10%.  This applied to 14.8% (N=105) of the participants.  This is illustrated by 
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Participant Z, for whom the estimated dense breast area for mammogram 5 was 67.4 cm2 while 
the observed dense breast area was 122.8 cm2 (bias=-55.4 cm2).  Interestingly, the quality of film 
for this mammogram was rated as poor, while the quality was rated higher for her other 
mammograms.   
The majority of the estimated mammogram films were of excellent (N=492, 69.3%) or 
good (N=178, 25.1%) quality, though some were judged to be of fair (N=31, 4.4%) or poor 
(N=9, 1.3%) quality.  The quality of the estimated film was more likely to be fair or poor in 
instances where the method worked poorly (10.5%), compared to instances where the method 
worked well (4.8% fair or poor, p=0.02).  The bias from Approach 4 differed by film quality 
with the mean bias for poor (-3.60 cm2) or fair (3.14 cm2) quality films being larger than for 
those of good (0.22 cm2) or excellent (-0.06 cm2) quality (p=0.10 based on the ANOVA model).  
4.4.2 Regression analyses 
Table 4.2 displays the results of the random intercept regression models for each of the five 
estimation approaches.  The association between BMI and square root transformed dense breast 
area was statistically significant only when dense breast area was estimated with the simple 
matching algorithm (Approach 1: β=-0.0155, p=0.04).  The magnitude of the estimated 
regression coefficient was greatest when using the simple matching algorithm.  The coefficient 
was smallest for the linear interpolation without noise terms (Approach 2: β=-0.0070).  The two 
multiple imputation approaches resulted in similar estimated regression coefficients (Approach 
4: β=-0.0098 and Approach 5: β=-0.0105).   
The estimated variance was lowest for linear interpolation without the addition of noise 
terms (Approach 2: variance=2.73x10-5) and was approximately doubled using either the simple 
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matching algorithm (Approach 1: variance=5.43x10-5) or single imputation (Approach 3: 
variance=5.89x10-5).  Variance was highest using multiple imputation of the noise terms 
(Approach 4: variance=11.86x10-5), and decreased slightly when observed data were used for 
mammograms within 90 days of a visit (Approach 5: variance=11.73x10-5).   
4.5 DISCUSSION 
We have presented a procedure for estimating off-schedule outcome data at the times of 
scheduled study visits using linear interpolation with multiply imputed noise terms.  Because 
mammographic density is generally a stable measure, linear interpolation was expected to work 
well.  In a validation study using the observed SWAN mammogram data, our estimate 
measurements were, on average, very close to the observed data.  Problems arose when the 
mammogram data exhibited a non-linear trend over the estimation interval.  We also have 
demonstrated how variations on our proposed method affect the results of regression analyses.   
Multiple imputation is recognized as a statistically valid method for obtaining unbiased 
estimates and appropriate variances in datasets with missing data.5, 7-11  This technique has been 
used to estimate missing data in a wide variety of variables, including depression scores,10 
medical costs,9 and serum cholesterol levels.12  Multiple imputation performs better than other 
methods of handling missing data, such as analyzing only cases with complete data, carrying the 
last observation forward, or using only a single imputation.7-14  For our method we used a novel 
application of multiple imputation as a way to account for uncertainty in the linear interpolation. 
Though this paper is not intended to draw etiologic inference, it is important to note how 
one’s conclusions might change based on the approach used to estimate dense breast area.  The 
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estimated regression coefficient was largest and statistically significant only when using a simple 
matching algorithm.  Though mammographic breast density is a relatively stable measure, 
substantial changes in breast density may occur over the course of a year due to changes in 
menopausal status,15 use of hormone therapy,16-18 and the aging process.19-22  Thus the simple 
matching algorithm is unlikely to provide the best estimates of breast density measurements at 
the time of the study visits, and appeared to overestimate the effects of BMI on the dense breast 
area.  Importantly, based on the simple matching algorithm we would infer that change in BMI 
was significantly associated with the dense breast area, while we would judge this association to 
be attenuated and non-significant when using our other approaches. 
Using raw interpolated values or only a single imputation of the noise terms resulted in 
substantially different estimates of the regression coefficient than did multiple imputation.  
Though the variance was considerably larger when multiple imputation was used, relying on 
only a single imputation could lead to bias.  As shown in Figure 4.3, estimating dense breast area 
using the single imputation approach resulted in a wider range of bias than did the multiple 
imputation approach.  The multiply imputed noise terms provided a more appropriate reflection 
of the error introduced by estimating the data.  These noise terms were randomly generated from 
distributions reflecting the variability of each participant’s observed mammographic density 
data.  However, the standard deviations used as the basis for the noise terms assume no trend in 
the mammogram data and are poorly estimated for women with fewer measurements.  The 
assumed distribution of noise terms could greatly influence the results.  Although other methods 
of choosing noise terms are possible, the relatively small number of mammograms for many 
participants limited our ability to consider more complicated functional forms.   
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In Approach 5, we preserved matches where the mammogram was taken within 90 days 
of the study visit.  We evaluated the effect of this assumption by comparing results using this 
approach to those using linear interpolation with multiple imputation for all observations 
(Approach 4).  The regression coefficients were very similar using either method, though the 
variances were slightly larger when no matches were maintained.  Using the observed data in 
cases where the measurements were taken close to the time of the study visit appears to be 
appropriate in our example, although not necessarily elsewhere.   
In cases such as ours that have missing data for a variable that is likely to change linearly 
over the study interval yet has short-term stability, we recommend using linear interpolation with 
multiple imputation while preserving closely aligned data (Approach 5) to account for off-
schedule observations.  Our proposed method has several advantages.  It provides a way for 
investigators to estimate data collected outside of planned study visits with data collected at 
those visits when necessary for specific analyses.  This increases the possibilities for ancillary 
studies and other analyses not planned at the onset of the study to utilize off-schedule data.  Use 
of linear interpolation produces estimates based on the observed data.  A previous simulation 
study demonstrated that linear interpolation was generally the best method for predicting missing 
values in time-oriented data.23  Also, the multiply imputed noise terms increase the 
appropriateness of the variance estimates so that statistical inferences can be made that account 
for uncertainty.  Further, this method is relatively easy to implement with the use of Stata 
routines to perform the interpolation, imputations, and combining of results according to Rubin’s 
rules.6 
The proposed method is not without its limitations, however.  Some study visits were 
excluded as participants lacked mammograms both before and after the visit and we did not use 
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extrapolation to estimate the density measurements.  This loss of observations may result in 
decreased power and raises the possibility of a selection bias.  Error was introduced when 
measurements were estimated rather than observed, and was further, albeit purposefully, 
introduced by the addition of the noise terms.  Thus our tests of statistical significance may be 
overly conservative.  This method does not account for measurement error from the original 
density readings or error in measurements introduced by differences in the degree of breast 
compression from mammogram to mammogram.  In at least one case where the method 
performed poorly (Participant Z), the quality of the film was rated as poor and possibly indicates 
measurement error.   
Finally, our method does not perform well when there is a substantially non-linear trend 
in the measurements over the estimation interval.  Our validation study, however, used 
observations to estimate the missing data that were typically a year before or after the timepoint 
with the missing data and were separated from one another by approximately two years.  In 
reality, both mammograms and study visits occurred at approximately one-year intervals, with 
most participants having less than six months between a mammogram and its nearest study visit.  
Thus, the time period over which the estimates for the regression analyses were made was 
generally much shorter than those in the validation study.  For this reason we believe that the 
level of error in the application of the method to real data is likely to be less than that observed in 
the validation study. 
Issues with off-schedule data are likely to be present in other studies and longitudinal 
datasets.  While we have developed and demonstrated our method in a study of mammographic 
breast density, the method is applicable to a wide variety of situations.  For example, one might 
use the proposed method to estimate body weight at the time of a phone interview based on 
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measurements recorded at preceding and subsequent clinic visits.  Further development and 
testing of our method may be necessary before implementing elsewhere.  Our hope is that this 
method will allow investigators to conduct statistically valid analyses in datasets with similar 
missing data problems due to off-schedule data.  As we have demonstrated, failure to account for 
the fact that observations are off-schedule observations can lead to incorrect conclusions about 
the magnitude and significance of associations.   
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Table 4.1 Characteristics of study population at SWAN enrollment 
Characteristic 
Total study 
 population 
 
N=834 
Age, years; mean (SD) 46.5 (2.7) 
Race/site; N (%)  
African American/Pittsburgh 62 (7.4) 
Caucasian 407 (48.8) 
Los Angeles 138 (16.5) 
Oakland 133 (15.9) 
Pittsburgh 136 (16.3) 
Chinese/Oakland 182 (21.8) 
Japanese/Los Angeles 183 (21.9) 
Menopausal status; N (%)  
Premenopausal 483 (58.3) 
Early perimenopausal 346 (41.7) 
Body mass index; N (%)  
Underweight: <18.5 kg/m2 16 (1.9) 
Normal: 18.5 – <25 kg/m2 474 (57.5) 
Overweight: 25 – <30 kg/m2 202 (24.5) 
Obese: ≥30 kg/m2 132 (16.0) 
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Table 4.2 Parameter estimates for the regression of body mass index on the square root 
transformed dense area by estimation approach, N=834*
Approach to Estimating Dense Breast Area N β Variance P value 
1) Simple matching of mammograms to visits 824 -0.0155 5.43x10-5 0.04 
2) Linear interpolation (LI) 823† -0.0070 2.73x10-5 0.18 
3) LI with single imputation of noise terms 823† -0.0091 5.89x10-5 0.24 
4) LI with multiple imputation of noise terms 823† -0.0098 11.86x10-5 0.38 
5) LI with multiple imputation for observations with 
>90 days between mammogram and visit and 
matching otherwise 
824 -0.0105 11.73x10-5 0.34 
 
 
*Density was modeled using a square root transformation due to non-normality; models were adjusted for age, 
race/site, menopausal status, 1st degree relative with history of breast cancer, number of previous breast biopsies, 
hormone use since previous visit; observations missing in these variables were excluded  
†One observation could not be interpolated due to lack of mammogram data both before and after the study visit, but 
was included in Approach 5 as the mammogram was within 90 days of the nearest visit 
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V0 V3V2 V4 V5 V6V1
2001
M1 M2 M3 M4
1997 19991998 2000 20032002 20052004
Participant X
Key
Mammogram
SWAN Visit 37 days 92 days 135 days 134 days
 
Figure 4.1 Observed data from SWAN visits and retrieved mammograms on a representative 
participant*
*Note: V0 – V6: Baseline to 6th annual SWAN visit; M1 – M4: 1st to 4th mammogram; Exact dates of visits 
and mammograms are not shown in order to preserve confidentiality 
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Figure 4.2 Observed and estimated dense area measurements using Approach 5 on a representative 
participant 
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Figure 4.3 Boxplots of bias of estimated breast density in validation study by each estimation 
approach, N=710 
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Figure 4.4 Correlation between dense breast area measurements estimated under each approach 
with observed data and other approaches used in the validation study, N=710* 
*For imputed data, the average dense breast area across 10 imputations is plotted 
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Figure 4.5 Examples of cases where the linear interpolation with multiple imputation (Approach 4) 
performed well (Participant Y, top) and where the method resulted in a large bias (Participant Z, bottom) in 
validation study 
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5.1 ABSTRACT 
Vascular endothelial growth factor (VEGF) is a key factor in angiogenesis and thereby plays an 
important role in carcinogenesis.  Previous studies relating circulating levels of VEGF to breast 
cancer have been limited by small numbers of participants and lack of adjustment for important 
confounders.  We studied the association between serum VEGF and breast cancer in an 
unmatched case-control study of 407 pre- and postmenopausal women (N=203 cases, N=204 
controls).  Breast cancer was confirmed through surgical and pathology reports.  Controls were 
selected from women with negative findings on screening mammograms.  Logistic regression 
models of natural log transformed VEGF and breast cancer were adjusted for age, Gail score, 
education, physical activity, history of breastfeeding, serum testosterone, and hormone therapy 
use.  The majority of the population was postmenopausal (67.6%) and the average age was 56 
years; age and menopausal status were similar among cases and controls.  Geometric mean 
VEGF levels were higher in cases (321.4 pg/mL) than controls (291.4 pg/mL), albeit not 
significantly (p=0.21).  In a multivariable model the odds of breast cancer were 37% higher for 
women with VEGF levels ≥314.2 pg/mL compared to those with levels below 314.2 pg/mL, 
although this association was not statistically significant (p=0.16).  Results were similar in 
separate regressions of pre- and postmenopausal women.  In this case-control study VEGF was 
non-significantly associated with increased breast cancer risk in pre- and postmenopausal 
women.   
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5.2 INTRODUCTION 
An estimated 178,480 women in the United States will be diagnosed with breast cancer in 2007.1  
While there are many recognized breast cancer risk factors, including age, family history, and 
nulliparity, it remains difficult to predict which women will develop the disease.  The Gail model 
is a statistical model often used to predict a woman’s 5-year and lifetime risk of breast cancer.2-4  
Application of the Gail model to the Nurse’s Health Study cohort, however, demonstrated that 
the ability of this model to discriminate between women who did and did not develop breast 
cancer was fairly low (concordance statistic 0.58, 95% CI 0.56-0.60).5  Little is known about 
biological factors that may increase breast cancer risk.  Biological risk factors that could be 
measured in blood or urine and used to refine current risk prediction models may enhance our 
ability to identify women likely to develop breast cancer.5
Angiogenesis is the process by which the body forms new blood vessels.  Tumor growth 
is dependent on angiogenesis.6, 7  Without vascularization tumors are unable to grow beyond 1-2 
mm3 in size.8  While angiogenesis is a tightly controlled biological process involving multiple 
factors, vascular endothelial growth factor (VEGF) has been identified as a primary promoter of 
angiogenesis.9  VEGF is a potent endothelial cell mitogen and does not act on other types of 
cells.9  VEGF has a wide range of functions, including promoting endothelial cell mitogenesis 
and survival, increasing stromal degradation by promoting the expression of enzymes involved 
in this process, and promoting vascular permeability.10  VEGF occurs in six different isoforms 
due to alternative splicing of the VEGF gene,11, 12 with the 121 and 165 isoforms secreted as 
soluble proteins being the most abundant.11, 12   
Despite strong evidence of an association between VEGF and breast cancer from in vitro 
and animal studies, studies in humans have not shown definitively that VEGF levels are related 
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to breast cancer risk.  Numerous studies have reported that plasma or serum VEGF levels are 
increased among women with breast cancer compared to those without.13-25  These studies, 
however, are limited by small sample sizes, incomplete description of the study populations, 
and/or failure to control for potential confounders in the analyses.  Thus, the true association 
between VEGF levels and breast cancer remains unclear.  Further, estrogen is known to be 
important to breast cancer development, and there is in vitro evidence that estrogen may 
upregulate VEGF mRNA and protein expression.26-31  Few studies have investigated associations 
between VEGF and estrogen in humans, however.  
We conducted an unmatched case-control study of serum VEGF levels in relation to 
breast cancer in an ancillary study to the Mammograms and Masses Study (MAMS).  Our 
primary hypothesis was that serum VEGF levels would be positively associated with breast 
cancer in this population of pre- and postmenopausal women.  We also investigated associations 
between VEGF and direct and indirect measures of estrogen exposure. 
5.3 METHODS 
5.3.1 Study population  
MAMS is an unmatched case-control study of hormonal determinants of mammographic breast 
density.32  Briefly, women were eligible for MAMS if they were age ≥18 and were receiving a) a 
breast biopsy, b) an initial surgical consultation after breast cancer diagnosis, or c) a routine 
screening mammogram.  Exclusion criteria were prior cancer history other than non-melanoma 
skin cancer, alcohol intake >5 alcoholic beverages per day, or weight <110 pounds or >300 
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pounds.  Women were enrolled from 2001-2005 through mammography and surgical clinics 
operated by Magee-Womens Hospital, Pittsburgh, PA.  Pathology reports were obtained for 
women recruited from biopsy and surgical clinics to determine their disease status: benign breast 
disease, in situ disease, or invasive cancer.  Controls were recruited from women with negative 
findings on screening mammograms.  Of the eligible respondents, 55% of cases and 55% of 
controls enrolled in MAMS.  The MAMS study population consists of 1,133 women, including 
264 cases with in situ or invasive breast cancer, 313 women with benign breast disease, and 556 
controls. 
A subset of MAMS participants was selected for this investigation of VEGF and breast 
cancer.  We included only breast cancer cases and healthy controls; thus participants with benign 
breast disease were excluded (N=313).  Cases and controls were excluded from this analysis if 
they had no available mammogram (38 cases, 36 controls), were missing questionnaires (13 
cases, 7 controls), had no available serum sample (5 cases, 5 controls), or if their blood draw was 
>14 days from enrollment (3 cases, 0 controls).  These exclusions resulted in 205 cases (66 
premenopausal and 139 postmenopausal) and 508 controls (105 premenopausal and 403 
postmenopausal) eligible for the VEGF analysis.  We included all 205 eligible cases.  A simple 
random sample of 66 premenopausal and 139 postmenopausal controls was selected from the 
508 eligible controls for this analysis.  After completion of the VEGF analyses, three participants 
(1 control and 2 cases) were discovered to have a previous history of cancer and were excluded.  
The final population for analysis was 407, including 203 cases and 204 controls. 
The Institutional Review Board at the University of Pittsburgh approved this study, and 
all participants provided written informed consent. 
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5.3.2 Data collection 
Participants completed a self-administered take-home questionnaire upon enrollment into 
MAMS.  Data collected included demographic characteristics as well as current and lifetime data 
on medical conditions and procedures, medications including hormone therapy (HT) and oral 
contraceptives (OC), reproductive events, family cancer history, weight, physical activity, 
smoking, and alcohol use.  At enrollment, a research nurse measured participants’ height and 
weight using a stadiometer and a standard balance beam scale while participants wore light 
clothing and no shoes.   
Participants gave a non-fasting, 40 mL sample of peripheral blood at enrollment.  The 
blood draw was not timed with the menstrual cycle for premenopausal women.  Premenopausal 
women reported the date of their last menstrual period and the expected date of their next 
menstrual period, and menstrual cycle phase was inferred from this information.  All blood 
samples were processed immediately at the Magee-Womens Hospital Satellite Clinical Research 
Center and stored at <-70°C. 
5.3.3 Laboratory assays 
Samples were relabeled with dummy identifiers and randomly distributed throughout the boxes 
transferred to the laboratories.  A random sample of 40 masked duplicates (including 10 each 
from premenopausal cases and controls and postmenopausal cases and controls) were randomly 
distributed throughout the boxes.  Samples were transferred packed in dry ice.  All laboratory 
staff were masked to the identity, disease status, and demographic and risk factor characteristics 
of the samples.   
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VEGF was measured in serum by enzyme-linked immunosorbant assay (Quantikine® 
Human VEGF Immunoassay, R&D Systems, Minneapolis, MN).33  This assay is specific for the 
165 isoform of VEGF-A and has a minimum detectable concentration of <5 pg/mL.  The 
coefficient of variation (CV) for the VEGF assay was 14.2%. 
Estradiol (E2), follicle stimulating hormone (FSH), sex hormone binding globulin 
(SHBG), and testosterone (T) were measured in serum at the Clinical Ligand Assay Service 
Satellite (CLASS) Laboratory at the University of Michigan, School of Public Health.  E2 was 
measured with a modified, off-line ACS:180 (E2-6) immunoassay (Bayer Diagnostics Corp, 
Tarrytown, NY).34  This assay has a detectable range of 1 – 250 pg/mL.  FSH was measured with 
a two-site chemiluminescence (sandwich) immunoassay.35, 36  This assay measures FSH 
concentrations from 0.3 – 200 mIU/mL.  SHBG was measured using a competitive immunoassay 
run on Bayer Diagnostic’s ACS:180 automated analyzer using chemiluminescent technology.35  
The detectable range for SHBG is 1.95 to 250 nM.  Total T was measured using a modification 
of the ACS:180 total T assay to measure with greater precision samples in the low ranges found 
in women in the peri- and postmenopause.37  The limit of detection of this assay is <5.15 ng/dL.  
CVs were 42.3% for E2, 5.5% for FSH, 14.6% for SHBG, and 13.6% for T.  The high CV for E2 
was related to the low concentrations of E2 observed in postmenopausal women; categorization 
into quartiles based on the distribution in controls provided better reliability and therefore was 
used in analyses. 
5.3.4 Statistical analysis 
Descriptive statistics were calculated for demographic and behavioral characteristics and the 
laboratory measures.  Biological measures below the detection limit for the assay were reset to 
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the stated detection limit.  A natural log transformation was applied to all biological measures to 
improve normality.  The distributions of the demographic, behavioral, and biological variables 
were compared by disease status using two-sample t tests for continuous variables and chi-square 
tests for categorical variables.   
Variables associated with breast cancer or VEGF in previous studies were evaluated for 
their association with VEGF: age (continuous), race (white, other), educational level (high 
school, >high school), BMI (normal: <25 kg/m2, overweight: 25–<30 kg/m2, obese: ≥30 kg/m2), 
alcohol intake in year prior to enrollment (none, <12 g/d, ≥12 g/d), current alcohol use (no, yes), 
smoking status (never, former, current), cumulative physical activity in metabolic equivalent 
(MET)-h/wk (0, 0.1 – 10, ≥10.1), age at menarche (<13, ≥13), menstrual cycle regularity (no, 
yes, sometimes), menopausal status (premenopausal, postmenopausal without hysterectomy,  
postmenopausal with hysterectomy), age at menopause (premenopausal, <50, ≥50), menstrual 
cycle phase (luteal, follicular, unknown, postmenopausal), ever pregnant (no, yes), number of 
live births (none, 1, 2, ≥3), age at first pregnancy lasting >6 months (no live births/pregnancy 
lasted <6 months, <20, 20–24, 25–29, ≥30), breastfeeding history (not applicable, no, yes), breast 
cancer family history (no, yes), cancer family history (no, yes), Gail score (<1.66%, ≥1.66%), 
previous breast biopsy (no, yes), diabetes (no, yes), myocardial infarction history (no, yes), heart 
disease history (no, yes), HT use (never, former, current), OC use (never, former, current), E2 
(quartiles), FSH (quartiles), SHBG (quartiles), and T (quartiles).  Categorizations of these 
variables were based on common cutpoints (e.g. BMI) or on the original response categories with 
collapsing of categories to prevent small cell counts (e.g. age at menarche).  Quartiles for E2, 
FSH, SHBG, and T were based on the distribution of these hormones among controls.  VEGF 
was dichotomized based on the median level among the controls (<314.2 pg/mL, ≥314.2 pg/mL).  
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Bivariate associations between VEGF and these variables among control participants were 
assessed using chi-square tests.  Fisher’s exact test was used in instances where the expected cell 
count was <5. 
Logistic regression was used to evaluate the association between VEGF and breast cancer 
adjusting for relevant covariates.  VEGF was modeled in separate regressions as a continuous 
variable and as a dichotomous variable.  A natural log transformation was applied to VEGF to 
improve normality when VEGF was modeled as a continuous variable.  The aforementioned 
variables were evaluated for inclusion as potential confounders using backward selection based 
on Wald tests.  Dummy variables were created for categorical variables as appropriate.  All 
covariates with a p value <0.10 from a likelihood ratio test were retained in the model.  
Fractional polynomials were used to assess the assumption that continuous variables were linear 
in the logit.  The Hosmer-Lemeshow test was used to assess model goodness of fit.  Potentially 
influential observations were identified as those having significant influence on model deviance 
(as assessed by Hosmer-Lemeshow’s delta deviance test) or parameter estimates (as assessed by 
Pregibon’s delta beta test).  Likelihood ratio tests were used to evaluate the significance of 
hypothesized interactions by comparing the model including the interaction term to the main 
effects model.   
All analyses were repeated among subgroups defined by menopausal status.  Stata 
version 10.0 was used for all analyses (Stata Corportation, College Station, TX).  Two-sided p 
values ≤0.05 were considered statistically significant, with no adjustment for multiple 
comparisons.  
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5.4 RESULTS 
The 407 participants comprising the study population are described in Table 5.1.  The mean age 
of both cases and controls was 56 (p=0.99).  The vast majority of the participants were non-
Hispanic whites, though participants of other ethnicities were somewhat more common among 
controls than cases (7.4% versus 2.5%, p=0.02).  BMI was similar between cases and controls, 
with a mean BMI of 27.8 kg/m2 among cases and 27.9 kg/m2 among controls (p=0.84).  
Compared to controls, cases exercised less (p<0.001), were less likely ever to have breastfed a 
child (p=0.01), had a higher mean Gail score (p=0.02), and were more likely to be current users 
of HT (p<0.001).  Of the 203 cases, 52 (25.6%) had in situ disease and 151 (74.4%) had invasive 
cancer. 
The distributions of VEGF and the measured reproductive hormones are summarized in 
Table 5.2.  The geometric mean of serum VEGF among cases, 321.4 pg/mL, was higher than that 
among controls (291.4 pg/mL, p=0.21), albeit not significantly so.  Similar results were obtained 
within the subgroups of pre- and postmenopausal women (data not shown).  No significant 
differences were observed between cases and controls for the geometric means of E2 (15.5 
versus 12.6 pg/mL, p=0.18), FSH (62.9 mIU/mL versus 55.5 mIU/mL, p=0.31), and SHBG (51.6 
nM versus 49.3 nM, p=0.45).  Geometric mean T levels were higher among cases (32.8 ng/dL) 
compared to controls (28.1 ng/dL; p=0.01).  When restricted to premenopausal women only, 
geometric mean FSH levels were significantly higher among cases (20.7 mIU/mL) than controls 
(13.4 mIU/mL; p=0.05).  Among postmenopausal women only, E2 levels were significantly 
higher among cases than controls (geometric mean 9.5 pg/mL versus 6.8 pg/mL, respectively, 
p=0.02; data not shown).  
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None of the evaluated personal characteristics were significantly associated with serum 
VEGF levels among controls (Table 5.3).  Characteristics related to breast cancer risk, such as 
Gail score, physical activity, age at menopause, parity, and HT use, were not different among 
women with VEGF levels at or above the median level of controls (314.2 pg/mL) compared to 
those below.  We observed a positive association between FSH and VEGF (p=0.04).  Similar 
results were observed in analyses restricted to premenopausal or postmenopausal women (data 
not shown). 
In unadjusted and age-adjusted logistic regression analyses, associations between serum 
VEGF and breast cancer were not significant (Table 5.4).  In a model adjusted for age, Gail 
score, education, physical activity, history of breastfeeding, serum T, and HT use, VEGF 
(modeled as a continuous variable) was non-significantly positively associated with breast cancer 
(OR 1.21 per 1 unit increase in ln(VEGF), 95% CI 0.91 – 1.59).  Figure 5.1 illustrates this 
association by displaying odds ratios for specific levels of VEGF calculated from the continuous 
logistic regression model.  For example, the odds of breast cancer were increased by 16% for a 
woman with a serum VEGF level of 691.4 pg/mL compared to a similar woman with a VEGF 
level of 291.4 pg/mL.  In a similar multivariable regression model with VEGF as a dichotomous 
variable, women with VEGF levels ≥314.2 pg/mL had a non-significant 37% increase in the 
odds of having breast cancer (OR 1.37, 95% CI 0.88 – 2.12), compared to women with VEGF 
<314.2 pg/mL (Figure 5.1).     
The magnitude of the association between serum VEGF, dichotomized at the control 
group median, and breast cancer was similar among premenopausal (OR 1.40, 95% CI 0.64 – 
3.07) and postmenopausal women (OR 1.28, 95% CI 0.74 – 2.22).  There was no indication of an 
interaction between VEGF and menopausal status (p=0.52).  Additionally, no significant 
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interactions were observed between VEGF dichotomized at the control median and Gail score 
(p=0.41), E2 (p=0.62), or T (p=0.88).   
We also performed exploratory analyses to investigate whether HT use affected the 
association between VEGF and breast cancer (Table 5.4).  The logistic regressions were repeated 
within subgroups defined by HT use (never, past, and current users).  In multivariable models 
with VEGF modeled as a dichotomous variable, no association between VEGF and breast cancer 
was observed among never HT users (OR 1.23, 95% CI 0.68 – 2.22) or current HT users (OR 
1.09, 95% CI 0.31 – 3.87).  VEGF was positively, though non-significantly, associated with 
breast cancer among past HT users (OR 2.28, 95% CI 0.86 – 5.68).  A likelihood ratio test of an 
interaction term between VEGF and HT use status was not statistically significant (p=0.45) in a 
multivariable model with VEGF as a dichotomous variable.   
Results were similar in a regression including cases with invasive cancer only (OR 1.41, 
95% CI 0.88 – 2.27; p=0.16).  Using the methods described earlier, we identified four potentially 
influential observations (3 controls and 1 case) in the multivariable regression with VEGF as a 
dichotomous variable.  In a sensitivity analysis excluding these four observations, the increase in 
breast cancer risk for women with VEGF greater than the median was similar to that observed in 
the full population (OR 1.45, 95% CI 0.92 – 2.27, p=0.11; data not shown). 
5.5 DISCUSSION 
In this case-control study of pre- and postmenopausal women, we found that serum VEGF levels 
were positively associated with breast cancer, although the association was not statistically 
significant.  A woman with a serum VEGF level greater than the control median of 314.2 pg/mL, 
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for example, had 37% higher odds of breast cancer compared to an otherwise similar woman 
with a serum VEGF level below 314.2 pg/mL.  Results were similar among subgroups of pre- 
and postmenopausal women.   
The role of VEGF in angiogenesis and carcinogenesis is complex and likely involves 
interaction with multiple pathways.  Of particular interest to breast cancer development is the 
possibility that hormones may regulate VEGF.  Numerous in vitro studies using the estrogen-
sensitive MCF-7 breast cancer cell line have reported that estrogen increases VEGF mRNA 
and/or protein expression by these cells,26-31 although one study found no effect38 and another 
reported decreased VEGF expression induced by estrogen.39  VEGF expression can be decreased 
by the selective estrogen receptor modulator tamoxifen,27, 28, 40 though some studies report that 
tamoxifen increases VEGF expression in MCF-7 cells.30, 39  Most studies exploring the effects of 
progestins in the progestin-sensitive T47-D breast cancer cell line report that progestin exposure 
increases VEGF expression,38, 41, 42 though at least one study found no effect.43  Both natural and 
synthetic progestins are able to increase VEGF expression in vitro, and the synthetic progestin 
medroxyprogesterone acetate (MPA) is reported to have the strongest effect on VEGF expression 
by T47-D cells.38, 41  MPA is commonly used in postmenopausal HT, and it has been suggested 
that the strong effect of MPA on VEGF expression may at least partially explain the increased 
breast cancer risk observed in women using combination estrogen and progestin preparations 
versus those using estrogen alone.41
Few studies in humans have investigated associations between hormones and VEGF in 
relation to breast cancer risk.  A study of 16 healthy, pre- and postmenopausal women reported 
high correlations between VEGF in breast tissue and E2 in both plasma (r=0.81, p<0.0001) and 
breast tissue (r=0.67, p=0.004).44  We observed no significant association between serum VEGF 
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and serum E2 among healthy controls, though women with VEGF levels ≥314.2 pg/mL were 
more likely to be in the lowest quartile of E2 level.  Differences in the study populations and in 
the medium in which VEGF and E2 were measured preclude a direct comparison between these 
studies and may explain the divergent results.  We also observed a stronger, positive association 
between VEGF and breast cancer among past HT users.  This association was not apparent 
among current HT users, though the number of current HT users was small.  Though such 
differences in the associations between VEGF and breast cancer by HT use are intriguing, a 
formal test of this interaction was not significant.  These exploratory findings provide limited 
evidence that steroid hormones have effects on VEGF. 
Our results are consistent with those of previous studies that have reported positive 
associations between serum or plasma VEGF and breast cancer,13-25, 45 though our results did not 
achieve statistical significance.  These previous studies, however, only performed comparisons 
of mean or median VEGF levels between cases and controls, and did not examine associations 
between VEGF and breast cancer in a multivariable context.  In our study, VEGF levels above 
the median were more common in cases compared to controls after adjusting for relevant 
covariates, although this association was not statistically significant (p=0.16).   
Previous studies all included fewer than 100 healthy female controls, and most failed to 
describe how such controls were selected.13, 14, 18-20, 24  Control participants in MAMS were 
recruited from healthy women seeking a screening mammogram.  Our study population 
consisted of pre- and postmenopausal women ranging in age from 35 to 84.  Many previous 
studies have failed to adequately describe the age13, 16, 20, 22-25 or menopausal status13-17, 19-21, 23-25, 
45, 46 of their study populations, making a direct comparison of results difficult.  The distribution 
of VEGF among the controls in our population differed substantially from those reported by 
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other studies.  For example, the arithmetic mean serum VEGF among controls was 387.5 pg/mL 
in our population, but ranged from 77.0 pg/mL to 230.0 pg/mL in other studies.13, 14, 23, 24  
Similarly, the median serum VEGF among our controls was 314.2 pg/mL compared to medians 
ranging from 17.0 pg/mL to 186.0 pg/mL reported in other studies.17-21  This may reflect the 
higher sensitivity of the assay used here, the influence of a selection bias within our study, or 
may indicate that serum VEGF levels among healthy women are higher and more variable than 
previously thought.    
A significant limitation to our study is the low statistical power.  Although we determined 
a priori that we would have greater than 80% power to detect a difference of 60 pg/mL in mean 
serum VEGF between cases and controls as statistically significant, the variability of VEGF in 
our study population far exceeded that observed in the study used as a basis for power 
calculations.13  In fact, a posteriori power calculations show that our study had only 24% power 
to detect a difference between the mean values of serum VEGF we observed among cases and 
controls.  Thus our ability to detect true differences in VEGF between cases and controls was 
limited. 
The case-control design prevents us from making a temporal inference.  However, case-
control studies are an important step towards recommending prospective studies.  VEGF levels 
were assessed at a single point in time.  Thus the levels may not be representative of a 
participant’s usual levels but may reflect recent changes in general health or medication use.  The 
extensive data on such factors collected in MAMS allowed for statistical control of these 
variables and minimized the impact of confounding on the observed results.  Only a small 
percentage of MAMS participants were non-White, thus these results may not apply to women of 
other races or ethnicities.  Further, MAMS participants were better educated and less likely to 
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smoke as compared to women from Allegheny County overall,32, 47  indicating a possible 
volunteer bias, a concern reflected in the modest enrollment levels.     
Our results add to the existing body of literature reporting that circulating levels of VEGF 
are positively associated with breast cancer.  Future studies should investigate whether VEGF 
levels measured prospectively are indicative of later risk of breast cancer.  Also, further work is 
needed to evaluate the relationships between endogenous and exogenous hormones and VEGF 
and how such relationships might impact breast cancer risk.   
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Table 5.1 Descriptive characteristics of the study population by breast cancer status, N=407 
Characteristic Controls 
N (%) 
Cases 
N (%) 
P value*
Age, years; mean (SD) 56.5 (10.1) 56.5 (10.3) 0.99 
<50 56 (27.5) 56 (27.6) 0.56 
50-59 81 (39.7) 73 (36.0)  
60-69 40 (19.6) 51 (25.1)  
≥70 27 (13.2) 23 (11.3)  
Ethnicity   0.02 
White 189 (92.7) 198 (97.5)  
Other 15 (7.4) 5 (2.5)  
Education level   0.001 
High school 37 (18.1) 66 (32.5)  
Greater than high school 167 (81.7) 137 (67.5)  
Body mass index, kg/m2; mean (SD) 27.9 (6.2) 27.8 (5.8) 0.84 
Normal, <25 kg/m2 76 (37.3) 76 (37.8) 0.99 
Overweight, 25-<30 kg/m2 66 (32.4) 64 (31.8)  
Obese, ≥30 kg/m2 62 (30.4) 61 (30.4)  
Physical activity, MET h/wk   <0.001 
0 20 (9.8) 54 (26.6)  
0.1 – <10 72 (35.3) 63 (31.0)  
≥10 112 (54.9) 86 (42.4)  
Age at menarche, years   0.99 
<13 106 (52.2) 105 (52.2)  
≥13 97 (47.8) 96 (47.8)  
Menopausal status   0.09 
Premenopausal 66 (32.4) 66 (32.5)  
Postmenopausal without hysterectomy 100 (49.0) 82 (40.4)  
Postmenopausal with hysterectomy 38 (18.6) 55 (27.1)  
Age at menopause, years   0.12 
Premenopausal 66 (32.8) 66 (33.5)  
<50 55 (27.4) 70 (35.5)  
≥50 80 (39.8) 61 (31.0)  
Number of live births   0.36 
None 48 (23.5) 41 (20.2)  
1 28 (13.7) 19 (9.4)  
2 68 (33.3) 73 (36.0)  
≥3 60 (29.4) 70 (34.5)  
History of breastfeeding   0.05 
Not applicable 48 (23.5) 41 (20.3)  
No 65 (31.9) 88 (43.6)  
Yes 91 (44.6) 73 (36.1)  
Previous breast biopsy 25 (12.3) 51 (25.5) 0.001 
First degree relative with breast cancer  28 (13.8) 39 (19.2) 0.14 
Gail score; mean (SD) 1.49 (0.67) 1.71 (1.08) 0.02†
< 1.66% 140 (69.0) 126 (62.4) 0.16 
≥ 1.66% 63 (31.0) 76 (37.6)  
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Table 5.1 (continued) 
Hormone therapy use status   <0.001 
Never 115 (56.4) 108 (53.7)  
Former 69 (33.8) 45 (22.4)  
Current (within previous 3 months) 20 (9.8) 48 (23.9)  
Oral contraceptive use status   0.44 
Never 66 (34.6) 64 (34.0)  
Former 118 (61.8) 121 (64.4)  
Current 7 (3.7) 3 (1.6)  
 
 
*P values from t tests for continuous variables and chi square tests for categorical variables 
†From t test with unequal variances 
Abbreviations used: SD, standard deviation; MET, metabolic equivalent  
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Table 5.2 Summary statistics of serum levels of VEGF, E2, FSH, SHBG, and T in the study population by 
breast cancer status, N=407*
 N Mean SD Geometric 
Mean 
Median 25th – 75th Percentiles 
Controls       
VEGF, pg/mL 204 387.5  293.3 291.4 314.2 180.5 – 510.9 
E2, pg/mL 204 44.5 82.8 12.6 11.2 4.1 – 40.9 
FSH, mIU/mL 204 92.4 66.2 55.5 88.8 31.4 – 138.9 
SHBG, nM 204 58.2 33.8 49.3 51.6 35.3 – 73.1 
T, ng/dL 204 32.9 18.9 28.1 29.2 18.4 – 42.2 
Cases       
VEGF, pg/mL 202† 415.7 287.8 321.4 341.7 190.8 – 579.4 
E2, pg/mL 203 36.8 56.2 15.5 13.7 6.9 – 38.7 
FSH, mIU/mL 203 97.3 66.7 62.9 101.0 30.7 – 138.0 
SHBG, nM 203 62.9 45.0 51.6 49.2 34.4 – 73.4 
T, ng/dL 203 38.0 22.0 32.8 34.1 24.6 – 44.9 
 
 
*P values from t tests comparing cases to controls on natural log transformed values: VEGF, p=0.21; E2, p=0.18; 
FSH, p=0.31; SHBG, p=0.45; T, p=0.01 
†VEGF could not be measured in one case due to insufficient sample volume 
Abbreviations used: VEGF, vascular endothelial growth factor; E2, estradiol; FSH, follicle stimulating hormone; 
SHBG, sex hormone binding globulin; T, testosterone 
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Table 5.3 Bivariate associations between serum VEGF level and personal characteristics among 
controls, by VEGF level, N=204
Characteristic VEGF <314.2 pg/mL 
N (%) 
VEGF ≥314.2 pg/mL 
N (%) 
P value†
Age, years   0.96 
<50 29 (28.4) 27 (26.5)  
50-59 39 (38.2) 42 (41.2)  
60-69 21 (20.6) 19 (18.6)  
≥70 13 (12.8) 14 (13.8)  
Ethnicity   0.79 
White 95 (93.1) 94 (92.2)  
Other 7 (6.9) 8 (7.8)  
Education level   0.20 
High school 22 (21.6) 15 (14.7)  
Greater than high school 80 (78.4) 87 (85.3)  
Body mass index, kg/m2   0.20 
Normal, <25 kg/m2 35 (34.3) 41 (40.2)  
Overweight, 25-<30 kg/m2 39 (38.2) 27 (26.5)  
Obese, ≥30 kg/m2 28 (27.5) 34 (33.3)  
Physical activity, MET h/wk   0.49 
0 9 (8.8) 11 (10.8)  
0.1 – <10 40 (39.2) 32 (31.4)  
≥10 53 (52.0) 59 (57.8)  
Age at menarche, years   0.63 
<13 55 (53.9) 51 (50.5)  
≥13 47 (46.1) 50 (49.5)  
Menopausal status   0.67 
Premenopausal 36 (35.3) 30 (29.4)  
Postmenopausal without hysterectomy 48 (47.1) 52 (51.0)  
Postmenopausal with hysterectomy 18 (17.7) 20 (19.6)  
Age at menopause, years   0.49 
Premenopausal 36 (36.0) 30 (29.7)  
<50 24 (24.0) 31 (30.7)  
≥50 40 (40.0) 40 (39.6)  
Number of live births   0.65 
None 27 (26.5) 21 (20.6)  
1 12 (11.8) 16 (15.7)  
2 35 (34.3) 33 (32.4)  
≥3 28 (27.5) 32 (31.4)  
History of breastfeeding   0.19 
Not applicable 27 (26.5) 21 (20.6)  
No 36 (35.3) 29 (28.4)  
Yes 39 (38.2) 52 (51.0)  
Previous breast biopsy   0.83 
No 90 (88.2) 89 (87.3)  
Yes 12 (11.8) 13 (12.8)  
First degree relative with breast cancer    0.43 
No 86 (84.3) 89 (88.1)  
Yes 16 (15.7) 12 (11.9)  
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Table 5.3 (continued) 
Gail score   0.42 
<1.66% 73 (71.6) 67 (66.3)  
≥1.66% 29 (28.4) 34 (33.7)  
Hormone therapy use status   0.64 
Never 59 (57.8) 56 (54.9)  
Former 35 (34.3) 34 (33.3)  
Current (within previous 3 months) 8 (7.8) 12 (11.8)  
Oral contraceptive use status   0.14†
Never 36 (36.7) 30 (32.3)  
Former 61 (62.2) 57 (61.3)  
Current 1 (1.0) 6 (6.5)  
Serum E2 level, pg/mL   0.33 
0.0 – <4.1 21 (20.6) 31 (30.4)  
4.1 – <11.2 29 (28.4) 21 (20.6)  
11.2 – <40.9 25 (24.5) 26 (25.5)  
≥40.9  27 (26.5) 24 (23.5)  
Serum FSH level, mIU/mL   0.04 
0.3 – 31.4 20 (19.6) 31 (30.4)  
31.4 – <88.8 33 (32.4) 19 (18.6)  
88.8 – <138.9 28 (27.5) 22 (21.6)  
≥138.9 21 (20.6) 30 (29.4)  
Serum SHBG level, nM   0.94 
1.95 – 35.3 26 (25.5) 25 (24.5)  
35.3 – 51.6 25 (24.5) 26 (25.5)  
51.6 – 73.1 27 (26.5) 24 (23.5)  
≥73.1 24 (23.5) 27 (26.5)  
Serum T level, ng/dL   0.17 
5.2 – <18.4 21 (20.6) 30 (29.4)  
18.4 – <29.2 24 (23.5) 27 (26.5)  
29.2 – <42.2 32 (31.4) 19 (18.6)  
≥42.2 25 (24.5) 26 (25.5)  
 
 
*P values from chi-square test 
†P value from Fisher’s exact test 
Abbreviations used: VEGF, vascular endothelial growth factor; MET, metabolic equivalent, E2, estradiol; FSH, 
follicle stimulating hormone; SHBG, sex hormone binding globulin; T, testosterone 
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Table 5.4 Results of multivariable logistic regressions for association between serum VEGF and breast cancer*
 Unadjusted Age adjusted Multivariable adjusted†
 N OR (95% CI) P Value N OR (95% CI) P Value N OR (95% CI) P Value 
Total sample          
Continuous VEGF** 406 1.17 (0.91 – 1.50) 0.22 406 1.17 (0.91 – 1.50) 0.21 402 1.21 (0.91 – 1.59) 0.19 
          
Categorical VEGF, split at median 406 1.22 (0.83 – 1.80) 0.32 406 1.22 (0.83 – 1.80) 0.32 402 1.37 (0.88 – 2.12) 0.16 
          
Menopausal status          
Premenopausal 132 1.44 (0.73 – 2.86) 0.30 132 1.46 (0.73 – 2.91) 0.29 131 1.40 (0.64 – 3.07) 0.40 
Postmenopausal 274 1.13 (0.70 – 1.81) 0.62 274 1.13 (0.70 – 1.82) 0.62 271 1.28 (0.74 – 2.22) 0.38 
          
Hormone therapy use          
Never user 223 1.13 (0.67 – 1.92) 0.64 223 1.12 (0.66 – 1.90) 0.66 223 1.23 (0.68 – 2.22) 0.50 
Past user 114 1.70 (0.79 – 3.65) 0.18 114 1.74 (0.81 – 3.77) 0.16 112 2.28 (0.86 – 5.68) 0.08 
Current user (within previous 3 months) 67 0.83 (0.28 – 2.39) 0.72 67 0.84 (0.29 – 2.43) 0.74 67 1.09 (0.31 – 3.87) 0.90 
 
 
*Odds ratios comparing individuals with VEGF≥314.2 pg/mL to those with VEGF<314.2 pg/mL unless otherwise specified 
†Adjusted for age, Gail score, education, physical activity, history of breastfeeding, serum testosterone, HT use  
**Odds ratios in this row are for a 1 unit increase in ln(VEGF) beyond the control population mean of 5.67 (219.4 pg/mL in the observed scale) 
Abbreviations used: OR, odds ratio; CI, confidence interval 
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Figure 5.1 Odds of breast cancer by serum VEGF level estimated from a multivariable logistic 
regression model, N=402* 
*Odds ratios are adjusted for age, Gail score, education, physical activity, history of breastfeeding, serum 
testosterone, and hormone therapy use 
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6.0  DISCUSSION 
6.1 SUMMARY OF FINDINGS 
Although breast cancer survival has improved over recent decades as a result of early detection 
and improved treatment,1 breast cancer still impacts the lives of thousands of women each year.  
During 2007 alone, nearly 180,000 women in the United States were diagnosed with breast 
cancer.1  The mechanisms which lead to the development of breast cancer, however, are not 
completely understood.  As a result, opportunities for disease prevention are limited.  Therefore, 
research which focuses on elucidating the mechanisms of breast carcinogenesis is extremely 
important.  Knowledge of the mechanisms which are responsible for breast carcinogenesis may 
reveal opportunities for disease prevention through either behavioral modification or 
chemoprevention.   
We undertook investigations of two factors of potential etiological importance to breast 
cancer: anthropometry and angiogenesis.  First, we sought to determine how two anthropometric 
measures, body mass index (BMI) and weight, related to longitudinal changes in mammographic 
breast density, a well-established, modifiable risk factor for breast cancer.  During the course of 
this investigation we also developed and validated an estimation approach for off-schedule 
outcomes data.  Additionally, we studied whether circulating levels of vascular endothelial 
growth factor (VEGF), a strong angiogenic factor, increase the risk of breast cancer. 
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6.1.1 Article 1: Longitudinal influence of anthropometry on mammographic breast 
density 
We used random intercept regression models to study the associations between anthropometry 
and mammographic breast density in 834 women who participated in an ancillary study to the 
Study of Women’s Health Across the Nation (SWAN).  Anthropometric data were measured 
annually at clinic visits, and breast density was estimated from retrospectively collected 
mammograms.  We found that both BMI and weight were positively and significantly associated 
with dense breast area in cross-sectional analysis, but neither measure was longitudinally 
associated with dense breast area.  Conversely, BMI and weight were significantly negatively 
associated with percent density in both cross-sectional and longitudinal analyses. 
The results of our cross-sectional analyses are in agreement with previous studies which 
demonstrate a negative association between anthropometry and percent density.127, 133, 175-180, 186, 
338  Inconsistent results have been reported from cross-sectional analyses of anthropometry and 
the dense breast area,133, 179, 186 though our finding of a positive association is in agreement with 
one previous study.133  Few studies have investigated these associations using longitudinal 
studies,136, 181, 187 and differences in methodology preclude direct comparison between two of 
these studies and our own.181, 187  Boyd et al. reported a negative association between weight 
change and change in percent density, in agreement with our results, yet a positive association 
between weight change and change in dense breast area.136  The reasons for the difference 
between our results and those of Boyd et al. in regard to the dense breast area are unclear, but 
they may relate to differences between the study populations in characteristics such as age, 
race/ethnicity, and level of breast cancer risk. 
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The results of our study indicate that changes in anthropometry do not impact breast 
cancer development through direct effects on the dense breast area.  Overweight and obese 
women tend to have larger breasts than underweight or normal weight women,338 explaining the 
positive cross-sectional associations between BMI and weight and the dense breast area.  Further 
increases in weight and BMI appear to preferentially affect the non-dense breast area.  Such an 
increase in the non-dense area also increases the total breast area.  Thus when there is not an 
equivalent increase in the size of the dense breast area, the overall effect of increased non-dense 
breast area is to decrease percent breast density.  Adipose tissue, such as that in the non-dense 
area of the breast, is the primary source of estrogen production for postmenopausal women.115, 116  
Local exposure of the neighboring dense breast tissue, where cancers arise, to estrogen produced 
by aromatization in non-dense breast tissue may be an important factor in breast cancer 
etiology.133, 187  Our results suggest that the non-dense breast area be investigated further for a 
potential role in breast cancer development, though previous research has focused primarily on 
the dense breast area in terms of disease etiology.  Additionally, we have demonstrated that 
investigators must consider effects of exposures on both the dense and non-dense tissues, rather 
than focusing solely on percent density. 
6.1.2 Article 2: Linear interpolation with multiple imputation to account for off-schedule 
observations in a longitudinal study 
The analysis of the research question posed in the first article was complicated by the design of 
the SWAN Mammographic Density Study.  Mammograms were collected retrospectively from 
participants’ mammogram facilities.  Though these mammograms were taken while the 
participants were enrolled in SWAN, they were not part of the SWAN protocol and therefore 
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rarely coincided with the dates of the participants’ SWAN visits.  As a result, we needed a way 
to estimate breast density measurements at the time of the SWAN visits from the off-schedule 
mammograms.  Using an approach that simply matched each mammogram to the participant’s 
nearest study visit was problematic because the length of time between each mammogram and its 
nearest visit varied both within and between participants.  We developed an estimation approach 
that used linear interpolation to estimate breast density measurements at the time of each SWAN 
visit from mammograms taken before and after the SWAN visit.  We further added a multiply 
imputed noise term to the interpolated estimate to account for the error introduced by estimating 
these measurements. 
In a validation study, we demonstrated that the bias of our method for estimating dense 
breast area was quite low on average (0.11 cm2).  Our linear interpolation with multiple 
imputation approach was compared to three other approaches, including simple matching, linear 
interpolation, and linear interpolation with single imputation of noise terms.  The bias from our 
approach was smaller on average and less variable than the bias from the other estimation 
approaches.  We also investigated how each estimation approach would affect the results of 
random intercept regression models with estimated dense breast area as the outcome variable and 
BMI as the independent variable.  The regression coefficient was largest in magnitude when 
breast density was estimated using the simple matching algorithm.  Further, the association 
between BMI and dense breast area was statistically significant only when the simple matching 
algorithm was used.  The variance of the regression coefficients was lowest when linear 
interpolation was used, and was substantially increased when singly or multiply imputed noise 
terms were added to the linear interpolation estimates.  The variance of the regression coefficient 
was slightly reduced when mammograms within 90 days of the nearest SWAN visit were used as 
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matches and linear interpolation with multiple imputation was used for visits without a 
mammogram within 90 days.  The magnitude of the regression coefficient was similar between 
these two approaches.  The approach where observed data were used for mammograms within 90 
days of the visit and estimated with linear interpolation and multiple imputation otherwise was 
employed in the analyses for Article 1. 
We have demonstrated that our method for estimating off-schedule outcomes data is 
valid.  Further, we have shown that the approach used to estimate such data can have important 
effects on the inferences made from analyses using the estimated data.  For instance, we would 
have judged the relationship between BMI and dense breast area to be strong and statistically 
significant when using the simple matching algorithm, a naïve approach, whereas all other 
estimation approaches showed a weaker, non-significant relationship.  Though further 
development and testing of our approach is warranted, our linear interpolation with multiple 
imputation approach may be applicable to other longitudinal studies with important data 
collected outside of the regularly scheduled study visits. 
6.1.3 Article 3: Vascular endothelial growth factor and breast cancer risk 
The final research aim focused on the relationship between angiogenesis and breast cancer.  
Angiogenesis is a key step in tumor growth and metastasis, as tumors cannot grow without an 
adequate blood supply.194  VEGF is the strongest known angiogenic factor,195 and is therefore of 
potential importance to breast carcinogenesis.  We performed an unmatched case-control study 
with 203 cases and 204 controls to investigate whether higher serum VEGF levels were 
associated with increased breast cancer risk.      
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No statistically significant differences were detected between serum VEGF levels in 
cases and controls, though the unadjusted geometric mean VEGF among cases (321.4 pg/mL) 
was higher than that of controls (291.4 pg/mL).  We observed a positive, but non-significant, 
association between VEGF levels ≥314.2 pg/mL and breast cancer (OR 1.37, 95% CI 0.88-2.12).  
Our results agree with previous studies in terms of the direction of the association between serum 
VEGF and breast cancer,220, 310, 311, 313-318, 320 though the positive association in our study did not 
achieve statistical significance.  The lack of statistical significance may be attributable to the low 
power of our study.  Though a priori calculations indicated sufficient power for this analysis, the 
variability of serum VEGF levels in our control population was much greater than that on which 
the power calculations were based.310  Although previous studies did not describe their study 
population or recruitment procedures in sufficient detail, it appears that ours may be the first 
breast cancer case-control study to recruit control subjects from the general population.  The 
higher than expected VEGF levels among our controls may reflect unique characteristics of our 
study population, or they may indicate that levels of VEGF in healthy women are higher than 
previously recognized.  Regardless, it does appear that VEGF levels are elevated among women 
with breast cancer compared to those without evidence of disease, though perhaps this difference 
is not statistically significant.  Prospective studies will be valuable in determining whether or not 
measurement of VEGF levels may be useful in predicting breast cancer risk. 
6.2 FUTURE RESEARCH 
As indicated within each article, there are many opportunities for future research related to the 
investigations reported here.  For example, it would be useful to replicate our findings regarding 
  151
   
anthropometry and breast density in a longitudinal study where mammograms were taken as part 
of the study protocol.  Such a study design would eliminate the need to estimate breast density 
measurements as in our study, and would help evaluate the extent to which our results were 
influenced by estimation of our outcome data.  Further, identifying the effects of weight loss on 
both the dense and non-dense breast tissue would aid in understanding the mechanisms by which 
weight loss affects breast cancer risk.  It is also important to demonstrate how changes in breast 
density relate to changes in breast cancer risk.  This latter point is integral to demonstrating that 
breast density is useful as a surrogate endpoint for breast cancer.   
Regarding our estimation approach for off-schedule outcome data, future research is 
needed to refine the approach.  We could also consider other methods for choosing the noise 
terms.  Additionally, our estimation approach should be applied and validated in another 
longitudinal dataset to evaluate its performance for estimating measures other than breast 
density. 
More research is needed to fully understand the association between VEGF and breast 
cancer risk.  Larger case-control studies with more power are an important next step, as are 
prospective studies which could evaluate the utility of circulating VEGF levels for predicting 
which women will develop breast cancer.  VEGF levels could also be measured in the 
participants with benign breast disease in the MAMS population to determine what the VEGF 
levels are in this population of high-risk women and how they compare to cases and controls.  
Also, there are many opportunities for future research focusing on the associations between sex 
steroid hormones and VEGF. 
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6.3 PUBLIC HEALTH SIGNIFICANCE 
Breast cancer is the most commonly diagnosed non-skin cancer among American women, and 
ranks second in terms of cancer mortality for this population as well.1  Though such statistics 
clearly indicate the importance of breast cancer as a public health problem, the symbolic pink 
ribbons which now appear on everything from cars to cookbooks convey the true importance of 
this disease to the public.  Greater understanding of the factors which influence the development 
of breast cancer are important for identifying opportunities for prevention of this disease.  We, 
therefore, focused on how anthropometry and angiogenesis relate to breast cancer etiology. 
This research makes a significant contribution to public health.  First, our demonstration 
of the longitudinal associations between anthropometry and breast density has increased our 
understanding of how a well known risk factor for postmenopausal breast cancer, elevated BMI, 
may influence breast density, another breast cancer risk factor.  Further, we have developed an 
estimation approach for off-schedule data that may be used by other longitudinal studies.  
Specifically, the application of this method may expand the research questions that can be 
answered in studies where data of interest were collected outside of planned study visits.  
Finally, we have demonstrated that VEGF levels are positively associated with breast cancer, 
though whether this association is statistically or clinically significant is not clear.  It is not yet 
known whether VEGF levels will be useful in distinguishing between women with and without 
breast cancer.  In summary, these investigations have increased our knowledge of breast cancer 
etiology.  Our results, along with those of future studies expanding upon our findings, may lead 
to improved opportunities for prevention or early detection of breast cancer.   
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APPENDIX A 
LONGITUDINAL INFLUENCE OF ANTHROPOMETRY ON MAMMOGRAPHIC 
BREAST DENSITY: THE STUDY OF WOMEN’S HEALTH ACROSS THE NATION 
(SWAN) 
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A.1 COMPARISON OF PARTICIPANTS TO NON-PARTICIPANTS FROM SWAN 
Table A.1 Comparison of baseline characteristics among SWAN participants enrolled in the SWAN 
Mammographic Density Study to SWAN participants at a participating SWAN site who did not enroll 
in the SWAN Mammographic Density Study 
Characteristic 
SWAN 
Mammographic 
Density Study 
participants 
N=1,007 
SWAN participants not 
enrolled in 
Mammographic Density 
Study*
N=411 
P value†
Age, years; mean (SD) 45.9 (2.7) 45.6 (2.7) 0.06 
Body mass index, kg/m2; mean (SD) 25.6 (5.9) 26.9 (6.8) <0.001 
Weight, kg; mean (SD) 66.8 (17.4) 71.0 (19.3) <0.001 
Race/ethnicity; N (%)   <0.001 
African American 91 (9.0) 71 (17.3)  
Caucasian 492 (48.9) 233 (56.7)  
Chinese 198 (19.7) 52 (12.7)  
Japanese 226 (22.4) 55 (13.4)  
Menopausal status; N (%)   0.01 
Premenopausal 584 (58.4) 208 (50.9)  
Early perimenopausal 416 (41.6) 201 (49.1)  
Education; N (%)   <0.001 
Less than high school 30 (3.0) 10 (2.4)  
High school 142 (14.1) 81 (21.2)  
Some college 313 (31.1) 150 (36.5)  
College 261 (25.9) 78 (19.0)  
Post-college 261 (26.0) 86 (20.9)  
SWAN clinical site; N (%)   <0.001 
Oakland, CA 341 (33.9) 118 (28.7)  
Los Angeles, CA 392 (38.9) 104 (25.3)  
Pittsburgh, PA 274 (27.2) 189 (46.0)  
 
 
*Includes only SWAN participants from one of three sites offering the Mammographic Density Study (Los Angeles, 
CA, Oakland, CA, Pittsburgh, PA) but who were either ineligible or chose not to enroll in this ancillary study 
†P value from ANOVA for continuous variables and chi square test for categorical variables 
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Table A.2 Comparison of SWAN Mammographic Density Study participants included and 
excluded from the present analysis 
Characteristic 
Included in Analysis 
N=834 
Excluded from Analysis 
N=173 
P value*
Age, years; mean (SD) 46.0 (2.7) 45.7 (2.6) 0.26 
Body mass index, kg/m2; mean (SD) 25.4 (5.9) 26.4 (6.2) 0.06 
Weight, kg; mean (SD) 66.3 (17.1) 69.1 (18.3) 0.06 
Race/ethnicity; N (%)   <0.001 
African American 62 (7.4) 29 (16.8)  
Caucasian 407 (48.8) 85 (49.1)  
Chinese 182 (21.8) 16 (9.3)  
Japanese 183 (21.9) 43 (24.9)  
Menopausal status; N (%)   0.85 
Premenopausal 483 (58.3) 101 (59.1)  
Early perimenopausal 346 (41.7) 70 (40.9)  
Education; N (%)   0.08 
Less than high school 26 (3.1) 4 (2.3)  
High school 110 (13.2) 32 (18.5)  
Some college 250 (30.0) 63 (36.4)  
College 223 (26.7) 38 (22.0)  
Post-college 225 (27.0) 36 (20.8)  
SWAN clinical site; N (%)   <0.001 
Oakland, CA 315 (37.8) 26 (15.0)  
Los Angeles, CA 321 (38.5) 71 (41.0)  
Pittsburgh, PA 198 (23.7) 76 (43.9)  
 
 
*P value from ANOVA for continuous variables and chi square test for categorical variables 
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A.2 HORMONE USE AND MENOPAUSAL STATUS OVER FOLLOW-UP 
Table A.3 Hormone use by study population and menopausal status throughout follow-up, N=834 
Visit 1 Visit 2 * Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 
        N % N % N % N % N % N % N %
Ever used hormone therapy/oral contraceptives† 67              8.1 138 17.0 201 24.3 253 30.9 300 36.4 328 40.1 348 42.4
Hormone therapy/oral contraceptive use since 
last visit 
67              8.1 124 15.3 158 19.1 200 24.4 222 27.0 224 27.4 143 17.7
Menopausal status               
Pre-/Early perimenopausal               716 86.9 603 74.4 529 64.1 426 52.1 335 40.7 269 32.8 215 26.2
Late perimenopausal/Postmenopausal** 44              5.3 102 12.6 191 23.2 276 33.7 379 46.1 455 55.6 558 68.0
Unknown due to hormone therapy use               64 7.8 106 13.1 105 12.7 116 14.2 109 13.2 95 11.6 48 5.9
 
 
*Visit 1 is the first follow-up SWAN visit and is not the baseline SWAN visit; not all 834 participants have complete data at each visit 
†This is a time-dependent variable evaluated at each SWAN visit 
**Includes women who are postmenopausal due to hysterectomy with bilateral oophorectomy
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Table A.4 Selected baseline characteristics of the study population by race/ethnicity, N=834 
Baseline characteristic African American Caucasian Chinese Japanese P value*
General characteristics          
Age, years; mean (SD) 46.0 2.3 46.3 2.8 46.5 2.5 46.9 2.6 0.03 
Family income; N (%)          <0.001
<$35,000 31         50.0 43 10.7 38 21.1 14 8.1
$35,000-$49,999          9 14.5 75 18.6 37 20.6 19 10.9
$50,000-$74,999          12 19.4 105 26.1 46 25.6 49 28.1
$75,000-$99,999          7 11.3 74 18.4 22 12.2 38 21.8
≥ $100,000 3         4.8 106 26.3 37 20.6 53 31.0
Education; N (%)          <0.001
≤ High school 14         22.6 45 11.1 51 28.0 26 14.2
>High school          22 35.5 121 29.7 41 22.5 66 36.1
College 11         17.7 100 24.6 52 28.6 60 32.8
Post-college          15 24.2 141 34.6 38 20.9 31 16.9
Anthropometric characteristics          
Body mass index, kg/m2; mean (SD)    31.5 6.4 26.5 6.5 23.4 3.8 23.1 3.5 <0.001
BMI category; N (%)         <0.001 
Underweight 0 0.0   7 1.7 4 2.2 5 2.8
Normal 7         11.7 199 49.4 133 73.9 135 74.6
Overweight          20 33.3 113 28.0 35 19.4 34 18.8
Obese      33 8455.0 20.8 8 74.4 3.9
Reproductive history          
Menopausal status; N (%)          0.64
Premenopausal 34         54.8 231 57.0 112 62.2 106 58.2
Early Perimenopausal          28 45.2 174 43.0 68 37.8 76 41.8
Other          
Gail Score; mean (SD)          0.62 0.36 1.13 0.52 1.03 0.32 1.09 0.34 <0.001
 
 
*P values from Kruskal-Wallis tests for continuous variables and chi square tests for categorical variables 
   
 
Table A.5 Selected baseline characteristics of Caucasian participants by site, N=407 
Baseline characteristic 
 Oakland, CA
N=131 
Los Angeles, CA
N=140 
Pittsburgh, PA
N=142 P value*
General characteristics        
Age, years; mean (SD) 46.5 3.0 46.4 2.8 46.2 2.6 0.88 
Family income; N (%)       <0.001 
<$35,000 13 9.9 11 8.0 19 14.2  
$35,000-$49,999 26 19.8 19 13.9 30 22.4  
$50,000-$74,999 39 29.6 25 18.3 41 30.6  
$75,000-$99,999 25 18.9 24 17.5 25 18.7  
≥ $100,000 29 22.0 58 42.3 19 14.2  
Education; N (%)       0.02 
≤ High school 9 6.8 12 8.7 24 17.7  
>High school 32 24.1 46 33.3 43 31.6  
College 38 28.6 35 25.4 27 19.9  
Post-college 54 40.6 45 32.6 42 30.9  
Anthropometric characteristics        
Body mass index, kg/m2; mean (SD) 27.6 7.8 24.9 5.9 27.0 5.2 <0.001 
BMI category; N (%)       0.003 
Underweight 3 2.3 4 3.0 0 0.0  
Normal 62 47.0 81 60.0 56 41.2  
Overweight 32 24.2 30 22.2 51 37.8  
Obese 35 26.5 20 14.8 29 21.3  
Reproductive history        
Menopausal status; N (%)       0.43 
Premenopausal 70 52.6 83 60.1 78 58.2  
Early Perimenopausal 63 47.4 55 39.9 56 41.8  
Other        
Gail Score; mean (SD) 1.09 0.4 1.20 0.6 1.10 0.5 0.51 
Number of available mammograms; N (%)       <0.001 
2 10 7.5 20 14.5 19 14.0  
3 18 13.5 18 13.0 33 24.3  
4 38 28.6 30 21.7 22 16.2  
5 27 20.3 21 15.2 13 9.6  
6 27 20.3 30 21.7 16 11.8  
≥ 7 13 9.8 19 13.8 33 24.3  
 
 
*P values from Kruskal-Wallis tests for continuous variables and chi square tests for categorical variables 
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Table A.6 Selected baseline characteristics of the study population by baseline body mass index 
category, N=834 
 BMI Category at Baseline  
Baseline characteristic Underweight Normal Overweight Obese P value*
General characteristics          
Age, years; mean (SD) 45.8 3.5 46.5 2.7 46.5 2.7 46.3 2.7 0.44 
Family income; N (%)         0.05 
<$35,000 2 12.5 62 13.4 31 15.7 29 22.0  
$35,000-$49,999 2 12.5 71 15.3 40 20.3 26 19.7  
$50,000-$74,999 2 12.5 118 25.4 52 26.4 39 29.6  
$75,000-$99,999 3 18.8 86 18.5 32 16.2 18 13.6  
≥ $100,000 7 43.8 127 27.4 42 21.3 20 15.2  
Education; N (%)         0.15 
≤ High school 1 6.3 86 18.1 25 12.4 24 18.2  
>High school 5 31.3 132 27.9 61 30.2 48 36.4  
College 4 25.0 137 28.9 50 24.8 29 22.0  
Post-college 6 37.5 119 25.1 66 32.7 31 23.5  
Reproductive history          
Menopausal status; N (%)         0.64 
Premenopausal 11 73.3 279 58.9 117 58.5 73 56.2  
Early Perimenopausal 4 26.7 195 41.4 83 41.5 57 43.9  
Other          
Gail Score; mean (SD) 1.15 0.51 1.10 0.46 1.04 0.44 0.93 0.41 <0.001 
 
*P values from Kruskal-Wallis tests for continuous variables and chi square tests for categorical variables 
   
Table A.7 Selected baseline characteristics of the study population by number of available mammograms, N=834 
 Number of Mammograms  
Baseline characteristic     2 3 4 5 6 ≥ 7 P value*
General characteristics              
Age, years; mean (SD)  45.9 2.4 46.4 2.8 46.3 2.8 46.3 2.5 46.8 2.6 47.2 2.8 0.01
Race/ethnicity             0.001 
African American 18 14.6 14 8.9 8 4.8 5 3.5 7 5.6 10 8.4  
Caucasian 49             39.8 69 43.7 90 54.2 61 43.0 73 57.9 65 54.6
Chinese 19             15.5 37 23.4 42 25.3 39 27.5 22 17.5 23 19.3
Japanese 37             30.1 38 24.1 26 15.7 37 26.1 24 19.1 21 17.7
Family income; N (%) 05             0.0
<$35,000 32       26.5 29 18.6 21 13.0 19 13.6 12 9.7 13 11.1 
$35,000-$49,999             24 19.8 24 15.4 40 24.8 17 12.1 20 16.1 15 12.8 
$50,000-$74,999             26 21.5 39 25.0 44 27.3 40 28.6 36 29.0 27 23.1 
$75,000-$99,999             12 9.9 27 17.3 23 14.3 31 22.1 25 20.2 23 19.7 
≥ $100,000 27            22.3 37 23.7 33 20.5 33 23.6 31 25.0 39 33.3 
Education; N (%) .11             0
≤ High school             29 23.6 24 15.2 28 16.9 21 14.8 16 12.7 18 15.2 
>High school             41 33.3 54 34.2 45 27.1 44 31.0 38 30.2 28 23.5 
College 31            25.2 49 31.0 41 24.7 37 26.1 32 25.4 33 27.7 
Post-college             22 17.8 31 19.6 52 31.3 40 28.2 40 31.8 40 33.6 
Anthropometric characteristics              
Body mass index, kg/m2; mean (SD)  26.3 7.1 25.4 6.0 25.6 6.3 24.7 4.7 25.3 5.8 25.3 5.0 0.80
Body mass index category; N (%) .36             0
Underweight 2 1.7 5 3.2 3 1.8 1 0.7 1 0.8 4 3.4  
Normal 65            54.6 88 55.7 94 57.3 87 61.3 78 62.9 62 53.0 
Overweight             24 20.2 38 24.1 45 27.4 38 26.8 25 20.2 32 27.4 
Obese 28            23.5 27 17.1 22 13.4 16 11.3 20 16.1 19 16.2 
Reproductive history              
Menopausal status; N (%)              0.04
Premenopausal 68 55.3 109 69.0 98 59.8 81 57.0 67 53.2 60 51.7  
Early Perimenopausal             55 44.7 49 31.0 66 40.2 61 43.0 59 46.8 56 48.3 
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Table A.7 continued 
Other              
Gail Score; mean (SD)           0.94 0.35 0.99 0.37 1.02 0.41 1.06 0.34 1.07 0.42 1.36 0.69 <0.001
Site; N (%)            01  <0.0
Oakland, CA              29 23.6 55 34.8 80 48.2 66 46.5 49 38.9 36 30.3
Los Angeles, CA              57 46.3 56 35.4 56 33.7 58 40.9 54 42.9 40 33.6
Pittsburgh, PA 37             30.1 47 29.8 30 18.1 18 12.7 23 18.3 43 36.1
 
 
*P values from Kruskal-Wallis tests for continuous variables and chi square tests for categorical variables 
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A.4 MAMMOGRAM CHARACTERISTICS 
Table A.8 Summary statistics of time between SWAN visit and matched mammogram, by 
study visit 
  
Time between visit and matched mammogram* 
(days) 
Visit N Mean SD Minimum 25% Median 75% Maximum 
0 518 -166.1 269.9 -1515 -328 -114.5 52 199 
1 361 9.4 115.8 -251 -93 12 107 480 
2 387 3.5 108.6 -360 -91 8 89 307 
3 431 -4.6 116.4 -334 -98 -7 88 564 
4 459 -3.8 109.2 -317 -95 4 86 257 
5 519 4.6 112.7 -324 -78 11 92 463 
6 631 8.6 108.9 -290 -84 22 88 227 
7 255 -62.8 130.2 -326 -161 -87 25 350 
 
 
*Negative value indicates mammogram taken before visit 
  
Table A.9 Distribution of mammograms taken within 90, 120, and 180 days of the 
matched SWAN visit 
  
Mammogram 
within 90 days 
Mammogram 
within 120 days 
Mammogram 
within 180 days 
Visit 
Total N with 
Mammogram 
at Visit N % N % N %
0 518 147 28.4 190 36.7 297 57.3 
1 361 163 45.2 226 62.6 339 93.9 
2 387 195 50.4 254 65.6 370 95.6 
3 431 207 48.0 279 64.7 405 94.0 
4 459 230 50.1 300 65.4 438 95.4 
5 519 264 50.9 347 66.9 483 93.1 
6 631 331 52.5 419 66.4 583 92.4 
7 255 94 36.9 125 49.0 203 79.6 
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Table A.10 Distribution of number of mammograms within 90 days of matched visit by participant for total population and stratitifed by baseline BMI 
category and by clinic site, N=834*
Total
Population 
 Underweight Normal Overweight Obese Oakland,
CA 
Los Angeles, 
CA 
Pittsburgh, 
PA 
Number of mammograms 
within 90 days N % N % N % N % N % N % N % N % 
0      116 13.9 6.31 60 12.7 32 15.8 23 17.4 35 11.1 15.650 31 15.7
1    65 .8 240 28.8 25.04 137 28.9 52 25.7 44 33.3 87 27.6 27.488  32
2 240 .5 0 87 .1 53 26.8 28.8 315 14.3 291 .8 2960 .7 3231 10 31.8 27
3 127 15.2 4 25.0 70 14.8 30 14.9 20 15.2 50 15.9 51 15.9 26 13.2 
4 56 6.7 1 6.3 38 8.0 10 5.0 7 5.3 23 7.3 28 8.7 5 2.5 
5 33 4.0 0 0.0 15 3.2 12 6.0 6 4.6 15 4.8 9 2.8 9 4.6 
6 14 1.7 1 6.3 8 1.7 3 1.5 1 0.8 4 1.3 4 1.3 6 3.0 
7 7 0.8 0 0.0 4 0.8 3 1.5 0 0.0 0 0.0 3 1.0 3 1.5 
8 1 0.1 0 0.0 1 0.2 0 0.0 0 0.0 1 0.3 0 0.0 0 0.0 
 
 
*P value from chi square tests of difference by BMI category p = 0.76; p value from chi square test of difference by site p  = 0.08 
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A.5 RESULTS OF RANDOM INTERCEPT REGRESSIONS BY SUB-GROUPS 
   
   
 
Table A.11 Random intercept regression estimates for the outcomes of dense area and percent density using multiple imputation, by race/ethnicity*
 African American Caucasian Chinese Japanese  
 N β P Value N β P Value N β     P Value N β P Value
Dense breast area             
Body mass index, kg/m2             
Model 1: BMI 62 -0.058 0.13 403 -0.031 0.03 182 -0.013 0.50 183 0.019 0.28 
Model 2: BMI + age 62 -0.053 0.18 403 -0.013 0.39 182 0.005 0.81 183 0.035 0.05 
Model 3: Fully adjusted† 62 -0.053 0.18 401 -0.012 0.42 180 0.005 0.82 181 0.029 0.13 
             
Weight, kg             
Model 1: Weight 62 -0.027 0.06 403 -0.013 0.02 182 -0.002 0.82 183 0.007 0.31 
Model 2: Weight + age 62 -0.026 0.07 403 -0.007 0.23 182 0.005 0.52 183 0.013 0.07 
Model 3: Fully adjusted† 62 -0.026 0.07 401 -0.006 0.27 180 0.005 0.53 181 0.011 0.18 
             
Percent breast density             
Body mass index, kg/m2             
Model 1: BMI 62 -1.135 <0.001 403 -1.422 <0.001 182 -1.729 <0.001 183 -1.401 <0.001 
Model 2: BMI + age 62 -1.104 <0.001 403 -1.230 <0.001 182 -1.455 <0.001 183 -1.200 <0.001 
Model 3: Fully adjusted** 61 -1.061 <0.001 401 -1.133 <0.001 180 -1.331 <0.001 181 -1.050 <0.001 
             
Weight, kg             
Model 1: Weight 62 -0.437 <0.001 403 -0.502 <0.001 182 -0.630 <0.001 183 -0.582 <0.001 
Model 2: Weight + age 62 -0.431 <0.001 403 -0.438 <0.001 182 -0.531 <0.001 183 -0.514 <0.001 
Model 3: Fully adjusted** 61 -0.447 <0.001 401 -0.409 <0.001 180 -0.486 <0.001 181 -0.442 <0.001 
 
 
*Dense area was square root transformed due to non-normality; percent density was modeled in the natural scale 
†Model 3 for dense breast area is adjusted for age, race/site, menopausal status, 1st degree relative with history of breast cancer, number of previous breast 
biopsies, hormone use since previous visit 
**Model 3 for percent density is adjusted for age, race/site, education, menopausal status, number of previous breast biopsies, age at menarche, age at first birth, 
number of births, history of oral contraceptive use at baseline, hormone use since previous visit 
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Table A.12 Random intercept regression estimates for the outcome of dense area using multiple imputation, by race/ethnicity and BMI category at 
SWAN enrollment*
 African American Caucasian Chinese Japanese  
 N β P Value N β P Value N β P Value N β P Value 
Normal BMI at SWAN enrollment           
Body mass index, kg/m2             
Model 2: BMI + age 7 0.041 0.70 197 0.027 0.21 133 0.024 0.34 135 0.018 0.51 
Model 3: Fully adjusted† 7 0.040 0.70 197 0.023 0.30 131 0.025 0.33 134 0.018 0.49 
             
Weight, kg             
Model 2: Weight + age 7 0.023 0.56 197 0.009 0.29 133 0.012 0.22 135 0.007 0.46 
Model 3: Fully adjusted† 7 0.020 0.59 197 0.008 0.35 131 0.013 0.22 134 0.007 0.44 
             
Overweight BMI at SWAN enrollment           
Body mass index, kg/m2             
Model 2: BMI + age 20 -0.023 0.74 112 0.019 0.51 35 0.001 0.98 34 0.001 0.98 
Model 3: Fully adjusted† 20 -0.013 0.85 111 0.018 0.51 35 -0.014 0.76 34 0.005 0.91 
             
Weight, kg             
Model 2: Weight + age 20 -0.014 0.59 112 0.004 0.67 35 -0.002 0.90 34 0.004 0.81 
Model 3: Fully adjusted† 20 -0.012 0.66 111 0.004 0.66 35 -0.006 0.70 34 0.006 0.75 
             
Obese BMI at SWAN enrollment           
Body mass index, kg/m2             
Model 2: BMI + age 33 -0.106 0.06 83 -0.007 0.82 8 -0.117 0.34 7 0.084 0.24 
Model 3: Fully adjusted† 33 -0.100 0.12 82 -0.006 0.86 8 -0.047 0.65 7 0.068 0.34 
             
Weight, kg             
Model 2: Weight + age 33 -0.047 0.01 83 -0.005 0.67 8 -0.036 0.51 7 0.032 0.27 
Model 3: Fully adjusted† 33 -0.045 0.04 82 -0.004 0.72 8 0.006 0.90 7 0.024 0.41 
 
 
*Dense area was square root transformed due to non-normality; percent density was modeled in the natural scale 
†Model 3 for dense breast area is adjusted for age, race/site, menopausal status, 1st degree relative with history of breast cancer, number of previous breast 
biopsies, hormone use since previous visit 
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Table A.13 Random intercept regression estimates for the outcome of percent density using multiple imputation, by race/ethnicity and BMI 
category at SWAN enrollment*
 African American Caucasian Chinese Japanese  
 N β P Value N β P Value N β P Value N β P Value 
Normal BMI at SWAN enrollment           
Body mass index, kg/m2             
Model 2: BMI + age 7 0.948 0.61 197 -1.258 <0.001 133 -1.212 0.01 135 -1.225 0.002 
Model 3: Fully adjusted† 7 0.227 0.95 197 -1.269 <0.001 132 -1.033 0.03 134 -1.213 0.002 
             
Weight, kg             
Model 2: Weight + age 7 0.571 0.41 197 -0.422 <0.001 133 -0.418 0.01 135 -0.535 <0.001 
Model 3: Fully adjusted† 7 0.211 0.89 197 -0.442 <0.001 132 -0.388 0.02 134 -0.492 0.001 
             
           
Body mass index, kg/m2             
Model 2: BMI + age 20 -1.499 0.07 112 -0.579 0.06 35 -0.653 0.30 34 -1.040 0.09 
Model 3: Fully adjusted† 20 -4.879 <0.001 111 -0.563 0.07 34 -0.820 0.21 33 -0.764 0.25 
             
Weight, kg             
Model 2: Weight + age 20 -0.619 0.05 112 -0.212 0.04 35 -0.251 0.27 34 -0.322 0.18 
Model 3: Fully adjusted† 20 -2.028 <0.001 111 -0.210 0.05 34 -0.317 0.19 33 -0.272 0.29 
             
           
Body mass index, kg/m2             
Model 2: BMI + age 33 -0.861 0.05 83 -0.295 0.06 8 -0.985 0.17 7 0.102 0.87 
Model 3: Fully adjusted† 33 -0.833 0.11 82 -0.287 0.09 8 -0.593 0.53 7 0.130 0.86 
             
Weight, kg             
Model 2: Weight + age 33 -0.350 0.02 83 -0.112 0.06 8 -0.265 0.44 7 0.006 0.98 
Model 3: Fully adjusted† 33 -0.399 0.04 82 -0.114 0.06 8 -0.226 0.57 7 0.065 0.83 
 
 
*Dense area was square root transformed due to non-normality; percent density was modeled in the natural scale 
†Model 3 for percent density is adjusted for age, race/site, education, menopausal status, number of previous breast biopsies, age at menarche, age at first birth, 
number of births, history of oral contraceptive use at baseline, hormone use since previous visit 
 
   
Table A.14 Random intercept regression estimates for the 
outcomes of dense area and percent density using multiple 
imputation restricted to participants with no hormone use 
throughout SWAN follow-up*
 N β P Value 
Dense breast area    
Body mass index, kg/m2    
Model 1: BMI 441 -0.006 0.63 
Model 2: BMI + age 441 0.011 0.40 
Model 3: Fully adjusted† 439 0.001 0.94 
    
Weight, kg    
Model 1: Weight  441 -0.002 0.62 
Model 2: Weight + age 441 0.003 0.50 
Model 3: Fully adjusted† 439 -0.002 0.71 
    
Percent breast density    
Body mass index, kg/m2    
Model 1: BMI 441 -1.504 <0.001 
Model 2: BMI + age 441 -1.297 <0.001 
Model 3: Fully adjusted** 438 -1.171 <0.001 
    
Weight, kg    
Model 1: Weight  441 -0.532 <0.001 
Model 2: Weight + age 441 -0.467 <0.001 
Model 3: Fully adjusted** 438 -0.428 <0.001 
 
 
*Dense area was square root transformed due to non-normality; percent density was modeled in the natural scale 
†Model 3 for dense breast area is adjusted for age, race/site, menopausal status, 1st degree relative with history of 
breast cancer, number of previous breast biopsies, hormone use since previous visit 
**Model 3 for percent density is adjusted for age, race/site, education, menopausal status, number of previous breast 
biopsies, age at menarche, age at first birth, number of births, history of oral contraceptive use at baseline, hormone 
use since previous visit 
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Table A.15 Random intercept regression estimates for the 
outcomes of dense area and percent density using multiple 
imputation, restricted to participants who were always 
premenopausal/early perimenopausal throughout follow-up*
 N β P Value 
Dense breast area    
Body mass index, kg/m2    
Model 1: BMI 183 0.016 0.32 
Model 2: BMI + age 183 0.021 0.20 
Model 3: Fully adjusted† 179 0.005 0.81 
    
Weight, kg    
Model 1: Weight  183 0.007 0.31 
Model 2: Weight + age 183 0.008 0.21 
Model 3: Fully adjusted† 179 0.0004 0.96 
    
Percent breast density    
Body mass index, kg/m2    
Model 1: BMI 183 -1.510 <0.001 
Model 2: BMI + age 183 -1.416 <0.001 
Model 3: Fully adjusted** 180 -1.288 <0.001 
    
Weight, kg    
Model 1: Weight  183 -0.551 <0.001 
Model 2: Weight + age 183 -0.521 <0.001 
Model 3: Fully adjusted** 180 -0.490 <0.001 
 
 
*Dense area was square root transformed due to non-normality 
†Model 3 for dense breast area is adjusted for age, race/site, menopausal status, 1st degree relative with history of 
breast cancer, number of previous breast biopsies, hormone use since previous visit 
**Model 3 for percent density is adjusted for age, race/site, education, menopausal status, number of previous breast 
biopsies, age at menarche, age at first birth, number of births, history of oral contraceptive use at baseline, hormone 
use since previous visit
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Table A.16 Random intercept regression estimates for the 
outcomes of dense area and percent density using multiple 
imputation restricted to participants with ≥80% of 
mammograms within 90 days of a SWAN visit*
 N β P Value 
Dense breast area    
Body mass index, kg/m2    
Model 1: BMI 98 -0.013 0.68 
Model 2: BMI + age 98 0.003 0.93 
Model 3: Fully adjusted† 98 -0.014 0.68 
    
Weight, kg    
Model 1: Weight  98 -0.003 0.76 
Model 2: Weight + age 98 0.002 0.85 
Model 3: Fully adjusted† 98 -0.005 0.65 
    
Percent breast density    
Body mass index, kg/m2    
Model 1: BMI 98 -1.511 <0.001 
Model 2: BMI + age 98 -1.326 <0.001 
Model 3: Fully adjusted** 97 -1.190 <0.001 
    
Weight, kg    
Model 1: Weight  98 -0.504 <0.001 
Model 2: Weight + age 98 -0.452 <0.001 
Model 3: Fully adjusted** 97 -0.411 <0.001 
 
*Dense area was square root transformed due to non-normality 
†Model 3 for dense breast area is adjusted for age, race/site, menopausal status, 1st degree relative with history of 
breast cancer, number of previous breast biopsies, hormone use since previous visit 
**Model 3 for percent density is adjusted for age, race/site, education, menopausal status, number of previous breast 
biopsies, age at menarche, age at first birth, number of births, history of oral contraceptive use at baseline, hormone 
use since previous visit 
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Table A.17 Random intercept regression estimates for the 
outcomes of dense area and percent density using multiple 
imputation restricted to mammograms rated as good or 
excellent film quality*
 N β P Value 
Dense breast area    
Body mass index, kg/m2    
Model 1: BMI 819 -0.017 0.08 
Model 2: BMI + age 819 -0.002 0.84 
Model 3: Fully adjusted† 813 -0.012 0.29 
    
Weight, kg    
Model 1: Weight  819 -0.006 0.10 
Model 2: Weight + age 819 -0.001 0.75 
Model 3: Fully adjusted† 813 -0.006 0.16 
    
Percent breast density    
Body mass index, kg/m2    
Model 1: BMI 819 -1.488 <0.001 
Model 2: BMI + age 819 -1.333 <0.001 
Model 3: Fully adjusted** 812 -1.201 <0.001 
    
Weight, kg    
Model 1: Weight  819 -0.526 <0.001 
Model 2: Weight + age 819 -0.479 <0.001 
Model 3: Fully adjusted** 812 -0.443 <0.001 
 
 
*Dense area was square root transformed due to non-normality 
†Model 3 for dense breast area is adjusted for age, race/site, menopausal status, 1st degree relative with history of 
breast cancer, number of previous breast biopsies, hormone use since previous visit 
**Model 3 for percent density is adjusted for age, race/site, education, menopausal status, number of previous breast 
biopsies, age at menarche, age at first birth, number of births, history of oral contraceptive use at baseline, hormone 
use since previous visit 
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A.6 EXAMPLES OF INTERPOLATION AND MULTIPLE IMPUTATION OF 
BREAST DENSITY DATA 
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Figure A.1 Actual and interpolated total breast area (top) and dense breast area (bottom) for a 
randomly selected participant 
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Figure A.2 Actual and interpolated total breast area (top) and dense breast area (bottom) for a 
randomly selected participant with no mammograms within 90 days of a SWAN visit 
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Figure A.3 Actual and interpolated total breast area (top) and dense breast area (bottom) for a 
randomly selected participant with no mammograms within 90 days of a SWAN visit 
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Figure A.4 Actual and interpolated total breast area (top) and dense breast area (bottom) for a 
randomly selected participant with 3 mammograms within 90 days of a SWAN visit 
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Figure A.5 Actual and interpolated total breast area (top) and dense breast area (bottom) for a 
randomly selected participant with 3 mammograms within 90 days of a SWAN visit 
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Figure A.6 Actual and interpolated total breast area (top) and dense breast area (bottom) for a 
randomly selected participant with 7 mammograms within 90 days of a SWAN visit 
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Figure A.7 Actual and interpolated total breast area (top) and dense breast area (bottom) for a 
randomly selected participant with 7 mammograms within 90 days of a SWAN visit 
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APPENDIX B 
LINEAR INTERPOLATION WITH MULTIPLE IMPUTATION TO ACCOUNT FOR 
OFF-SCHEDULE OBSERVATIONS IN A LONGITUDINAL STUDY 
  182
   
  183
B.1 ILLUSTRATIONS OF MULTIPLE IMPUTATION METHOD  
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Figure B.1 Selection of noise terms for multiple imputation for visit 4 for a randomly 
selected participant 
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B.2 REGRESSION RESULTS IN SUB-COHORT WITH ≥80% OF MAMMOGRAMS WITHIN 90 DAYS OF VISIT 
Table B.1 Random intercept regression estimates for the outcome of dense area by estimation approach in sub-cohort 
 Body Mass Index Weight 
Appr
1)
oach to Estimating Dense Breast Area N β Variance P value N β Variance P value 
 Simple matching of mammograms to visits 412 -0.0185 10.9x10-5 0.08 412 -0.0078 14.8x10-6 0.04 
2) Linear interpolation without added noise terms 411 -0.0120 15.0x10-5 0.33 411 -0.0066 20.3x10-6 0.14 
3) Single imputation of noise terms 411 -0.0114 20.1x10-5 0.42 411 -0.0060 26.5x10-6 0.24 
4) Multiple imputation of noise terms 411 -0.0134 26.3x10-5 0.41 411 -0.0069 31.6x10-6 0.22 
5) Multiple imputation for all observations, 
regardless of time between mammogram and visit
410 -0.0167 33.3x10-5 0.36 410 -0.0082 43.3x10-6 0.22 
 
 
*Density was modeled using a square root transformation due to non-normality; models are adjusted for age, race/site, menopausal status, 1st degree relative with 
history of breast cancer, number of previous breast biopsies, hormone use since previous visit 
   
            APPENDIX C 
 VASCULAR ENDOTHELIAL GROWTH FACTOR AND BREAST CANCER RISK 
 185
   
C.1 ASSOCIATIONS BETWEEN VEGF AND MEASURED HORMONES
 
Table C.1 Correlations between VEGF and the measured hormones, N=406*
 E2 SHBG FSH T 
 r P value r P value r P value r P value 
Total Population -0.09 0.06 -0.07 0.15 0.01 0.77 -0.06 0.23 
Control -0.06 0.38 -0.03 0.63 0.41 0.01 0.88 -0.06 
Case -0.15 0.03 -0.12 0.10 0.01 0.86 -0.08 0.26 
Premenopausal -0.15 0.09 0.02 0.80 -0.05 0.60 -0.08 0.37 
Premenopausal Control -0.23 0.06 0.12 0.34 -0.14 0.25 -0.17 0.17 
Premenopausal Case -0.04 0.78 -0.08 0.53 0.02 0.87 -0.01 0.92 
Postmenopausal -0.02 0.76 -0.10 0.10 -0.08 0.19 -0.04 0.50 
Postmenopausal Control 0.10 0.27 -0.08 0.34 -0.05 0.57 -0.01 0.93 
Postmenopausal Case -0.18 0.04 -0.12 0.16 -0.11 0.20 -0.09 0.27 
 
 
*Correlations displayed as Pearson’s correlation coefficients calculated on natural log transformed 
values of VEGF and hormones 
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C.2 SUMMARY STATISTICS FOR VEGF WITHIN MENOPAUSAL SUBGROUPS
 
Table C.2 Summary statistics of serum levels of VEGF, E2, FSH, SHBG, and 
T in the premenopausal women by case/control status, N=132*
 N Mean SD Geometric 
Mean 
Median 25th – 75th Percentiles 
Controls       
VEGF, pg/mL 66 338.5 230.0 263.0 261.8 166.4 – 475.5 
E2, pg/mL 66 104.5 119.1 46.2 69.8 22.1 – 141.2 
FSH, mIU/mL 66 27.0 36.8 13.4 11.9 6.4 – 35.3 
SHBG, nM 66 66.7 38.4 56.6 57.9 36.9 – 82.7 
T, ng/dL 66 34.9 17.2 31.3 32.6 22.9 – 42.3 
Cases       
VEGF, pg/mL 66 375.2 247.4 296.4 338.1 170.4 – 526.2 
E2, pg/mL 66 76.6 78.6 42.4 52.8 16.0 – 106.6 
FSH, mIU/mL 66 43.3 55.9 20.7 16.5 8.9 – 52.0 
SHBG, nM 66 70.9 50.9 58.0 53.4 40.1 – 82.3 
T, ng/dL 66 40.6 22.5 35.7 31.4 25.2 – 52.5 
 
 
*P values from t tests comparing cases to controls on natural log transformed values: VEGF, 
p=0.36; E2, p=0.73; FSH, p=0.05; SHBG, p=0.82; T, p=0.12 
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Table C.3 Summary statistics of serum levels of VEGF, E2, FSH, SHBG, and T in the 
postmenopausal women by case/control status, N=275*
 N Mean SD Geometric 
Mean 
Median 25th – 75th Percentiles 
Controls       
VEGF, pg/mL 138 410.9 317.3 306.0 321.1 192.4 – 522.7 
E2, pg/mL 138 15.8 29.3 6.8 7.3 2.5 – 16.8 
FSH, mIU/mL 138 123.6 53.0 109.5 121.9 83.5 – 157.9 
SHBG, nM 138 54.1 30.6 46.1 47.5 33.2 – 68.2 
T, ng/dL 138 32.0 19.6 26.7 27.4 17.8 – 42.0 
Cases       
VEGF, pg/mL 136† 435.4 304.4 334.3 346.0 200.0 – 600.0 
E2, pg/mL 137 17.6 24.5 9.5 11.3 5.2 – 17.1 
FSH, mIU/mL 137 123.3 54.9 107.4 116.2 84.5 – 154.0 
SHBG, nM 137 59.1 41.5 48.8 48.3 32.8 – 71.2 
T, ng/dL 137 36.9 21.7 31.4 34.3 23.0 – 44.1 
 
*P values from t tests comparing cases to controls on natural log transformed values: VEGF, 
p=0.37; E2, p=0.02; FSH, p=0.81; SHBG, p=0.45; T, p=0.03 
†VEGF could not be measured in one case due to insufficient sample volume 
 188
   
 
Table C.4 Bivariate associations between serum VEGF level and personal characteristics 
among premenopausal controls, by VEGF level, N=66 
Characteristic VEGF <314.2 pg/mL 
N (%) 
VEGF ≥314.2 pg/mL 
N (%) 
P value†
Age, years   0.29 
<50 29 (80.6) 27 (90.0)  
50-59 7 (19.4) 3 (10.0)  
Ethnicity   0.65*
White 34 (94.4) 27 (90.0)  
Other 2 (5.6) 3 (10.0)  
Education level   0.28*
High school 6 (16.7) 2 (6.7)  
Greater than high school 30 (83.3) 28 (93.3)  
Body mass index, kg/m2   0.23 
Normal, <25 kg/m2 16 (44.4) 14 (46.7)  
Overweight, 25-<30 kg/m2 12 (33.3) 5 (16.7)  
Obese, ≥30 kg/m2 8 (22.2) 11 (36.7)  
Physical activity, MET h/wk   0.55*
0 1 (2.8) 2 (6.7)  
0.1 – <10 16 (44.4) 10 (33.3)  
≥10 19 (52.8) 18 (60.0)  
Age at menarche, years   0.37 
<13 22 (61.1) 15 (50.0)  
≥13 14 (38.9) 15 (50.0)  
Number of live births   0.72*
None 8 (22.2) 6 (20.0)  
1 7 (19.4) 3 (10.0)  
2 13 (36.1) 13 (43.3)  
≥3 8 (22.2) 8 (26.7)  
History of breastfeeding   0.49 
Not applicable 8 (22.2) 6 (20.0)  
No 10 (28.8) 5 (16.7)  
Yes 18 (50.0) 19 (63.3)  
Previous breast biopsy   0.68*
No 32 (88.9) 28 (93.3)  
Yes 4 (11.1) 2 (6.7)  
First degree relative with breast cancer    0.32 
No 30 (83.3) 22 (73.3)  
Yes 6 (16.7) 8 (26.7)  
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Table C.4 (continued) 
Gail score   0.99*
<1.66% 31 (86.1) 26 (86.7)  
≥1.66% 5 (13.9) 4 (13.3)  
Hormone therapy use status   0.09*
Never 35 (97.2) 27 (90.0)  
Former 0 (0.0) 3 (10.0)  
Current (within previous 3 months) 1 (2.8)   
Oral contraceptive use status   0.18*
Never 6 (18.2) 5 (17.9)  
Former 26 (78.8) 18 (64.3)  
Current 1 (3.0) 5 (17.9)  
Serum estradiol level, pg/mL   0.36*
0.0 – <4.1 2 (5.6) 6 (20.0)  
4.1 – <11.2 2 (5.6) 1 (3.3)  
11.2 – <40.9 8 (22.2) 6 (20.0)  
≥40.9  24 (66.7) 17 (56.7)  
Serum testosterone level, ng/dL   0.10*
5.2 – <18.4 4 (11.1) 9 (30.0)  
18.4 – <29.2 8 (22.2) 6 (20.0)  
29.2 – <42.2 16 (44.4) 6 (20.0)  
≥42.2 8 (22.2) 9 (30.0)  
 
 
*P value from Fisher’s exact test 
Abbreviations used: VEGF, vascular endothelial growth factor; MET, metabolic equivalent 
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Table C.5 Bivariate associations between serum VEGF level and personal characteristics 
among postmenopausal controls, by VEGF level, N=138 
Characteristic VEGF <314.2 pg/mL 
N (%) 
VEGF ≥314.2 pg/mL 
N (%) 
P value†
Age, years   0.75 
50-59 32 (48.5) 39 (54.2)  
60-69 21 (31.8) 19 (26.4)  
≥70 13 (19.7) 14 (19.4)  
Ethnicity   0.99*
White 61 (92.4) 67 (93.1)  
Other 5 (7.6) 5 (6.9)  
Education level   0.37 
High school 16 (24.2) 13 (18.1)  
Greater than high school 50 (75.8) 59 (81.9)  
Body mass index, kg/m2   0.40 
Normal, <25 kg/m2 19 (28.8) 27 (37.5)  
Overweight, 25-<30 kg/m2 27 (40.9) 22 (30.6)  
Obese, ≥30 kg/m2 20 (30.3) 23 (31.9)  
Physical activity, MET h/wk   0.76 
0 8 (12.1) 9 (12.5)  
0.1 – <10 24 (36.4) 22 (30.6)  
≥10 34 (51.5) 41 (56.9)  
Age at menarche, years   0.93 
<13 33 (50.0) 36 (50.7)  
≥13 33 (50.0) 35 (49.3)  
Age at menopause, years   0.47 
<50 24 (37.5) 31 (43.7)  
≥50 40 (62.5) 40 (56.3)  
Number of live births   0.24 
None 19 (55.9) 15 (44.1)  
1 5 (7.6) 13 (18.1)  
2 22 (33.3) 20 (27.8)  
≥3 20 (30.3) 24 (33.3)  
History of breastfeeding   0.23 
Not applicable 19 (28.8) 15 (20.8)  
No 26 (39.4) 24 (33.3)  
Yes 21 (31.8) 33 (45.8)  
Previous breast biopsy   0.59 
No 58 (87.9) 61 (84.7)  
Yes 8 (12.1) 11 (15.3)  
First degree relative with breast cancer    0.07 
No 56 (84.9) 67 (94.4)  
Yes 10 (15.2) 4 (5.6)  
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Table C.5 (continued) 
Gail score   0.48 
<1.66% 42 (63.6) 41 (57.8)  
≥1.66% 24 (36.4) 30 (42.3)  
Hormone therapy use status   0.41 
Never 24 (36.4) 29 (40.3)  
Former 35 (53.0) 31 (43.1)  
Current (within previous 3 months) 7 (10.6) 12 (16.7)  
Oral contraceptive use status   0.48*
Never 30 (46.2) 25 (38.5)  
Former 35 (53.9) 39 (60.0)  
Current 0 (0.0) 1 (1.5)  
Serum estradiol level, pg/mL   0.33 
0.0 – <4.1 19 (28.8) 25 (34.7)  
4.1 – <11.2 27 (40.9) 20 (27.8)  
11.2 – <40.9 17 (25.8) 20 (27.8)  
≥40.9  3 (4.6) 7 (9.7)  
Serum testosterone level, ng/dL   0.77 
2.0 – <18.4 17 (25.8) 21 (29.2)  
18.4 – <29.2 16 (24.2) 21 (29.2)  
29.2 – <42.2 16 (24.2) 13 (18.1)  
≥42.2 17 (25.8) 17 (23.6)  
 
 
*P values from Fisher’s exact test 
Abbreviations used: VEGF, vascular endothelial growth factor; MET, metabolic equivalent 
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